<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2102233283
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CAPRELSA 300 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VANDETANIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19053.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="IPR PHARMACEUTICALS INC." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            IPR PHARMACEUTICALS INC.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GENZYME EUROPE B.V. 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Caprelsa is used to treat medullary thyroid cancer that cannot be removed by surgery or has spread to<br />other parts of the body.<br />Caprelsa works by slowing down the growth of new blood vessels in tumours (cancers). This cuts off<br />the supply of food and oxygen to the tumour. Caprelsa may also act directly on cancer cells to kill<br />them or slow down their growth.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Caprelsa:</strong><br />- if you are allergic (hypersensitive) to vandetanib or any of the other ingredients of Caprelsa<br />(listed in Section 6).<br />- if you have a heart problem that you were born with called &lsquo;congenital long QTc syndrome&rsquo;.<br />This is seen on an electrocardiogram (ECG).<br />- if you are breast-feeding.<br />- if you are taking any of the following medicines: arsenic, cisapride (used to treat heartburn),<br />erythromycine intravenous and moxifloxacine (used to treat infection), toremifene (used to treat<br />breast cancer), mizolastine (used to treat allergies), Class IA and III antiarrhythmics (used to<br />control heart rhythm).<br />Do not take Caprelsa if any of the above applies to you. If you are not sure, talk to your doctor.<br /><strong>Take special care with Caprelsa:</strong><br />- Sensitivity to sun<br />Some people who are taking Caprelsa become more sensitive to the sun. This can cause<br />sunburn. While you are taking Caprelsa, protect yourself when you go outside by always using<br />sunscreen and wearing clothes to avoid exposure to the sun.</p><p>- Monitoring of your blood and your heart<br />Your doctor or nurse should perform tests to check the levels of your blood potassium, calcium,<br />magnesium, and thyroid-stimulating hormone (TSH) as well as the electrical activity of your<br />heart with a test called an electrocardiogram (ECG). You should have these tests:<br />&bull; Before starting Caprelsa<br />&bull; Regularly during Caprelsa treatment<br />&bull; 1, 3 and 6 weeks after starting Caprelsa<br />&bull; 12 weeks after starting Caprelsa<br />&bull; Every 3 months thereafter<br />&bull; If your doctor or pharmacist changes your dose of Caprelsa<br />&bull; If you start taking medicines that affect your heart<br />&bull; As instructed by your doctor or pharmacist<br /><strong>Taking other medicines:</strong><br />You must tell your doctor or pharmacist if you are taking or have recently taken any medicines,<br />including medicines that you buy without a prescription and herbal medicines. This is because<br />Caprelsa can affect the way some medicines work and some medicines can have an effect on Caprelsa.<br />Tell your doctor or pharmacist if you are taking any of the following medicines:<br />&bull; itraconazole, ketoconazole, ritonavir, clarithromycin, rifampicin and moxifloxacine (medicines<br />used to treat infections)<br />&bull; carbamazepine and phenobarbital (used to control seizures)<br />&bull; ondansetron (used to treat nausea and vomiting)<br />&bull; cisapride ( used to treat heart burn), pimozide (used to treat uncontrolled repeated movements of<br />the body and verbal outbursts) and halofantrine and lumefantrine (used to treat malaria)<br />&bull; methadone (used to treat addiction), haloperidol, chlorpromazine, sulpiride, amisulpride, and<br />zuclopenthixol, (used to treat mental illness)<br />&bull; pentamidine (used to treat infection)<br />&bull; Vitamin K antagonists and dabigatran often referred to as &lsquo;blood thinners&rsquo;<br />&bull; Cyclosporine and tacrolimus (used to treat transplant rejection), digoxin (used to treat irregular<br />heart rate), and metformin (used to control your blood sugar)<br />&bull; Proton pump inhibitors (used to treat heartburn)<br />You will also find this information in the Patient Alert Card you have been given by your doctor. It is<br />important that you keep this Alert Card and show it to your partner or caregivers.<br /><strong>Pregnancy and breast-feeding:</strong><br />Talk to your doctor before taking Caprelsa if you are pregnant or trying to become pregnant. This is<br />because Caprelsa may harm an unborn child. Your doctor will discuss with you the benefits and risks<br />of taking Caprelsa during this time.<br />&bull; If you may become pregnant you must use effective contraception when you are taking Caprelsa<br />and for at least four months after the last dose of Caprelsa.<br />You must not breast-feed during treatment with Caprelsa for the safety of your baby.<br /><strong>Driving and using machines:</strong><br />Use caution before driving or using machines. Keep in mind Caprelsa may make you feel tired, weak,<br />or cause blurred vision.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Caprelsa exactly as your doctor has told you. Check with your doctor or pharmacist if<br />you are not sure.</p><p>&bull; The usual dose is one 300 mg tablet each day.<br />&bull; Take Caprelsa about the same time each day.<br />&bull; Caprelsa may be taken with or without food.<br /><strong>If you have trouble swallowing the tablet:</strong><br />If you have trouble swallowing the tablet, you can mix it with water as follows:<br />&bull; Take half a glass of still (non-carbonated) water. Only use water, do not use any other liquids.<br />&bull; Put the tablet into the water.<br />&bull; Stir the tablet until it has dispersed into the water. This may take about 10 minutes.<br />&bull; Then drink it straight away.<br />To make sure there is no medicine left, refill the glass halfway with water and drink it.<br /><strong>If you get side effects:</strong><br />If you get side effects always tell your doctor. Your doctor may tell you to take Caprelsa at a lower<br />dose (such as two 100 mg tablets or one 100 mg tablet). Your doctor may also prescribe other<br />medicines to help control your side effects. The side effects of Caprelsa are listed in Section 4.<br /><strong>If you take more Caprelsa than you should:</strong><br />If you take more Caprelsa than you have been prescribed, talk to a doctor or go to a hospital straight<br />away.<br /><strong>If you forget to take Caprelsa:</strong><br />What to do if you forget to take a tablet depends on how long it is until your next dose.<br />&bull;<strong> If it is 12 hours or more until your next dose:</strong> Take the missed tablet as soon as you<br />remember. Then take the next dose at the normal time.<br />&bull; <strong>If it is less than 12 hours until your next dose:</strong> Skip the missed dose. Then take the next dose<br />at the normal time.<br />Do not take a double dose (two doses at the same time) to make up for a forgotten tablet.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>effects, your doctor may tell you to take Caprelsa at a lower dose. Your doctor may also prescribe<br />other medicines to help control your side effects.<br /><strong>Tell your doctor straight away if you notice any of the following side effects &ndash; you may need<br />urgent medical treatment:</strong><br />&bull; Fainting, dizziness or heart rhythm changes. These may be signs of a change in the electrical<br />activitiy of your heart. They are seen in 8% of people taking Caprelsa for medullary thyroid<br />cancer. Your doctor may recommend you take Caprelsa at a lower dose or stop taking Caprelsa.<br />Caprelsa has uncommonly been associated with life-threatening changes in heart rhythm.<br />&bull; Severe skin reactions affecting large areas of your body. The signs may include redness, pain,<br />ulcers, blisters and shedding of the skin. The lips, nose, eyes and genitals may also be affected.<br />These may be common (affecting less than 1 in 10 people) or uncommon (affects less than 1 in<br />100 people) depending on the type of skin reaction.<br />&bull; Severe diarrhoea.<br />&bull; Serious breathlessness, or sudden worsening breathlessness, possibly with a cough or a high<br />temperature (fever). This may mean that you have an inflammation of the lungs called<br />&lsquo;interstitial lung disease&rsquo;. This is uncommon (affects less than 1 in 100 people) but can be<br />life-threatening.</p><p>&bull; Seizures, headache, confusion or finding it difficult to concentrate. These may be signs of a<br />condition called RPLS (Reversible Posterior Leukoencephalopathy Syndrome). These usually<br />go away when Caprelsa is stopped. RPLS is uncommon (affects less than 1 in 100 people).<br />Tell your doctor straight away if you notice any of the side effects above.<br /><strong>Other side effects include:<br />Very common (affects more than 1 in 10 people):</strong><br />&bull; Diarrhoea. Your doctor may prescribe a medicine to treat this. If it gets severe, tell your doctor<br />straight away.<br />&bull; Abdominal pain.<br />&bull; Skin rash or acne.<br />&bull; Depression.<br />&bull; Tiredness.<br />&bull; Feeling sick (nausea).<br />&bull; Upset stomach (dyspepsia).<br />&bull; Nail disorders.<br />&bull; Being sick (vomiting).<br />&bull; Loss of appetite (anorexia).<br />&bull; Weakness (asthenia).<br />&bull; High blood pressure.Your doctor may prescribe a medicine to treat this.<br />&bull; Headache.<br />&bull; Fatigue.<br />&bull; Trouble sleeping (insomnia).<br />&bull; Inflammation of the nasal passages.<br />&bull; Inflammation of the main air passages to the lungs.<br />&bull; Upper respiratory tract infections.<br />&bull; Urinary tract infections.<br />&bull; Numbness or tingling of the skin.<br />&bull; Abnormal sensation of the skin.<br />&bull; Dizziness.<br />&bull; Pain.<br />&bull; Swelling caused by excess fluid (oedema).<br />&bull; Stones or calcium deposits in the urinary tract (nephrolithiasis).<br />&bull; Blurred vision, including mild changes in the eye which can lead to blurred vision (corneal<br />opacity).<br />&bull; Sensitivity of the skin to sunlight. While you are taking Caprelsa, protect yourself when you go<br />outside by always using sun cream and wearing clothes to avoid exposure to the sun.<br /><strong>Common (affects less than 1 in 10 people):</strong><br />&bull; Dehydration.<br />&bull; Severe high blood pressure.<br />&bull; Weight loss.<br />&bull; Stroke or other conditions where the brain may not get enough blood.<br />&bull; A type of rash that affects the hands and feet (hand foot syndrome).<br />&bull; Sore mouth (stomatitis).<br />&bull; Dry mouth.<br />&bull; Pneumonia.<br />&bull; Toxins in the blood as a complication of infection.<br />&bull; Flu.<br />&bull; Inflammation of the urinary bladder.<br />&bull; Inflammation of the sinuses.</p><p>&bull; Inflammation of the voice box (larynx).<br />&bull; Inflammation of a follicle, especially a hair follicle.<br />&bull; Boil.<br />&bull; Fungal infection.<br />&bull; Kidney infection.<br />&bull; Loss of body fluid (dehydration).<br />&bull; Anxiety.<br />&bull; Tremor.<br />&bull; Drowsiness.<br />&bull; Fainting.<br />&bull; Feeling unsteady.<br />&bull; Increased pressure in the eye (glaucoma).<br />&bull; Coughing up of blood.<br />&bull; Inflammation of the lung tissue.<br />&bull; Difficulty swallowing.<br />&bull; Constipation.<br />&bull; Inflammation of the lining of the stomach (gastritis).<br />&bull; Gastrointestinal bleeding.<br />&bull; Gallstones (cholelithiasis).<br />&bull; Painful urination.<br />&bull; Kidney failure.<br />&bull; Frequent urination.<br />&bull; Urgent desire to urinate.<br />&bull; Fever.<br />&bull; Nose bleed (epistaxis).<br />&bull; Dry eye.<br />&bull; An irritation of the eyes (conjunctivitis).<br />&bull; Visual impairment.<br />&bull; Halo vision.<br />&bull; Seeing flashes of light (photopsia).<br />&bull; Disorder of the cornea of the eye (keratopathy).<br />&bull; A type of diarrhoea (colitis).<br />&bull; Loss of hair from the head or body (alopecia).<br />&bull; Changes in taste of foods (dysgeusia).<br /><strong>Uncommon (affects less than 1 in 100 people):</strong><br />&bull; Heart failure.<br />&bull; Inflammation of the appendix (appendicitis).<br />&bull; Bacterial infection.<br />&bull; Inflammation of the diverticula (small bulging pouches that can form in your digestive system).<br />&bull; Bacterial skin infection.<br />&bull; Abdominal wall abscess.<br />&bull; Malnutrition.<br />&bull; Involuntary muscle contraction (convulsions).<br />&bull; Rapidly alternating muscular contraction and relaxation (clonus).<br />&bull; Swelling of the brain.<br />&bull; Clouding of the lens of the eye.<br />&bull; Heart rate and rhythm disorders.<br />&bull; Loss of heart function.<br />&bull; Failure of the lungs to function properly.<br />&bull; Pneumonia that happens when you breathe in foreign matter into your lungs.<br />&bull; Bowel obstruction.</p><p>&bull; Hole in your bowel.<br />&bull; Inability to control your bowel movements.<br />&bull; Abnormal color of urine.<br />&bull; Lack of urine.<br />&bull; Inability to heal properly.<br />&bull; Inflammation of the pancreas (pancreatitis).<br />&bull; Blistering of skin (bullous dermatitis).<br /><strong>The following side effects may be shown in tests that may be carried out by your doctor:</strong><br />&bull; Protein or blood in your urine (shown in a urine test).<br />&bull; Heart rhythm changes (shown in an ECG). Your doctor may tell you to stop taking Caprelsa or<br />take Caprelsa at a lower dose.<br />&bull; Abnormalities in your liver or pancreas (shown in blood tests). These do not usually cause<br />symptoms but your doctor may want to monitor them.<br />&bull; Decreased levels of calcium in your blood. Your doctor may need to prescribe or change your<br />thyroid hormone treatment.<br />&bull; Decreased levels of potassium in your blood.<br />&bull; Increased levels of calcium in your blood.<br />&bull; Increased levels of glucose in your blood.<br />&bull; Decreased levels of sodium in your blood.<br />&bull; Decrease in thyroid function.<br />&bull; Increased levels of red cells in your blood.<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please<br />tell your doctor or pharmacist <strong>straight away.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use Caprelsa after the expiry date which is stated on the blister and the carton after EXP. The<br />expiry date refers to the last day of the month.<br />Do not store above 30&deg;C.<br />Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose<br />of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Caprelsa contains:<br />&bull; The active substance is vandetanib. Each tablet contains 300 mg of vandetanib.<br />&bull; The other ingredients are calcium hydrogen phosphate dihydrate, microcrystalline cellulose,<br />crospovidone (type A), povidone (K29-32), magnesium stearate, hypromellose, macrogol and<br />titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Caprelsa 300 mg is a white oval-shaped film-coated tablet with “Z300” imprinted on one side.
Caprelsa comes in blister packs of 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong><br />AstraZeneca AB, S-151 85 S&ouml;dert&auml;lje, Sweden</p><p><strong>Manufacturer</strong>:<br />IPR Pharmaceuticals Inc, Street188 Lot 17 San Isidro, Industrial Park, Canovanas, Puerto Rico.<br />Packaging at AstraZeneca UK Limited, Macclesfield, Cheshire, SK10 2NA, United Kingdom</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May, 2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يستخدم كابريلسا لعلاج سرطان الغدة الدرقية النخاعي الذي لا يمكن إزالته عن طريق الجراحة أو قد<br />انتشر إلى أجزاء أخرى من الجسم.</p><p>يعمل كابريلسا عن طريق إبطاء نمو الأوعية الدموية الجديدة في الأورام )السرطان(. هذا يقطع إمداد<br />الأكسجين والمواد الغذائية إلى الورم. قد يعمل أيضا كابريلسا مباشرة على الخلايا السرطانية لقتلها أو<br />إبطاء نموها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول كابريلسا :</strong><br />- إذا كنت تشكو من حساسية )فرط الحساسية( لفانديتانيب أو أي من المكونات الأخرى للكابريلسا<br />)المذكورة في قسم 6(.<br />- إذا كان لديك مشكلة في القلب والتي كنت قد ولدت بها وتدعى المتلازمة الخلقية لإستطالة موجة<br />QTc &quot;. ويتضح هذا على رسم مخطط كهربية القلب ) .)ECG<br />- إذا كن ت تمارسين الرضاعة الطبيعية.<br />- إذا كنت تتناول أي من الأدوية التالية: الزرنيخ، السيسابرايد )المستخدم في علاج حرقة المعدة(،<br />إريثرومايسين عن طريق الوريد وموكسيفلوكساسين )المستخدمة لعلاج العدوى(، تورميفين )المستخدم<br />في علاج سرطان الثدي(، ميزولاستين )المستخدم لعلاج الحساسية(، وصنف IA و III من مضادات<br />اضطرابات نبضات القلب )تستخدم للسيطرة على ضربات القلب(.<br />لا تتناول كابريلسا إذا كان أي بند مما سبق ذكره ينطبق عليك. إذا كنت غير متأكد، تحدث مع طبيبك.<br /><strong>الإحتياطات عند الاستعمال:</strong><br />- حساسية لأشعة الشمس:<br />بعض الناس الذين يتناولون كابريلسا يصبحون أكثر حساسية لأشعة الشمس. مما قد يسبب حروق<br />الشمس. أثناء تناولك لكابريلسا، قم بحماية نفسك عندما تذهب للخارج باستخدام دائم للواقي من<br />الشمس وارتداء الملابس لتجنب التعرض لأشعة الشمس.<br />- متابعة حالة الدم والقلب.<br />يجب على طبيبك أو الممرضة إجراء فحوصات للتحقق من مستويات البوتاسيوم في الدم لديك،<br />والكالسيوم، والمغنيسيوم، والهرمون المحفز للغدة الدرقية ) TSH (، وكذلك النشاط الكهربائي لقلبك<br />باختبار يسمى رسم مخطط كهربية القلب ) ECG (. يجب أن يتم إجراء الفحوصات التالية لك:<br /> قبل البدء بتناول كابريلسا.<br /> أثناء تناولك لكابريلسا بانتظام.<br /> بعد اسبوع و 3 أسابيع و 6 أسابيع من بداية تناولك لكابريلسا .<br /> بعد 12 أسبوعا من بداية تناولك لكابريلسا .</p><p>كل 3 أشهر بعد ذلك.<br /> إذا قام طبيبك أو الصيدلي بتغيير جرعة كابريلسا .<br /> إذا بدأت بتناول الأدوية التي تؤثر على قلبك.<br /> وفقا لتعليمات طبيبك أو الصيدلي .<br /><strong>تناول أدوية أخرى:</strong><br />يجب عليك إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية، بما في ذلك الأدوية التي<br />تشتريها بدون وصفة طبية والأدوية العشبية. وذلك لأن كابريلسا يمكن أن يؤثر على طريقة عمل بعض<br />الأدوية وبعض الأدوية يمكن أن يكون لها تأثير على كابريلسا.<br /><strong>أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</strong><br /> الايتراكونازول، الكيتوكونازول، ريتونافير، كلاريثروميسين، ريفامبيسين و موكسيفلوكساسين<br />)الأدوية المستخدمة لعلاج العدوى(<br /> كاربامازبين والفينوباربيتال )التي تستخدم للسيطرة على التشنجات(<br /> أوندانسيترون )الذي يستخدم لعلاج الغثيان والقيء(<br /> سيسابرايد )يستخدم لعلاج حرقة القلب(، بيموزاد )يستخدم لعلاج الحركات الغير منضبطة<br />والمتكررة من الجسم، والنوبات اللفظية( وهالوفانترين ولوميفانترين )التي تستخدم لعلاج<br />الملاريا(<br /> الميثادون )يستخدم لعلاج الإدمان(، هالوبيريدول، الكلوربرومازين، سلبيرايد، أميسلبرايد، و<br />زوكلوبينثيكسول )والتي تستخدم لعلاج المرض العقلي(<br /> البنتاميدين )المستخدم لعلاج العدوى(<br /> مضادات فيتامين ك و دابيجاتران والتي غالبا ما يشار إليها باسم &quot; مسيلات الدم &quot;<br /> السيكلوسبورين و التاكروليموس )المستخدم في علاج رفض الزراعة(، الديجوكسين )الذي<br />يستخدم لعلاج دقات القلب الغير منتظمة(، والميتفورمين )يستخدم للسيطرة على نسبة السكر<br />في الدم(<br /> مثبطات مضخة البروتون )التي تستخدم لعلاج حرقة المعدة(<br />ايضا سوف تجد هذه المعلومات في بطاقة تنبيه المرضى التي أعطيت لك من قبل الطبيب. من المهم<br />أن تحافظ على بطاقة التنبيه هذه وتعرضها لشريك حياتك أو من يقوم على رعايتك.<br /><strong>الحمل والرضاعة الطبيعية:</strong></p><p>تحدثي مع طبيبك قبل تناول كابريلسا إذا كن ت حاملا أو تحاولي أن تصبحي حاملا. وذلك لأن كابريلسا قد<br />يضر الطفل الذي لم يولد بعد. سوف يناقش طبيبك معك فوائد ومخاطر تناول كابريلسا خلال هذه<br />الفترة.<br />* إذا كن ت عرضة لأن تصبحي حاملا يجب عليك استخدام وسائل منع الحمل الفعالة عند تناولك<br />لكابريلسا ولمدة لا تقل عن أربعة أشهر بعد آخر جرعة من كابريلسا .<br />يجب أن لا تمارسي الرضاعة الطبيعية أثناء العلاج بكابريلسا من أجل سلامة طفلك.<br /><strong>القيادة واستخدام الآليات:</strong><br />يجب توخي الحذر قبل القيادة أو استخدام الآلات. يجب الأخذ في الاعتبار أن كابريلسا قد يجعلك تشعر<br />بالتعب، والضعف، أو قد يسبب عدم وضوح الرؤية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول كابريلسا تماما كما قال لك طبيبك. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.<br /> الجرعة المعتادة هي 300 ملجم كل يوم.<br /> تناول كابريلسا في الوقت نفسه تقريبا كل يوم.<br /> يمكن أن تتناول كابريلسا مع أو بدون الطعام.<br /><strong>إذا كان لديك صعوبة في بلع القرص:</strong><br />إذا كان لديك صعوبة في بلع القرص، يمكنك مزجه مع الماء على النحو التالي:<br /> تناول نصف كوب من الماء )غير المياه الغازية(. فقط استخدام الماء العادي، ولا تستخدم أي<br />سوائل أخرى.<br /> ضع القرص في الماء.<br /> قم بتحريك القرص حتى يذوب في الماء. قد يستغرق ذلك حوالي 10 دقائق.<br /> ثم اشرب على الفور.<br />للتأكد من عدم وجود بقايا من الدواء، أعد تعبئة الكأس لمنتصفه بالماء واشربه.<br /><strong>إذا تعرضت للآثار الجانبية:</strong><br />اذا تعرضت للآثار الجانبية فاخبر الطبيب دائما. فقد يطلب منك طبيبك أن تتناول كابريلسا بجرعة أقل<br />)مثل قرصين 100 ملجم أو 100 ملجم حبة واحدة(. قد يصف الطبيب أيضا أدوية أخرى للمساعدة في<br />السيطرة على الآثار الجانبية الخاصة بك. سيتم سرد الآثار الجانبية للكابريلسا في القسم 4.</p><p><strong>إذا كنت تتناول أكثر مما يجب من كابريلسا :</strong><br />إذا كنت تتناول من كابريلسا أكثر مما تم وصفه لك، فتحدث إلى الطبيب أو عليك الذهاب إلى المستشفى<br />على الفور.<br /><strong>إذا كنت قد نسيت أن تتناول كابريلسا :</strong><br />ما يجب عليك فعله إذا كنت قد نسيت أن تتناول الجرعة يعتمد ذلك على المدة التي انقضت إلى وقت<br />الجرعة التالية.<br /> إذا كانت المدة 12 ساعة أو أكثر حتى يحين وقت تناول الجرعة التالية: تناول الحبة المنسية<br />حالما تتذكر. ثم تناول الجرعة التالية في الوقت العادي.<br /> إذا كانت المدة أقل من 12 ساعة حتى يحين وقت تناول الجرعة التالية: تخطي الجرعة<br />الفائتة. ثم تناول الجرعة التالية في الوقت العادي.<br />لا تأخذ جرعة مضاعفة )جرعتين في نفس الوقت( للتعويض عن القرص المنسي.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يتسبب كابريلسا في آثار جانبية، وإن لم يتعرض لها الجميع. إذا ظهرت<br />لديك الآثار الجانبية، فقد يطلب منك طبيبك أن تتناول كابريلسا بجرعة أقل. قد يصف لك الطبيب أيضا<br />أدوية أخرى للمساعدة في السيطرة على الآثار الجانبية الخاصة بك.<br /><strong>أخبر طبيبك فورا إذا لاحظت أي من التأثيرات الجانبية التالية - قد تحتاج إلى علاج طبي عاجل:</strong><br /> الإغماء، الدوخة، أو التغير في إيقاع القلب. قد تكون هذه علامات على التغير في نشاط<br />كهربائية قلبك. لوحظ حدوث ذلك في 8٪ من الأشخاص الذين يتناولون كابريلسا لعلاج<br />سرطان الغدة الدرقية النخاعي. قد يوصي طبيبك بأن تتناول كابريلسا بجرعة أقل أو أن<br />تتوقف عن تناول كابريلسا. وقد ارتبط وبشكل غير مألوف تناول كابريلسا بحدوث تغيرات في<br />ضربات القلب قد تهدد الحياة.<br /> ردود الفعل الجلدية الحادة والتي قد تصيب مناطق واسعة من الجسم. قد تشمل العلامات<br />حدوث احمرار، ألم، قرحة، وظهور بثور وتقشر الجلد. ويمكن أيضا أن تؤثر على الشفاه<br />والأنف والعينين والأعضاء التناسلية. . قد تكون هذه شائعة )التي تؤثر على أقل من مريض<br />واحد من بين 10 أشخاص( أو غير شائعة )تؤثر على أقل من مريض واحد من بين 100<br />شخص( تبعا لنوعية ردة فعل الجلد.<br /> الإسهال الشديد.<br /> ضيق التنفس الشديد، أو التدهور المفاجيء في ضيق التنفس، ربما مع سعال أو ارتفاع في<br />درجة الحرارة )الحمى(. وهذا قد يعني أن لديك التهاب في الرئتين يسمى &quot;مرض الرئة</p><p>الخلالي&quot;. وهو غير شائع )يؤثر في أقل من مريض واحد من بين 100 شخص( ولكن يمكن<br />أن يهدد الحياة.<br /> التشنجات، الصداع، الارتباك أو صعوبة في التركيز. قد تكون هذه دلائل على وجود حالة<br />تسمى RPLS )متلازمة اعتلال بيضاء الدماغ الخلفي الإنعكاسية(. هذه عادة ما تزول عند<br />إيقاف كابريلسا. .هذه المتلازمة غير شائعة )تؤثر في أقل من مريض واحد من بين 100<br />شخص(.<br />أخبر طبيبك فورا إذا لاحظت أي من الآثار الجانبية المذكورة أعلاه.<br /><strong>الآثار الجانبية الأخرى تشمل ما يلي:<br />شائعة جدا )تؤثر على أكثر من مريض واحد من بين كل 10 أشخاص(:</strong><br /> الإسهال. قد يصف لك الطبيب دواء لعلاج ذلك. إذا أصبح شديدا، فأخبر طبيبك على الفور.<br /> آلام في البطن.<br /> طفح جلدي أو حب الشباب.<br /> الاكتئاب.<br /> التعب.<br /> الشعور بالغثيان )الغثيان(.<br /> اضطراب في المعدة )عسر الهضم(.<br /> اضطرابات الأظافر.<br /> الشعور بالمرض )القيء(.<br /> فقدان الشهية )فقدان الشهية(.<br /> ضعف )وهن(.<br /> ارتفاع ضغط الدم. قد يصف لك طبيبك علاجا لذلك.<br /> الصداع.<br /> التعب.<br /> مشاكل في النوم )الأرق(.<br /> التهاب في الممرات الأنفية.</p><p>التهاب الممرات الهوائية الرئيسية في الرئتين.<br /> التهابات الجهاز التنفسي العلوي.<br /> التهابات المسالك البولية.<br /> خدر أو وخز الجلد.<br /> الإحساس غير الطبيعي للجلد.<br /> الدوخة.<br /> ألم.<br /> الانتفاخ الناتج عن تجمع السوائل الزائدة )وذمة(.<br /> الحصيات أو ترسبات الكالسيوم في المسالك البولية )تحصي الكلية(.<br /> عدم وضوح الرؤية، بما في ذلك تغيرات خفيفة في العين مما قد يؤدي إلى عدم وضوح<br />الرؤية )عتامة القرنية(.<br /> حساسية الجلد لأشعة الشمس. أثناء تناولك لكابريلسا، قم بحماية نفسك عندما تذهب للخارج<br />دائما باستخدام كريم واقي من الشمس وارتداء الملابس لتجنب التعرض لأشعة الشمس.<br /><strong>الشائعة )تؤثر في أقل من مريض واحد من بين 10 أشخاص(:</strong><br /> الجفاف.<br /> ارتفاع ضغط الدم الشديد.<br /> فقدان الوزن.<br /> السكتة الدماغية أو ظروف أخرى حيث قد لا يحصل الدماغ على كمية كافية من الدم.<br /> نوع من الطفح الجلدي الذي يؤثر على اليدين والقدمين )متلازمة اليد القدم(.<br /> تقرح الفم )التهاب الفم(.<br /> جفاف الفم.<br /> الالتهاب الرئوي.<br /> السموم في الدم نتيجة مضاعفات العدوى.<br /> انفلونزا.<br /> التهاب المثانة البولية.</p><p>التهاب في الجيوب الأنفية.<br /> التهاب الحنجرة )الحنجرة(.<br /> التهاب المسام، خصوصا بصيلات الشعر.<br /> دمامل.<br /> العدوى الفطرية.<br /> عدوى الكلى.<br /> فقدان السوائل في الجسم )الجفاف(.<br /> القلق.<br /> الرعشة.<br /> النعاس.<br /> الإغماء.<br /> الشعور بعدم الإستقرار.<br /> زيادة الضغط في العين )الجلوكوما(.<br /> سعال مصحوب بدم.<br /> التهاب في أنسجة الرئة.<br /> صعوبة في البلع.<br /> الإمساك.<br /> التهاب بطانة المعدة )التهاب المعدة(.<br /> النزيف المعوي.<br /> حصى في المرارة )تحص صفراوي(.<br /> التبول المؤلم.<br /> الفشل الكلوي.<br /> التبول المتكرر.<br /> الرغبة الملحة للتبول.<br /> حمى.</p><p>نزيف الأنف )الرعاف(.<br /> جفاف العين.<br /> تهيج العيون )التهاب الملتحمة(.<br /> ضعف البصر.<br /> هالة في الرؤية.<br /> رؤية ومضات من الضوء )ترائي الومضات(.<br /> اضطراب في قرنية العين )اعتلال القرنية(.<br /> نوع من الاسهال )التهاب القولون(.<br /> فقدان الشعر من الرأس أو الجسم )ثعلبة(.<br /> التغييرات في مذاق الأطعمة )خلل الذوق(.<br /><strong>غير شائعة )تؤثر في أقل من شخص واحد من بين 100 شخص(:</strong><br /> قصور في القلب.<br /> التهاب الزائدة الدودية )التهاب الزائدة الدودية(.<br /> عدوى بكتيرية.<br /> التهاب الرتوج )البروزات المنتفخة الصغيرة التي يمكن أن تتشكل في الجهاز الهضمي(.<br /> عدوى الجلد الجرثومية.<br /> خراج جدار البطن.<br /> سوء التغذية.<br /> تقلص العضلات غير الطوعي )التشنجات(.<br /> التناوب السريع لتقلص العضلات واسترخائها )رمع(.<br /> تورم في الدماغ.<br /> تغيم عدسة العين.<br /> اضطراب معدل وإيقاع ضربات القلب.<br /> فقدان وظيفة القلب.<br /> فشل الرئتين على العمل بشكل صحيح.</p><p>الالتهاب الرئوي الذي يحدث عندما تستنشق مواد غريبة في رئتيك.<br /> انسداد في الامعاء.<br /> ثقب في الأمعاء.<br /> عدم القدرة على التحكم في حركة الأمعاء لديك.<br /> لون البول غير طبيعي.<br /> قلة البول.<br /> عدم القدرة على التماثل للشفاء بشكل صحيح.<br /> التهاب البنكرياس )التهاب البنكرياس(.<br /> ظهور تقرحات في الجلد )التهاب الجلد الفقاعي(.<br /><strong>قد تظهر الآثار الجانبية التالية في الفحوصات التي يمكن القيام بها من قبل الطبيب الخاص بك:</strong><br /> بروتين أو دم في البول )كما هو موضح في فحص البول(.<br /> تغير ضربات القلب )كما يتضح في مخطط كهربية القلب(. قد يطلب منك طبيبك أن تتوقف عن<br />تناول كابريلسا أو قد يطلب منك أن تتناول كابريلسا بجرعة أقل.<br /> اضطرابات في الكبد أو البنكرياس )كما هو موضح في فحوصات الدم(. هذه عادة لا تسبب<br />الأعراض ولكن الطبيب قد يرغب في متابعتها.<br /> انخفاض مستويات الكالسيوم في الدم. قد يحتاج طبيبك إلى وصف أو تغيير علاج هرمون<br />الغدة الدرقية الخاص بك.<br /> انخفاض مستويات البوتاسيوم في الدم.<br /> زيادة مستويات الكالسيوم في الدم.<br /> زيادة مستويات الجلوكوز في الدم.<br /> انخفاض مستويات الصوديوم في الدم.<br /> انخفاض في وظيفة الغدة الدرقية.<br /> زيادة مستويات الخلايا الحمراء في الدم.<br />إذا حدث أي من الآثار الجانبية الخطيرة، أو إذا لاحظت أي آثار جانبية غير المدرجة في هذه النشرة،<br />يرجى إخبار الطبيب أو الصيدلي فورا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداْ عن متناول ومرأى الأطفال.<br />لا تستخدم كابريلسا بعد تاريخ انتهاء الصلاحية المدون على عبوة القرص والكرتون بعد كلمة .EXP<br />تاريخ الانتهاء يشير إلى اليوم الأخير من الشهر.<br />لا تقم بالتخزين فوق درجة حرارة 30 درجة مئوية.<br />لا تتخلص من الأدوية في مياه المجاري أو في النفايات المنزلية. اسأل الصيدلي حول كيفية التخلص<br />من الأدوية التي لم تعد مطلوبة. وهذه الإجرءات سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا يحتوي كابريلسا:<br /> المادة النشطة هي فانديتانيب. كل قرص يحتوي على 300 ملجم من فانديتانيب.<br /> المكونات الأخرى هي كالسيوم فوسفات الهيدروجين ثنائي الموه، سليلوز دقيق البلورات،<br />كروس بوفيدين )نوع A(، البوفيدون ) 32 - K29 (، مغنيسيوم ستيريت، هايبرميللوز، ماكروجول و<br />ثاني أكسيد التيتانيوم ) .)E171</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right"><strong>كيف تبدو أقراص كابريلسا وما محتويات العبوة:</strong><br />كابريلسا 300 ملجم هو قرص أبيض مستدير مغلف بغشاء رقيق مطبوع عليه &quot; Z300 &quot; على جانب<br />واحد.<br />تتوفر أقراص كابريلسا في علب من الاشرطة بها 30 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>المالك لحقوق التسويق:</strong><br />استرا زينيكا S-151 85 ،AB ,سودرتاليا في السويد.</p><p><strong>المصنع:</strong><br />شركة آي بي آر فارماسيوتيكالز , شارع 118 لوت 11 سان اسيدرو, اندستريال بارك,<br />كونوفاناس, بورتوريكو.<br />تمت التعبئة في استرا زينيكا البريطانية المحدودة، ماكليسفيلد، شيشاير، SK10 2NA ، المملكة المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Caprelsa 300 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 300 mg of vandetanib.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated (tablet)
Oval-shaped, biconvex, white film-coated tablets with ‘Z300’ impressed on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in<br />patients with unresectable locally advanced or metastatic disease.<br />For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a<br />possible lower benefit should be taken into account before individual treatment decision (see important<br />information in sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and supervised by a physician experienced in treatment of MTC and in the<br />use of anticancer medicinal products and experienced in the assessment of electrocardiogram (ECG).<br />Only one supply per prescription is allowed. For a further supply, a new perscription is required.<br /><u>Posology</u>:<br />The recommended dose is one 300 mg tablet once a day, taken with or without food at about the same<br />time each day.<br />If a dose is missed, it should be taken as soon as the patient remembers. If it is less than 12 hours to the<br />next dose, the patient should not take the missed dose. Patients should not take a double dose (two doses<br />at the same time) to make up for a forgotten dose.<br />Patients treated with Caprelsa must be given the patient alert card and be informed about the risks of<br />Caprelsa (see also package leaflet).<br /><u>Duration</u>:<br />Vandetanib may be administered until patients with MTC are no longer benefiting from treatment.<br /><u>Dose adjustments:</u><br />QTc interval should be carefully assessed prior to initiation of treatment. In the event of common<br />terminology criteria for adverse events (CTCAE) grade 3 or higher toxicity or prolongation of the ECG<br />QTc interval, dosing with vandetanib should be at least temporarily stopped and resumed at a reduced<br />dose when toxicity has resolved or improved to CTCAE grade 1 (see section 4.4). The 300 mg daily dose<br />can be reduced to 200 mg (two 100 mg tablets), and then to 100 mg if necessary. The patient must be<br />monitored appropriately. Due to the 19-day half-life, adverse reactions including a prolonged QTc<br />interval may not resolve quickly (see section 4.4).<br /><u>Special patient populations:</u></p><p>Paediatric population:<br />The safety and efficacy in children have not been established. Therefore, vandetanib is not indicated for<br />use in paediatric patients.<br /><u>Elderly</u>:<br />No adjustment in starting dose is required for elderly patients. There is limited clinical data with<br />vandetanib in patients with MTC aged over 75.<br /><u>Renal impairment:</u><br />A pharmacokinetic study in volunteers with mild, moderate and severe renal impairment shows that<br />exposure to vandetanib after single dose is increased up to 1.5, 1.6 and 2-fold respectively in patients with<br />mild, moderate (creatinine clearance &ge; 30 to &lt; 50 ml/min) and severe (clearance below 30 ml/min) renal<br />impairment at baseline (see section 5.2). Clinical data suggest that no change in starting dose is required<br />in patients with mild renal impairment. There is limited data with 300 mg in patients with moderate renal<br />impairment: the dose needed to be lowered to 200 mg in 5 out of 6 patients. The starting dose could be<br />reduced to 200 mg in patients with moderate renal impairment; safety and efficacy have however not been<br />established with 200 mg (see section 4.4). Vandetanib is not recommended for use in patients with severe<br />renal impairment since there is limited data in patients with severe renal impairment, and safety and<br />efficacy have not been established<br /><u>Hepatic impairment:</u><br />Vandetanib is not recommended for use in patients with hepatic impairment (serum bilirubin greater than<br />1.5 times upper limit of normal), since there is limited data in patients with hepatic impairment, and safety<br />and efficacy have not been established (see section 4.4).<br />Pharmacokinetic data from volunteers, suggests that no change in starting dose is required in patients with<br />mild, moderate or severe hepatic impairment (see section 5.2).<br /><u>Method of administration:</u><br />For patients who have difficulty swallowing, vandetanib tablets may be dispersed in half a glass of<br />non-carbonated drinking water. No other liquids should be used. The tablet is to be dropped in water,<br />without crushing, stirred until dispersed (approximately 10 minutes) and the resultant dispersion<br />swallowed immediately. Any residues in the glass are to be mixed with half a glass of water and<br />swallowed. The liquid can also be administered through nasogastric or gastrostomy tubes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients.
• Congenital long QTc syndrome.
• Patients with a QTc interval over 480 msec.
• Concomitant use of vandetanib with the following medicinal products known to also prolong the
QTc interval and/or induce Torsades de pointes: Arsenic, cisapride, erythromycine intravenous
(IV), toremifene, mizolastine, moxifloxacine, Class IA and III antiarrhythmics (see section 4.5).
• Breast-feeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In view of the associated risks, it is important to limit treatment with vandetanib to patients who are in<br />real need for treatment, i.e., with a symptomatic-aggressive course of the disease. Either symptomatic<br />disease or progressive disease alone is not enough to prompt the need of treatment with vandetanib. Rate</p><p>of change in biomarker levels such as of calcitonin (CTN) and/or carcinoembryonic antigen (CEA) as<br />well as the rate of change of tumor volume during watchful waiting might help to identify not only<br />patients in need for treatment but also the optimal moment to commence treatment with vandetanib.<br />Posterior reversible encephalopathy syndrome, PRES (Reversible posterior leukoencephalopathy<br />syndrome-RPLS):<br /><u>PRES is a syndrome of subcortical vasogenic oedema diagnosed by a MRI of the brain, has been<br />observed infrequently with vandetanib treatment in combination with chemotherapy. </u>PRES has also been<br />observed in patients receiving vandetanib as monotherapy. This syndrome should be considered in any<br />patient presenting with seizures, headache, visual disturbances, confusion or altered mental function.<br />Brain MRI should be performed in any patient presenting with seizures, confusion or altered mental<br />status.</p><p><u><strong>Rearranged during transfection (RET) status:<br />Patients without RET mutation may have a decreased benefit from vandetanib treatment and the<br />benefit/risk balance for this group of patients may therefore differ from that of the group with RET<br />mutations. For patients whose RET mutation status could be negative, a possible lower benefit<br />should be taken into account before individual treatment decisions and the use of vandetanib<br />should be carefully considered because of the treatment related risks. Therefore RET mutation<br />testing is recommended. When establishing RET mutation status, tissue samples should be obtained<br />if possible at the time of initiation of treatment rather than at the time of diagnosis (see sections 4.1<br />and 5.1).</strong></u></p><p><u>Skin reactions:</u><br />Rash and other skin reactions (including photosensitivity reactions and palmar-plantar<br />erythrodysaesthesia syndrome) have been observed in patients who have received vandetanib.<br />Mild to moderate skin reactions can be managed by symptomatic treatment, or by dose reduction or<br />interruption. More severe skin reactions (such as Stevens-Johnson syndrome) may require systemic<br />glucocorticosteroids and permanent discontinuation of vandetanib.<br />Care should be taken with sun exposure by wearing protective clothing and /or sunscreen due to the<br />potential risk of phototoxicity reactions associated with vandetanib treatment.<br /><u>Diarrhoea:</u><br />Diarrhoea is a disease related symptom as well as a known undesirable effect of vandetanib. Routine<br />anti-diarrhoeal agents are recommended for the treatment of diarrhoea. QTc and serum electrolytes should<br />be monitored more frequently. If severe diarrhoea (CTCAE grade 3-4) develops, vandetanib should be<br />stopped until diarrhoea improves. Upon improvement, treatment should be resumed at a reduced dose (see<br />sections 4.2 and 4.8).<br /><u>Haemorrhage:</u><br />Caution should be used when administering vandetanib to patients with brain metastases, as intracranial<br />haemorrhage has been reported.<br /><u>Heart failure:</u><br />Heart failure has been observed in patients who received vandetanib. Temporary or permanent<br />discontinuation of therapy may be necessary in patients with heart failure. It may not be reversible on<br />stopping vandetanib. Some cases have been fatal.<br /><u>Hypertension:</u></p><p>Hypertension, including hypertensive crisis, has been observed in patients treated with vandetanib.<br />Patients should be monitored for hypertension and controlled as appropriate. If high blood pressure<br />cannot be controlled with medical management, vandetanib should not be restarted until the blood<br />pressure is controlled medically. Reduction in dose may be necessary (see section 4.8).<br /><u>Patients with renal impairment:</u><br />Vandetanib is not recommended for use in patients with moderate or severe renal impairment since there<br />is limited data, and safety and efficacy have not been established (see sections 4.2, 5.1, and 5.2).<br /><u>Patients with hepatic impairment:</u><br />Vandetanib is not recommended for use in patients with hepatic impairment (serum bilirubin greater than<br />1.5 times upper limit of normal), since there is limited data in patients with hepatic impairment, and safety<br />and efficacy have not been established. Pharmacokinetic data from volunteers, suggests that no change in<br />starting dose is required in patients with mild, moderate or severe hepatic impairment (see sections 4.2<br />and 5.2).<br /><u>Alanine aminotransferase elevations:</u><br />Alanine aminotransferase elevations occur commonly in patients treated with vandetanib. The majority of<br />elevations resolve while continuing treatment, others usually resolve after a 1-2 week interruption in<br />therapy. Periodic monitoring of alanine aminotransferase is recommended.<br />Interstitial lung disease:<br />Interstitial Lung Disease (ILD) has been observed in patients receiving vandetanib and some cases have<br />been fatal. If a patient presents with respiratory symptoms such as dyspnoea, cough and fever, vandetanib<br />treatment should be interrupted and prompt investigation initiated. If ILD is confirmed, vandetanib should<br />be permanently discontinued and the patient treated appropriately.<br /><u>CYP3A4 inducers:</u><br />The concomitant use of vandetanib with strong CYP3A4 inducers (such as rifampicin, St Johns&rsquo;Wort,<br />carbamazepine, phenobarbital) should be avoided (see section 4.5).<br />CTN less than 500 pg/ml:<br />The benefit of vandetanib in patients with CTN less than 500 pg/ml has not been determined, therefore<br />use in patients with CTN &lt; 500 pg/ml should be carefully considered because of the treatment related<br />risks of vandetanib.<br /><u><strong>Patient Alert Card:</strong></u><br /><strong>All prescribers of Caprelsa must be familiar with the Physician Information and Management<br />Guidelines. The prescriber must discuss the risks of Caprelsa therapy with the patient. The patient<br />will be provided with the Patient Alert Card with each prescription.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetic interactions:</u><br />Effect of vandetanib on other medicinal products:<br />In vitro data suggest that vandetanib is a moderate CYP3A4 inducer. Therefore, since no clinical<br />interaction studies have been performed, caution should be made when vandetanib is combined with<br />CYP3A4 substrates, especially estroprogestatives, immunosuppressants like cyclosporine or tacrolimus,<br />or antineoplastic agents like docetaxel and bortezomib.</p><p>Vandetanib is a weak inhibitor of the efflux pump P-glycoprotein (P-gp). The co-administration of<br />vandetanib and medicinal products excreted by P-gp, such as dabigatran or digoxin may result in<br />increased plasma concentrations of these medicinal products. Patients receiving dabigatran or digoxin and<br />vandetanib may require increased clinical and biological surveillance and appropriate dose adjustments, if<br />needed.<br />Vandetanib is an inhibitor of the organic cation transporter 2 (OCT2) transporter. Therefore vandetanib<br />may have the potential to decrease the elimination of medicinal products known to be excreted by OCT2<br />and increase a patient&rsquo;s exposure to these medicinal products. Metformin is a substrate of OCT2 and<br />patients who are receiving vandetanib and metformin (or other substrate of OCT2) may require more<br />careful monitoring, and possible dose adjustment of metformin.<br />The effect of proton pump inhibitors on the gastrointestinal absorption of vandetanib has not been<br />determined. Vandetanib demonstrates pH dependent solubility; therefore the co-administration of<br />vandetanib with proton pump inhibitors may reduce a patient&rsquo;s exposure to vandetanib. The concomitant<br />use with these therapeutic classes is therefore not recommended.<br />Effect of other medicinal products on vandetanib:<br />In a clinical study performed with healthy volunteers, the co-administration of vandetanib (a single dose<br />of 300 mg) with itraconazole (repeated-doses of 200 mg, once daily), a potent CYP3A4 inhibitor,<br />increases vandetanib plasma exposure about 9%. Since the itraconazole dose was under the minimal<br />recommended dose to inhibit CYP3A4, (i.e 400 mg once day) caution should be made when itraconazole,<br />and other potent CYP3A4 inhibitors (e.g. ketocoanzole, ritonavir and clarithromycin) are combined with<br />vandetanib.<br />In a clinical study performed with healthy male subjects, the exposure to vandetanib was reduced by 40%<br />when given together with the potent CYP3A4 inducer, rifampicin. Therefore, administration of<br />vandetanib with rifampicin and other potent CYP3A4 inducers (e.g. carbamazepine, phenobarbital and St.<br />John&rsquo;s Wort) should be avoided (see section 4.4).<br />Pharmacodynamic interactions:<br />Biliary excretion of unchanged vandetanib is one of the excretion pathways for vandetanib. Vandetanib is<br />not a substrate of multidrug resistance protein 2 (MRP2), p-glycoprotein (Pgp) or breast cancer resistance<br />protein (BCRP).<br />Medicinal products known to prolong QTc interval:<br />Vandetanib has been shown to prolong the ECG QTc interval; Torsades de pointes have been<br />uncommonly reported. Therefore the concomitant use of vandetanib with medicinal products known to<br />also prolong the QTc interval and/or induce Torsades de pointes is either contraindicated or not<br />recommended depending on existing alternative therapies.<br />&bull; Combinations contraindicated (see section 4.3): Cisapride, erythromycine intravenous (IV),<br />toremifen, mizolastine, moxifloxacine, arsenic, Class I A and III antiarrhythmics<br />&bull; Combinations not recommended: Methadone, haloperidol, amisulpride, chlorpromazine, sulpiride,<br />zuclopenthixol, halofantrine, pentamidine and lumefantrine.<br />If there is no appropriate alternative therapy, not recommended combinations with vandetanib may be<br />made with additional ECG monitoring of the QTc interval, evaluation of electrolytes and further control<br />at onset or worsening of diarrhoea.</p><p>Results of a pharmacodynamic and pharmacokinetic interaction study indicated that co-administration<br />with ondansetron in healthy patients appeared to have little effect on the pharmacokinetics of vandetanib,<br />but had a small additive effect on the prolongation of the QTc interval of approximately 10 ms. Therefore,<br />the concomitant use of ondansetron with vandetanib is not-recommended. If ondansetron is administered<br />with vandetanib, closer monitoring of serum electrolytes and ECGs and aggressive management of any<br />abnormalities is required.<br /><u>Vitamin K antagonists:</u><br />Due to the increased thrombotic risk in patients with cancer, the use of anticoagulation is frequent. In<br />consideration of the high intra-individual variability of the response to anticoagulation, and the possibility<br />of interaction between vitamin K antagonists and chemotherapy, an increased frequency of the INR<br />(International Normalised Ratio) monitoring is recommended, if it is decided to treat the patient with<br />vitamin K antagonists.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential:</u><br />Women of childbearing potential must use effective contraception during therapy and for at least four<br />months following the last dose.<br /><u>Pregnancy:</u><br />There is a limited amount of data on the use of vandetanib during pregnancy. As expected from its<br />pharmacological actions, vandetanib has shown significant effects on all stages of female reproduction in<br />rats (see section 5.3).<br />Pregnancy category D:<br />&ldquo;Caprelsa can cause fetal harm when administered to a pregnant woman. If this drug is used<br />during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should<br />be apprised of the potential hazard to a fetus&rdquo;.<br />If vandetanib is used during pregnancy or if the patient becomes pregnant while receiving vandetanib, she<br />should be apprised of the potential for foetal abnormalities or loss of the pregnancy. Treatment should<br />only be continued in pregnant women if the potential benefit to the mother outweighs the risk to the<br />foetus.<br /><u>Breast-feeding:</u><br />There are no data on the use of vandetanib in breast-feeding women. Vandetanib and/or its metabolites is<br />excreted into milk in rats and found in plasma of pups following dosing to lactating rats (see section 5.3).<br />Breast-feeding is contraindicated while receiving vandetanib therapy.<br /><u>Fertility:</u><br />In rats, vandetanib had no effect on male fertility but impaired female fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies to establish the effects of vandetanib on ability to drive and use machines have been<br />conducted. However, fatigue and blurred vision have been reported and those patients who experience<br />these symptoms should observe caution when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>To report any side effect(s):<br />&bull; Saudi Arabia:</strong><br />- National Pharmacovigilance Center (NPC):<br />o Fax: +966-11-205-7662<br />o Call NPC at :<br />+966-11-2038222 Exts: 2317-2356-2353-2354-2334-2340<br />o Toll free: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC states:</p><p>&nbsp;</p><p>- Please contact the relevant competent authority.<br /><u>Overall summary of adverse drug reactions:</u><br />The most commonly reported adverse drug reactions have been diarrhoea, rash, nausea, hypertension, and<br />headache.<br /><u>Adverse drug reactions during clinical trials:</u><br />The following adverse reactions have been identified in clinical studies with patients receiving vandetanib<br />as treatment for MTC. Their frequency is presented in Table 1, adverse drug reactions using Council for<br />International Organizations of Medical Sciences (CIOMS III), listed by MedDRA System Organ Class<br />(SOC) and at the preferred term level and then by frequency classification. Frequencies of occurrence of<br />undesirable effects are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon<br />(&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1000); very rare (&lt; 1/10,000) and not known (cannot be<br />estimated from the available data). This section includes only data derived from completed studies where<br />patient exposure is known.</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM2MQAAkpIAAgAAAAM2MQAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNCAxMToyNzoxNwAyMDIxOjA2OjI0IDExOjI3OjE3AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjRUMTE6Mjc6MTcuNjEwPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAfkBhAMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiiuHcazqer+Kpk8R6zawaVeLDb2Om29m5ZRZwTEDzYWZmLSt1bHQcUAdxRXmGi6zLqlneXeoeMPFWg2tnObZ7jVk0iONpQ5RkDLEwyGGOcZyMZpJNejjXVB/wnniR7nS7xLS4tEj0ozDe6IsoXyP9WS45OD14zxTtrb+v61Dbc9QorhL9J7TQ9S1S18fa/qcemB/tMViulu6FBl15twAwHJBINJrq3Xh7wzJrl9438TvaxxrIUhtdPaTaeTx9m7DJPPQGkOzO8orzvWL6LQ9S0yxvviPrYm1IkxgDSx5cYRnMrhrcER4QjcARnFTrcWDoGT4u3TKVZgRPpZBCoHJ/wCPfoFIY+xB6UCO9orhFe0eEzJ8WrxohE0xcS6WVEanDPn7N90EEE9ARUPiK4/4RnRodSv/AIia48Vw6JbpEul7rgsQB5Ya3Afg54OcA4zQB6DRXn73umRSNHL8YLhHRmVla40oFSudwI+z8EYOfTFW4rdZ7y7tIfilqMlzZLvuoUbTC9uvq6/ZsqPc4oA7WiuGhNtcrGbf4sX0olR5IykultvVPvsMW3IHc9qbJJaxW8M7/Fi+EVxC88LCTTCJY1GWdP8ARvmAHUjNGwbnd0V5/pt1barHHJafFLUmjnnMFs4l0phcsFDHZtgJJAPKnDDHIxg1NbvaXio1p8Wb2dZJhAhil0tg0hGQgxbcsRzjrTsw3O6oriruBLC4mt774pajbTW8QnmjmbTEaOMnAdgbbIXPGTxWffX8FncaRAnxK1m8k1i4EFqLU6W5bqC+Ps4JQEYJXOCRSDY9ForhrkW9lcvb3nxXvreeOQRPFLJpasrldwUg22QSozj05piS2kpt/J+K+oTfaZvs8JibTHDybS23ItjzgZ//AF0Ad5RXns2o6TbRpJcfGOaJJF3I0lzpShhkjIJt+RlSPqD6VozafJbraNcfEzVYlvWC2pf+zVFwxGQEzbfMSOeM0AdjRXAtdaeqK7fF65CtL5CsZ9KwZP7g/wBH+97dadJLZQlhN8W7uMrM0DBptLGJAMlD/o/3hnkdaAO8orgfEch8L6fPcal8RNdMsVvJcrZxppnnzIgy5RGtxuwOalYQxySRz/FPUIZYfLEsUj6YrxGT7gYG24LdgevaiwHc0VyVno91qKytp/xG1i6WGRopDAunOEdeqnFtwR3HWrP/AAi+r/8AQ9+IP+/Gn/8AyLQB0lFc3/wi+r/9D34g/wC/Gn//ACLR/wAIvq//AEPfiD/vxp//AMi0AdJRXN/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDItAHSUVzf/CL6v/0PfiD/AL8af/8AItH/AAi+r/8AQ9+IP+/Gn/8AyLQB0lFc3/wi+r/9D34g/wC/Gn//ACLR/wAIvq//AEPfiD/vxp//AMi0AdJRXN/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDItAHSUVzf/CL6v/0PfiD/AL8af/8AItH/AAi+r/8AQ9+IP+/Gn/8AyLQB0lFc3/wi+r/9D34g/wC/Gn//ACLR/wAIvq//AEPfiD/vxp//AMi0AdJRXN/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDItAHSUVzf/CL6v/0PfiD/AL8af/8AItH/AAi+r/8AQ9+IP+/Gn/8AyLQB0lFc3/wi+r/9D34g/wC/Gn//ACLVnwVqF1q/gHw/qWoS+dd3mmW088m0Lvd4lZjgAAZJPAGKANuiiigArg9O1q903xX4xjtfDep6pGdWidp7SW1VFP2C0+U+bMjZGM9McjnrjvK5XQ4Tcar46hCoxk1VUCyZ2nOnWgwcc4pO9tBrc4eDS7TxD4Ru9NttE8Vanp95fTXj3EF9o7kSSBg6q6TYAy7H15xnGRUlz4Ra7ub2eTwz41El04cFbrSf3LbomYp+9/iMEed27ocYya1bXwlq9tfafZ3OoXkC/a3KQ2V1dNGtksSrsknUJuk3Ku0vlgCQCwBNM1fwP4vvY1On6x9jljW9ETnVrh2Qy7PLbcU5IxIMYwm4EAlaq9tV/W3/AA3yDWT1/rf+vmRWOhHS/C+q6HpvgzxVaw6q0hnnil0kS4cnIz52DwSMsGbB68DEXii+tZ9M0vSvFmha4luEMEUN/c6KBeSFNiuVkmwZFzldgAyeh6VR1b4d/EWW6B0vxHJ5aRxiOSfxFdo24RbcsiRbG+fDHgbscgbjXU+LfBusavqlzeaa2ny/2jpDaVcpeyOBbKzEmWPah3H5jlTtztX5hik1pb+tFp/l+IRfy/4LV/8AP5WMC38LywarpWoHw141mm02OKNfNutJIuBGsiJ5n77PCyuvylc55yRmom8FWhWzA8E+LN9nazWkMrXGlu6pJnBDNOSGUHCkY4GDuHFP8VeHfEOgeGtXmi1HX7rfcWsVkNInubmdYVjRX/cK8YUlkLZVh164JBt3PhLxpex3k+laxcRW13YQR2sN9qtxFNC6mI7n2q2xiFkDYySTyWB+Vv3r/wBdP6RKvFJf1uM1jw/JrukW+mX/AIT8XG1t7NLQIs+k/vAhUq75m+YgqOD8nJ+Xmna9oB13T9NtP+EN8V6emmwmCE2U+lLmMlDsKtOygZjQ8AYxxgcV3PhKx1XTPCtlZ+IJ1uNQhVlllW4ecN8x2/O6hmO3HJGa2abbuC2seNaxodvqVvB4Zu/DnjSK4uJ7zVYmiuNLEjByFnGTKV25uFGCN3zcE4OKPhLXb3T/ABN4ojvPDkKwajdG0hew1axe8EjNIRHIr3flo/LEIijJ3EgnJPp99/yVPQv+wLqX/o+xqrJ4T1BPGWrapY3kNvaX1orIm0l0vVRoxLjGMbCo9yB6czfv2/r8vvK3+/8Ar8Xc5F/B9tIbJ5PBHil5bHSxpcUskukuwjAIDfNMcOAzDjAOeQeMOg8K/ZrSe1h8K+NBDc2MthOpvdMPmxu7uMkz5yplfB9/m3VdsPBGv2VnZHxP4g1a7s7TTp1u2tNWu2uGnLqysoiVGkAAfHGfmC4bGTrHw5r8nw/sLK21Gd9RaWKa8a4v7iFpkGN8YlBaSLIA+73B9TVNt7v+m3/wWSm07r+rW/4BzEXg8LqEd5P4W8aXMqXP2g+ZdaUA5zGwU7Zh8oaGNuMHK4zgkU/RPDFxoQcWvh/xtJuuIrgmW40fIMZJCgrICAdxBxyQcZq7qPgvx1KdTNt4gDie7ilgQ6pcwDy1kLMuVUmL5CI9q5DY3n5qxV+HnxNXwuth/wAJGpu1lZvPPiG8zhrfy87/ACtx/ejzAvQdAepoT032/wCAPlV7Gnrvhxtf1XUNQufCXjCGbULR7SUQXOlBRG4QNgGY8/u15OT26AAVLLwa1he6ddQ+G/GzS2MwmJe50j9+wleUbx5vADSyfc28N7DF6z8E+Po7XTo5/ECr9mafeo1a5kOxnLKC5QGU7Tsy/KY3Lk8U/wAA+DfHeg+J0vPEmsreWRtzFLGdaubrc2yMBhHJGFB3JI2Qc/vMduSPrtsKTvox+sRavqF1M6+CfEU0d7cQPOst7p0Qt1ibcGjCTZZzgKdzdO/GCl5pNxf3huLvwn4uf/SZLgRC50tUXfC0TIAJx8pV2OfvZ53V6bRU9LD63PFJPh5F9ms4LTwz40so7SJY1W2k0VQ+194ZgXI3ZxnAGccgkknZuNA+1abodlN4N8WsmixLBC32vTA00alDsk/0jGMxIcqFPy9cEg+pUU7v9RWV7nhF/baxcWui3PhbwXfX1hpOp3kl5Prl3aRsjC5zKF8q4QNtkjfAf5PlU/NgES/8IppninT5Z9M0nxdcWt1O07S2N/o0iMzRtGcHzWAG1iMD+fNdlaaDL4l+GWraVb3C28k2s6kVZ1yhK6nM21h3U7cH2JqxrmgeLtYsbF7S7sdGvFud9xHY3UoTaFAVjIEUylcE7GVVIIB6ZIm/6+X9fmNmXrul3OvzXck/hTxhbG907+zrkW91pYEsWWIJ3TnDDe2CMDnkHiqv/CPXA1C7vk8NeM0uLtESV1uNJHCnIwPN+U5z8wweTz0xWsfAfxGtvEgvJ9dWS0DyAxHxBeMGRvOwNhj2ggSRAHPHlZHJ4ZovgD4lWUl0b3xGpE1k0GTrl3P8+yIAhXjGwlkkO9fmHm8Z28i73B9jrdJ1HVNJ+1bPB3ii4+0zmciafTAEJABChbhQBxn1JJJJzWj/AMJRq/8A0IniD/v/AKf/APJVcxp/hDx1aeLNEvZ9bSfT7WJFvIm1S4O/HnZHllNsnEkY3sQT5WTyePS6GI5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KrpKKQzm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+Sq6SigDm/8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+Sq6SigDm/8AhKNX/wChE8Qf9/8AT/8A5KrNl+JBt4tRluvCms20OmTLBeS3F1p8SQuUSQAs10B92VDnOPmx1yK7auIj0p9dh+I2lRSrE99f/Z1kYZCltNtBkj8aBxs2kyaw+IL6q0i6X4W1W9MQRpBbX2mybA67lJ23Zxkcj1HNXf8AhKNX/wChE8Qf9/8AT/8A5KrnvFHhjxvrfhqCPS7yz0rVBcFpRa6rcRRiPyDGv7xIwzndtfBUDjHvUeo+D/G95aX4h1xIbme5SSORNTuUBjEZGzAXEexyGyo/ebcNgE09LiWyudL/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVXD6h4E+Isviw39nr6m0W6EqI2u3cQZcw5BhWMpjEcvy5I/e/7IyaB4E+Iun+IIrq919RbiN43zrl3dDmORQwikjCkhmjPUfc9zS6XA7j/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KrjLfwR8Q7fUNGm/wCEgSSG1mDXMT6xcsCnmxsRzGfNyqyD58Y8zHRRXq9O2lxXd7WOb/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSq6SikM5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqukooA5v/AISjV/8AoRPEH/f/AE//AOSqPhx/ySzwp/2BbP8A9EJXSVzfw4/5JZ4U/wCwLZ/+iEoA6SiiigArk9FNyNS8d/YApuv7VXyQ/Tf/AGdabc+2cV1lcHpvhqw1jxZ4xuby41SJ01aJALPVrq1TAsLQ5KxSKpPPUjPTngUpaoa0ZhW82pweG9GnRPFrapFqFqdUFwt0ytIW/fYUAgx4B+4PKweOa1tF8X+LLy1tm1TSTaSvdSxOg0e6OY/LV436/KuSQSeSRgKDkDNtb3wgdPafUbzxHbzrE05hh1/VZv3YUurbg4GWQbsfh2q9pdv4ZvrXdPeeIkugNz28Gv6pKV6nH+sBJAHzADg8dxm97/12/wAvkTbVP+uv+Z2nh29vNR8P2t1qcRiunU+aptnt+QSMiNyWUHGQCc1p15vbL4Pubm5iTUPEy/Z2KnfreqAuQXB2jzfmA8p+R/dq1YWPg3U7ye2s9Y8QO9ujSSM2vamqKqkBjuMoXjI7980nqw2O+orzaeTwLbTmG41nxLG4baQ2s6qMf6s/89OmJYzntu+tXtK0LRNY1a9t7OfxA1raxxH7QfEmoje7gttCmUcBdhzk53ikM7uiub/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+gAvv8Akqehf9gXUv8A0fY10led3ngrS1+JOjW4utc2SaTfuSdfvi4KzWYGH87cB8xyAcHgkHaMUXt7GLWm0u4t9aiuEvPKOfFupESW+zcZY8Nl2HAMeBgkfMQQSdbB0uepUV51Zp4H1CxjvLTWvETwSRSTBzrWqrhY22uGBkBVgwI2nDHBwDVO5u/Bn2e5XTtQ8S3F7FbvKlvPrWrwKzKrtsZ2fCN+7cYPOVIxkEUbAtdj1GivM5LjwJBBayXOr+J4jdJM0anVtXJJiBMi/f8AvAKxx1IGQCKVp/AyRhpNR8YJmXydrX2tBg3y4yN2QDvTBPBLAAmjYFqel0V5pPJ4KTMdtqviSeU2oukI1nV/KKEKwJkV2C8OpI6gMMjmnWo8I3U8q/bPFMSRyeT+91fV1Zn81o+BvwVyh+YE4HUCnZ3sHS56TRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0gOkorm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+gA8B/8i7df9hrVf8A04XFdJXklpomn6N8PNT1hZNUla11XUQyy+J7+0iCLqEybmZHbGFGS20ljkk5JNS6VqHg27sYZNT1DxBYzSK7fJ4h1Sa3ZVMg3pOHCsjCJip4JGOOQKNw8z1aivNnk8DRxCR9W8UhfL8w/wDE01jIAEhII35DDyZAVPIK4IyQCqP4GkjkdNW8Ut5fVBqmsb2O4rhU37mIKkkKCQOTwQadmgPSKK83YeDHklhtNW8QzTx7Dg65qwRgzRjIYOQR+9Q5GQAwJwOa0tG0Pwtr63Z0rU/EUps7hra4V9e1ONo5FAJUq8oPQg56HPFFmB21FedXCeCLaJJJtX8TBX8zGNY1Zj8hwTgScAnhT/ESAucioi3gyXT7i4s9U8SSNDBJOVk1jV48BACd3zkqCCCOCSOQCKS12DrY9Korj7Dwt4e1MT/Y7/xE/wBnlMMmfEGpKA46gFphke44q5/wgekf8/niD/wo9Q/+P0AdJRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0AdJXN+F/8AkYvGf/Yaj/8ATfZ0f8IHpH/P54g/8KPUP/j9c3ofhHR01bxg9zea3HDaaog3Lr98nyixtXJYiYFj8x5bJwAM4AATdlcNz0iivJ9I1PwZf+GrfWL2+8Q20c9xPbqtv4h1O7XMROTvikIxsG/PTGeeCaupc+AZIZJRrfiUJG4Q79X1dTnLAkAyZKjy3yw+VdrZIxVWd7Ael0V5dqd14Ns9F1K8s9Q8SXU9irD7Mdb1dGkcb8KPnLYzE+WCkDaxPAq5BaeGZAyyXfiXztzKIodb1eUrtRWJfa/yj5sA8qeMEk4pB28z0WivMLeXwlM7q934njEMZeZ/7Z1cqf3cb/uju/ecSLxw3otdTH4H0aWNZEvPEBVwGB/4SPUBwf8AttTs0JNNXOmorm/+ED0j/n88Qf8AhR6h/wDH6P8AhA9I/wCfzxB/4Ueof/H6QzpKK5v/AIQPSP8An88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8foA6Sub+HH/JLPCn/YFs/wD0QlH/AAgekf8AP54g/wDCj1D/AOP0fDj/AJJZ4U/7Atn/AOiEoA6SiiigArlvD8CXWs+N4Jd2yXV0RtjFTg6faA4I5FdTXKaHDJcap46hhkEUkmqqiuy7gpOnWgBI7/Sk9hrcS78I6G0ENzEy2tpCDJcM7P8AvIwqAg5YADbEgOQflBxjOau6boOiSRW15YxXUQV3eLdNNEyhiCy7WIIQlQduMHAOK42T4dWK6tFp8E1pcs8YivEMSDyosQqo2l9wzHAwGFOSSTjArZj+HTJbRIb+BpYnL+ebQlpG2kKWBcqcE5wABnkYPNU+4lY1IvCfhmC0eRIx5BBLyNduVK4IYElvukZyOhqxb+GNCEN0kFqRHcwyW0y+a4DKXZnGM9dzt8w5564xXIt8NolvNMsZ9Y09hbLvhtXsRvkjR4ScfvM7QEC8DHz85JObrfDPztK+w3GqgoybXeO2Ck5jKOB83yqd8j4H8T5zgYJZW0BeZsTfD/w3d2tzBcWcsyXRzMXu5izHcrfe3ZGSik4PO0Vq6TodhoaTrp0cifaJBLKZJnkLNtC5yxPZQPwqHw3oSeHdLks4mjZWuZZwY49gAdywGMnoCBnvjNa1G2iEFFFFIZzd9/yVPQv+wLqX/o+xp1tovh3WhdSLBLdFL6YyG5km3Rz7DFJs3nKrtJGFwuDketNvv+Sp6F/2BdS/9H2NZGpfDK31DWLy9M9kUu7mOeSOfT/MLqsiuyud43fdwpx8odxhs0L4rPb/AIYd7LT+tzZTwF4cSGCL7A7pbiURiS6mfHm/fPLHJPPJ5GTjGax5PAuhWviM/wBoTTyW+pW4s7W1Et1uDKsrSO8okO52Dv8AOwDDnDHJrM1P4SSXOnywW+radb5laTzJNKL4BjdN5xMuZfnyZOMlE+UbeZdT+Gl1rWny/Zda0kC7uGujdHSPNeXejqrM4mG8r5h2MegCjBxkv+v6/EW2xpHwB4OlhEDW+pMRIwwdRvfNyzMpYnzN+0kt8x+XBY5wTnTuPBen6g1yNUMkiSeSkRtppreRI4smMNIkm9mDEndkZ444ycC0+GU9tfWl89/pL3kU4lkmXRyrEfaHnKxnziUyXK9W4xxW5o3ha50/RLzQ764s7zTZ0lVFW02FfMZsqV3EMoUgZPJOSeuAvsh9ry/q5lQ/CnSItcnumkk+xSWSWKwR3FykohUACMy+fynGfuhs/wARHFbEvgLw9ObjzrW5kW54lRr+4KH94ZDhd+B85J4A6kdOK4eP4Y38HicNdQWV7axWvnG7h06OJpJQR+5UtOSpY7ssVKlXZcgkmjS/hFfS6DoTT6nHpN3asJ7mzTT43iLeXGpXG9sMfL+Z1b5wzjgNiq6Xv/Wv9f8ADh1s/wCtEetgYGBRWX4a0SPw74bsdJi8gi1hVGeCDyVkbHL7cnBJ5PJ5PWtSk7X0EtgooopDOM8O6fZ6p4HvrXUluGt21vUiwtpJUfI1KcjBiIbqB0/HipfF/hzwrcSLqvie3vrkkLbiKCa7kEvDYX7PESH4Z/4TwTnis/T7OO++Ht7by3tnYhvEF+VnvIvMjVhqspUY3L8xYADnqR16VSs/hVe2uvJftqeiSRLeC8EB0JuHDSsCG+0cN++I3Y/gT05W4+hr6f8AD7wVqHhrTk0uxni0wWwNqLe8ubcmNstzh1Yk72+9z8zA9SKtQ/Dbw3AzskWos7j78msXbsvOcqWlJU57jBwSOhNcxd/B65uNP+zQa7Z2ztbLDJMmjqxkYLEpLBpCGU+QmUYEEZBPTFbUfhBPdzNat4h0lnubQRMLvRzJPOiJCjMxE67uY0OdvBI9jVu120Gh2Mnw48NSXkl19mvUkkABEeqXSIB8nCosgVR+7TgAfdHpWhpPhTTNDujNpQuYNxYyRm7kdJCQoyVZjyAoA9BwK5zwv4IuNA1WfVtK1LSpzcxQ2sqwWJhj2RFVIG2UjcoEgGeRkAk7eU1zw5ZyaxqETTafdanqZSeyi8iFbuBkIxKXd8vHGwBAC8ZYfNkCjqkiS3rPw38K3WLk2MEWpLJNLaXU7ySlJ5FwW27xv6AhM4+XjFNsPA3hqXSLKwuo7i8mjt2iknE9yjkvGocuS5ZGKEAB23BflHFY9x4J0C4uriKw1fQREs0Lw2c1nFMsUkYaAlgJAWYs4XqMMoHWpY/hU0Xmn7dpX761aGeT+yMPITDHHkt5vK5iDbTnOSM96laJjfxI7Gy8NadpuoSXtj9ohlmk8yf/AEmR1mbYEG4MTnAAx789Sa045VlDbQ42sVO5CvI9Mjke44rk7jTv+Eg8FT6Y+vabMqxQyQX8USyKqKqlZXTdtOWR2H8PA9DWK/wwvLrXItSfVtGkgFw04VdFO9keQuy7/Px8wZgTtwQ7ccmm97C+zfqejyOI42dgxCgkhVLH8AOT9BUUd5BLMscTMzEEnCNhcYyGOMK3zD5Tg9eODXn8Pwsu4bUQjWNPOI5I+dIyGV7dYSpBlPBKKxxgnGM06T4Vu0l48V/pcTXUEiO6aR8zO/knex835wGhyFI/iwT3JpcfY9FrkdI0+31XVPG1neeb5MmsxbxFM8THFhZnG5CDjjkZ5HB4rpNOivIbYxX8sMzI22N4kK7kAGCwz97OenFcra6WNbk8f6azxoLnVEj3SR+Yozp9nyVyNw9s80npqgjruP1PwDpera0l1b3MkaC+NzqNuLmdvPfyTGF4lAj+VhkAEMMAgiqEfw68LvbjQfFEC6vdXlxLqCFknVAFlLBV+dggXzsbAwDZJ28mqMfw+sdU1C21PT9a0q9khmiv2e3sY2knIRI871kAw3kyL/d+dhztzVDQfhRqo0LSXkudN0m5g2Sy2j6UJPLdTHtYFLjb5mIgC4znPRcYqlp/X9bW/DoH9fn/AF8/I6ix8AeDdU0+ae0t76SG8Zg7PqN4rAqzhgN0gZOXkBAxncwPBrSi8BaBCxaOG9DEsSx1O5LNuUKQSZMkYVcDoCARg81hJ8PHnvnkl123e5jjmjeS3s9k0Jl8whVbzCVTEuShzuKKcjpTLrwPaWaLHe6rodlvsWhRBpaQqgQ73EYMnywEcyR87u7DmpDqjfXwB4eUALb3YUQmDb/aNxtKmNYzkeZgnYijd14znPNXNJ/s3Sre8sLB7po9PZVeF0lkMQ2KVVMgll24xtzzkdc1ysnw5ieI2B1HS3aXTzAI5tMWRkTflliBkykHzBfLHTCfMMc3LPwFe2nhG+0P+17WUT28FvBNLYM3lCJAuWUy/OflBHK4PrT7v+t/6+8R1epanbaTZm6vWkEYYKBFC8rsxOAFRAWY+wBqy0qJCZZGCRqu5mf5Qo9TnpXlM/w5TShI+ueI/D0EdxdLdDzNJ8lQ0bTSsybrg4cLI3zfwqg4OKnsfhhBpOjxW+r+ItPvreVJbdJbzTIlCmb5VEGGCxs27DYBMhPYml0/r+tytLrsemxTpPv8vdhG2klCAeAcgkcjnqMj8qkrziP4exNbWa/2xo4jN20lqkGm7IhlE/1K+cdsoEJO8E/KzjbzmtbwT4N1Lwcj2wvtNuLSZ1aRLbT2tiu2MICB5rgk7VyeKehOvU7Gub+HH/JLPCn/AGBbP/0QldJXN/Dj/klnhT/sC2f/AKISkM6SiiigArktIW7e/wDHiaY8cd42qKIHk+6r/wBnWm0n2zXW1zfhf/kYvGf/AGGo/wD032dA1ozBj8IeJheXlz9sjhkuVkCsmoysUJWNYzymDtCOfq7YxnixN4S8R3cltFPrcsECy/v3tryYPJGHVlVc/dwqBSckt5jkn17qigR52vhDxU9/HNcahHtWFbdpEv5fNZMuXIYodpJ8k8dQmCT1OlZeFNYt9Qt7iXVbmTddtPco9/MybNzFI1U9gCvORnGCCOK7KincHqFFFFIAooooA5u+/wCSp6F/2BdS/wDR9jWFqHhTxhLqMd1perRWg/tdp5Y5tSuplNtkFdq/KAw+f92QU+bqdq43b7/kqehf9gXUv/R9jXOXvjPXrDxVJZWul3k1r9v2SOdDvpAYy8S7lk5QAK0hyPlPl5x81C1kl/W6B/D/AF2ZSbQfFx8SQWBu7ovFbSSm4Gp3qwFRM2xS2wo8jKSG6FQQyg7VqwPB3jWXS083UhBqAvYZmeLX7t08uOMDbzGB8zhiylcEN1yBWdo3ivxjp87wNoupXyXEUtzJfTaXdBI33kcRySlhtUDEKKN+cqR32b3xD4qg1iApbS38JjSSGGPR7qAM3kTElnDlVBcINkmSu4ZwcGnHRf13/r+rg9ZP+uhGfBPim3t5IbHUdieTcLH/AMTq6GC5k2j7p6l0bf8AeQptXIOa2/DeiT2msXZku9Te2hRVEd1eXMg89lHm7Wlb50G1SpAwCz4xyBh23jXxUdZs7WbTXlgmABlXw/exBs+YA5YkiIZEeVbJwTzyCN+28SaleeDLi5htZI9ct7Pz3tZtPlTccsABHu3fNsOFDFhkZ9CdBbtI5OP4feLrfSZbWx1FrWZHj+zyjxHfSDChizFWXC5YR5TDLjcMjv0dr4Y1ltRs7rUZlka21NrlmXVbkiSMxuoOwgKuNyjywNp2k55xWOfF3ia+uQv2KeO2guIRMh8P38byqboqSjhwMCMI54YdQRgkCqvxC8XkqF0SeTZcx+ax8OX6AwFiH25Od4A3jqDnbjOCRbf15Dep6rRXFaFrHi28m0r+0vsIj1CHznUaZNbSWwTG9WWSYtk7gAcDHcHjNC78ReM7W7voIkjl8o3Txk+H7qQBVkVYl3LIFfKtuyvJCnAJpf8AB/AD0SivO4PFHjC/sYneyOm3KizMsJ0W4lGGaPzmDlgCBucbANyhdxOCDXolNqwjh9Gs7zUPAGoW2nJA9w2uaiVE8pjTA1OZjlgrHoD2rMPhHxImq3lxreo3TaM889y4sNcvjPEpUhUjjRAxGVRtgY4JYAEHBsRT31v8KtafSZJo7v8AtfU1RoLWW4cZ1KcHakRD5wTyDx17VBD4k8VWdzFosNu4dZkt4bubQb+eMr5jrveQyHPyeU25n67sn+6krsrZXG3fh3xlEbDUbG6klaOBZbtZdYuY2Z8klVg2OhOz5QCfvHPUA1meHfC/izV/DMC6hPMM+YZvP1fUYmlbzYXTCzIJEAEbrk4wWJAINXZ/iB4ttoUEmj3D3CsPMSPw3fsrjy0JCspIB3+YoJJ4KnkDLT6h4o8SJbpqcGmalPexJchbOHSrlEQDZ8rKXCzMuCVbKB+ikZNO/Ld/1/X5CtdpGvo2leLNKvIbm6Nvdx+Q0UlsdUnlwTPlWUugB2xsckjcSAM45qHxD4U1++8TXuoaVMkMNxDBHgavcwM+zzM5CKQmC6sNud2wqcBjVm88QanqHw1vbm3gurDXV09ZHtxYyvJFI68ARqdxPsCSp69K56bxZ4o0KAafb2dzciHCR3DaBqNzvXghmbezE7WXq2cqwznhU97dgXw3XX/gGifC/i1dQjmibTxsuC7TrqM0buhuIpDlVhx8yRsCucfNjkUk3hXxcqRTWt4jXcczNIH1y8WOceZG4YjaVTOwqY1XaoZsFgSKybv4ieL5b68h0vSTGUtIXt0n0K7kDzMIyyFw6/d3NuG3KgA/N8wG6usajFomu3xtdUD/AG22kSB7O7kYI0cG9YkXD4B8z7vAOcjqDSul6f5iVr+pmP4K8W3FrGJWtYntwphjt9eu41D+VMjEFYht5eM8Dnac4PXqdCs/EWm6jP8A2l5N1bXUkZ3C9kka3xEdxw6gY3hQFUDqWPORXESeLPFOuT2ttLYajH5dz5u2DRNRsxcKschWNpSw2AuqZJODvAIIBzftfGPjTU9BeX+yLjS7w2M0sSz6HMzSyKWA+USkREbVOxixfd8vSkuo97HptFeeWvinxKs0caWEro1xKJJZNGvF80BjyoZiYgq4bByH+6mDWp4I8WX+uW7ReILOazvy2YlbTbi1WRRHGzYEo/hZ2XOeduRQldB1Ovrira1vb6Xx7baXKIrqTV4xGxlaLP8AoFnkb1BZMjI3AEjOR0rta4iG8vNPPj+60uPzLyPVozCv2d5xu+wWYGY0IZh3IBziplsNbmbovgvxTZWkcVxdRW/2dU8mODWrqRGPmTF9+UXOUlXk5JZAT60reCvF0viO5+16z52hyXStGkWrXkFwsIR1IJUkZG5RhSobbuJ3c1Bba/4ytppL5tMnJvbKKee2ezuZVtpBHh2j+bgBh/qQA7ZyPUx6T4n8W2Ph63jWwu7h47Sdy93pF48kjgyFWO5twAKooibLsHBDcGqlu7/1/Vv61JXZf1/X9dC/o3hDxTp0dlbTTxNZ27xZjGu3jE7Y1UvnYCQGUnys7G3ckYqtc+EfG5WSC3ns5I1Ev2e4m1y686MmKSNGBMRKnDIxw3UHr1MC+P8AxDKwS80y+KiZCGg8M6mnAk5J9RtIOOh2kHO4ASWPjvxZeQ2AuNDuFEl2sV5jRL2EiFki3FCTlWVpHGSCCIyRjjJdvUOvp/w/zLbeEPFcD6gNOu4oRcebNGz61dsDK0yuuU2fKoAZTtIyDjGCa6TWrPWtW0MQwxx29wtz88S6hLAJ4gSOJol3oTw2AO20nBJrn59d8UaR4K8P3OnWNxeyPZIt1DcafPNc+YqqTu+dWUlVkHzAktt6k4MGr+IPFH24WN3Y3JtPskMz3Gn6bdJIlx5kbbQyMwZCpYFeo2nOQabVvd7D217kZ8H+OWvr57zUdN1G3e7eW1jlup0KI0E0fO5XCnMqDauFwmeWJzP/AMIp4tjZ41eznty8Eixz6xcMFKTRSkAGIgfdkUEdtvQcLPca7r2l+ENNl0myvLueTUZIpkvLG5lk8gSvn0dDsA2swIPA7g1Bous+K9L0+G1urC4vI4b6O2LvZzvMY2LA5Z3+bb8jGbO3BIwSM0k7O/8AX9ag3e1/66jbTwb4qhvLe4e7VZGiWO5dddu3OBFKmArR4Y5eNtxwcg9xk9j4cTV7fS4bTXI4TPBDGrTw3DSrK2Pm5cbuOOTyetch/wAJn4vF5pESaBcXCXski3DjSpYltSAMI5aTIC8/vApWTGFAzmtrw54i1rUtRtIdT0yeCGewMzSNp8kISVX2kMWY7dwwVTlsAkntT1f9eonvqdXXN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJUjOkooooAK5vwv/yMXjP/ALDUf/pvs66SuE0y28RzeLfGDaHqul2dv/a0QaO80yS4ct9gtMkMs8YAxjjB6HnnAAO7ori9OvvFOqswsvEmisFLDe/hm7jUlWKthmugDgg9KmkfxdFqcVg/iXQBcyxPMq/8I9cY2KVDEn7XgcuvU96AOuormvsfjb/oY/D3/ghm/wDkymx2/jSVSU8R+Hz8xXnQJxyCQf8Al89jQB09Fc0LLxuRx4i8Pn/uAzf/ACZS/YfG/wD0MPh//wAEM/8A8mUAdJRXN/YfG/8A0MPh/wD8EM//AMmUfYfG/wD0MPh//wAEM/8A8mUAF9/yVPQv+wLqX/o+xqGfxzBY6y2n3djeuWu/s6yxxxhI/miQbj5hJy0ycgdG6DBrFvLPxj/wsnRlbXdDNwdJvykg0WYIq+dZ7gV+1ZJJK4ORjB4OQQ+b4c3lxqDX9xD4GlvHk81rh/CJaRnzncWN1nOec0L4tdgewzS/itbC7ey16B4NQm3yW1miwrIF3lUjP79tzHaTvwqDoSp66d34+FnqHlXmlXlnbRANNO/kyj/UyyGP5JSVYeWRkBhkY75FOLwDqUEeyH/hCo08p4dqeE2A8tjlkx9q+6TyR0NSt4K1lriCdpvBxmt0WOGQ+Fn3RKAQFU/auAAxAA7E+tPp/X9f1951LcPxCtJNRjspdH1WCVvlfesJET4kOw7ZDk/uz93I5HPXHQaPqkGtaTb6hahljnXIRmUshBwVJUkZBBBwT0rjU+Hl9FcW9xHH4HSa1AWCRfCTBogCSAp+1ZXkk8etalnoni7T7RLWw1jwza28YwkMPh2VEUewF3gUdBa3Ororm/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MpDN5bS2W8e7W3iFzIgjecIN7KCSFLdSASSB7mpq5v7D43/6GHw//wCCGf8A+TKPsPjf/oYfD/8A4IZ//kygDpKK5v7D43/6GHw//wCCGf8A+TKPsPjf/oYfD/8A4IZ//kygDN0HWU0HwRd30tpcXa/2/qEQittm8mTU5kX77KMZYd6lk+JOnw20lxc6ZqNvHFb/AGl2l8gYjw25v9b0V12H0Yj+H5q4uXSNcv8A4aahFq3iLTbfTP7bvTOsXhua7eRl1KUkbBO2UZx93YcKcEnBY9Fpel6/qVxqCW2v6HNDbj+z3tLjwrPFDAoUExorXC7lIIJ+8OmDjijWz/r+tR9v6/rS5btviVaTRyXscMl3YywxzW62qoZEXEhlLN5mxgvlE5QnI+7u4y3Uvi1oWj+d/atrfWixzeUrzGFVkw0illJk6DymODhjkAAscUg8C6qqBFbwWFHl4UeFGwPL/wBX/wAvX8OTt9M8Vnw+DzNrE8EB8DveSj7RM6+EHPmESEFi/wBpwzBxyM5B5NPTm8iVdR1L198TFjkVrTSr4RQXEqTrLHEzXEcYlVjERLgENGD8+Mg9M9LN78QWgknNvoOpSxQCTDH7OFuGXbwjedleHDfMuCD1BGKx7X4W6jHDdx6hd+E9WN3eSXksmoeFfMYyOSeouBkDcQM5IHGadP4Ql0axuWdPBtvbWcEk0nleC5Sqo4xJtC3PzEhMMq5JAGRyKXTUp3b903fD+raTc+IJCukJZatfCbzbk20MUkghlaPYzK7M5Xb1BIxz8ucV1tcJpPhnWYPLu9IuvCdqY94jki8KSwsoc5bb/pQOGOCSODWv9h8b/wDQw+H/APwQz/8AyZTYt3c6Siub+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkykB0lFc39h8b/APQw+H//AAQz/wDyZR9h8b/9DD4f/wDBDP8A/JlAHSVzfhf/AJGLxn/2Go//AE32dH2Hxv8A9DD4f/8ABDP/APJlc/4cs/GJ17xYINd0NHXVoxMz6LMwdvsNryoF0No27Rgk8gnPOAAeiUVzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUAdJRXN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZQB0lFc39h8b/9DD4f/wDBDP8A/JlH2Hxv/wBDD4f/APBDP/8AJlAHSUVzf2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUAdJRXN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZQB0lc38OP+SWeFP8AsC2f/ohKPsPjf/oYfD//AIIZ/wD5Mo+HH/JLPCn/AGBbP/0QlAHSUUUUAFcv4eWRtb8bLAypKdXQIzDIB/s+0wSO9dRXnY8YaP4c1nx1Fd6zpNpqf9orNbWt9fRQNKf7PtQvDsOCwIz04NJ7DW5Ld/DP7fpcOn3F/AYYIGVQbdmLTMgjaViX5yu75RgZOc5FSxfDy7XUPtdxrEMzhFQBrI4bHmcv8/zHdIrYPAMa46DHGReN7ZdWv9Qj8UaRHPOriN5NT09jlVjWLOJOnMxOOm7HOBV+b4gPcyW0EPjvQrINLtuLg6nYybIw6kMozySiPk4HzSDAwOK3F0Ooi+HFs2m2um6lcw39tbziQtNb5muEUNtSR93zYJToAMJjGDWfD8JUt4Lf7PqMEE9vGI0kis9gVREyYAD/AC5aSRjjqCBxtBrmP+E6WfWoLybxRoqSxW4tvtR1SwZk3ljIyL5g4zHD17FiAOg17Lx7AuoW8l38QdHkhmu2aWE6jYhYYAzbV3A5LEbM8HuAQeaP1FselaRpsek6XDZwrGqxgk+WpVSxJJOCSeSSeSfrVyub/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qluM6Siub/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qgAvv+Sp6F/2BdS/9H2NdJXnd54+8Ht8SdGul8WaGbePSb+N5RqUOxWaazKqTuwCQjEDvtPoa6D/hY/gj/ocvD/8A4NIP/iqAOkorm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KoA6Siub/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qgDpKK5v/AIWP4I/6HLw//wCDSD/4qj/hY/gj/ocvD/8A4NIP/iqAOkorm/8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KoA6Siub/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4qgDJ0rR5fEHw61PTIZraE3Gs6mGa6tjcRlRqU5KtHuXcCBjr3qM/Dq0hMdmNOsHtWv5LiMWdhHBFawMirJAVLncJAMHaACeSBgVD4L8feD7XQbmO68WaHC7atqUgWTUoVJV76dlbBboVYEHuCD3roP+Fj+CP+hy8P/wDg0g/+Ko2Dc4/QvhbNL4ZEd2lrpM0s+82X2FGSJVLqrEJKVMwVgVlDDbtT5flxVu8+Fji4hlhm0uaytppZzZHSA0k4eUu6bzMq7mU+WWK8jrwcV0v/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FUdbh0sc9H8LLaaG3ldbGCdbN4W86wSWXcWTZvcMAyrGgjK45UsNwzUeofCeW+02WzXVNPSOW3jhMT6UXiyhm/g80fKvnHYufk2Jy2K6X/hY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqm22rAtDnJPhdfTaabeTWNNErx3MTumjkIyzYP3TMSMNljhhk7c9OdbwV4Ju/Cl/eT3F/p9wlym0R2enNbbf3juOTM+QPMKgYGAB6Vd/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KouxW0sdJRXN/8ACx/BH/Q5eH//AAaQf/FUf8LH8Ef9Dl4f/wDBpB/8VSGdJRXN/wDCx/BH/Q5eH/8AwaQf/FUf8LH8Ef8AQ5eH/wDwaQf/ABVAHSVzfhf/AJGLxn/2Go//AE32dH/Cx/BH/Q5eH/8AwaQf/FVz/hzx94Pg17xZJP4s0ONLjVo5IWfUoQJF+w2q7lJbkblYZHdSO1AHolFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lc38OP+SWeFP+wLZ/8AohKP+Fj+CP8AocvD/wD4NIP/AIqj4cf8ks8Kf9gWz/8ARCUAdJRRRQAVyei3cVhqXjq7uH2RQ6sjsx7AadaGusrl/Drxxa342km/1aawjNxngafaHpSew1uc8vjnVbWw0uO+K/aIWm/tKTaFMhjk8sBflwFLtHufGACcd8T3PxOe0kvVns7MNbwB0i+2/ffYHK7gpGSJIgMZHLHOFrctvHvhi9AeC9ZgU3KWtJRuGIzxleciaPAHXcMVHD8QtAujGtu9w0svlFEazlGRI+2NiwQgBuoz2quuovMzLLxxeQ3t/wDbYUlt5bphaytMFSFFVwysQnH+pZh94neucZqpa/ES5867u5EEkJDyLZvKqSQBNiNHjbliGE7dc/JgDkV0dr450O7gedZJI4RGJgXt3DMuGbft2/d2qGz6MM4JFWrHxZoepTXcdrdhvsas87vC6IgV2VjuYAHDK3Q9qNmHmc9YfEW7vPEEOnNo0KRzXCwLcC9JBy0gJAMYyf3LkDuB2yMmqfExbXXI9O06xt7x3kkjIe88t08twrsV2HgAO3XO1M9wK0ofHemnVb63uEaCC1dUWZopMuzbABt2cHdIFxkng1auvGnh+ziMtxdOF3hAUtpHLksUwoCkt8wI478UuisHcxdE8cS+KdZ0a2sjHZ74pLm7hWZZGKqigp93pvkUgjBOwnGDXdVy7eO9IXWltFfMLW6zCYI+5iz7UCrt+YHa3IPYDuKtWHjTQ9T1Q6dZXMslzvkTb9llUEo+x8MVAIDcEg4HHrVPXZC9SG+/5KnoX/YF1L/0fY1z2t/EKbS/GwWGa3l0YQz2il7iFIpb9FEgj3gmRWwCpG3GSOp4rob7/kqehf8AYF1L/wBH2NYup+N2m1e78Pajokxt3upLOaaBrsgweQZS6ukGDJt48tX3Z6Go16dn/l+v69Clbr/XX9P06lS0+LMl1caYg0uxdNQYiNoNV8wygNGD5I8oeaQJckAjGyQZ+XJpW/xjOp28VxFa2dhaNLJFLJdXrQOHSSFdqeZDhiBKQy4+8pAbADHdtvEngm01jTmiuL6O4gsltrWWWC88nyHKdXZfLPJjBZiSCQCQeK3bbxlot4YRazXMrzSGNY0sZy4IAO5l2ZVMMp3sApDLg8itNO39f1+JCvbX+v6/I53w78S21XxZbeHb6wgju54ppd9rNJKoCOy9TGFwNuDlshiBgg5GF/wuNbHVtQe7WK5ga9t7aG1hn8x7bcHBVtkW5ZGKf6tsgNxvA6djD8QdIumt7i0dptOlhnYziKUSrLFJHGYvIKbyxMmABzkYAOann8f+Hba6uLW4vJ4ri2SJ5IXsZw4WQEqQpTLcAk4zt2ndjBqbbf11/pfiU09f6/rX/IwD8UCXPk2On3AEN1O0EOpM1wqwhSUMXlf6znlATtx1Oao2Xxmiv44ZLfTbUxS6fJdh3v2jwyMwA2vEreWyozB8ZwDlQeK6/wD4Trw//aDWX2ubzxJ5WPsU+0tnHDbMEZKjIOPmX+8uZdF8W6Xrd1HZW8/+nNZx3rQ+VKq+W4GGVnRdw5x0yO4B4oWq0/rf/h/kDav/AF/XkcVqfxhgK6vZ2VuttNbW0bx3dxM0McfmJlXd3hKoOfl+/uIwQtd34Y1eLWvDdheR3kN3K9tE07xOrYdo1Y528A/MDj0IrWpqRRxs7RoqmRtzlRjccYyfU4A/KhWsxWd0OooopDPODqU2k/CnV7y11NNLnj1rURHcySRoqk6nMMFpEdQDnGdpxngVJpHi3XYo70zrZ6vN/aj2bRw6grpZuY1MUe5LdSVLEgsy5XP8VXdC1Y6J4GvL8QCdU17UFddxBCtqcykjCsSQGyBjnGOKsX3jXwoyxahd3F+UtlWVSljdlVWRCwkKKmCAFPzEEIQQSp4oXX+u39f07j2MWD4sSSaXJdS6VYq0c4hby9U3xBsNui8zyhibKYWMj5tycjPFCH4ujT9O1PzjBqU9jqUkBE12kDtH5sv3QqFTtjjxyQWIIPOC3T6T4s8IaNpAs9Ou7pLa1iklKSwXUjxgMxdWLqW3AhjsPzYBOMCr0/jzQLWyku7me7hto5EieaTTrhUVnOACTHjg8N/dPDYNV1/ry/r5h0OUg+Ki2NybSUR6wAb6Tz4blfNHlSTGOPy1TDApERuBJ4GRyCaI+PNg1rDOLfS0WWDzFE+r+SzHEp4V4g20+VwxAJ8xOBmu8tPFtpJcXNtdxSx3Fu825LaGW4URxkgMzKmFLAHCnkkEDdiq8fxF8LzWsdzDqMkkMkPnKy2kx+XOMH5OG4J2n5gATjAJpXVv68/6+Q3a7/r+v+CYNh8VrGfWLG2WWwuLO8uLhZL1NTRhbKgYq2AgDKQvPzZUkZzkE+iKwdQykMpGQQeCK5yPxroepPFb2sjTrO5jkSa0nQ48uRsBTHyf3bDBxyrDO4bTqaFreneIdHi1HRZvOs5CyoxjaMgqxUgqwBUggjBA6UW0J6mhRRRSGFFFFABXn91dy2Fj8Q7m31aPR5o9VjMd9IEKwt9gswCQ4KkZ4wfXjB5r0Cub8L/8jF4z/wCw1H/6b7OkxrRnJr8R7uKa8vLie2D2mmx40eaZIPMuPO8p3L7WYLv+VT93ueCCIIvjJaW2oFZbvTZ0u5onSG41OKKW1jeK3OwKEO/mWQ8kH5SM46er0VSff+tbi/r8v6+Z5ZqPxieyjaQW2hqbdmW6jn1rZghX+RW8r726N1AI5x2OcTap8SrvT571J20qKOB3W4f+1l/csIYXCxMYMEkyNw4ySDzjgem0UKyA8y1f4xwaQbhprPTwkMzoPM1URthVdtrAx/LIfL+5zxJGc/Nx6XFIk0KSxsGR1DKwOQQe9Ooo6B1CiiikAUUUUAFc38OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJQB0lFFFABXK6FaxX2q+ObS5BaGfVkjkCsVJU6daA8jkceldVXN+F/wDkYvGf/Yaj/wDTfZ0BsOuPAfh66uPOmspC4k8wbbmVQGyh4AbA5jTjp8tWIPCOi21mlrBausSSJIB58hO5IxGmTuyQFAGOnfrW1RR0sHmYEPgjQII9iWTbNgjIaeRtyBETYctypWJAQeDt571NH4S0aKC5hjtWVLqAQSgTP8yBmb14O52O4c5PWtmindsDnYvAnh+Hz9lrMRck+cHu5mEmWdiCCxzkyMfqfYVbh8K6NBcRTx2f7yF98ZaRm2cMABk8AeY+B0BOeta9FIPM56y8DaBp99FeWlrNHcRKqI/2uUkKAAF5b7uABjpwPSrtt4c0yzmtZYLdg1ou2DMrMEyGBOCcbjvbJ6nPNalFAHN33/JU9C/7Aupf+j7GrEnhLTvtD3dt9oS8+1NexvJeXDos5QpuKeYAV2nGzhcelV77/kqehf8AYF1L/wBH2NdJQByP/CAWkmqaXPcyxyWen28sZs1jeNZpZJFkLsFk2lQy5CMrDODnIFX4vBGgQrCI7WYeSzMrG8mJO4AFWJfLJhVARsqNq4AwK36KOlgOZT4eeG47eOFLW6CRqyp/xMbjK5KEkHzMhsxIQ3UFcgg1FqPwx8I6tHPHqelNdJcFTIst3MQSu3BA38H5RyMZ5z1Oerop3YHJzfDPwzPctO0WpI7PvxFrN5GqnIb5VWUBeVUgAADaPQVoaP4N0PQbxbrS7aaKZYfIDPdzS/JhFxh3I6RoM9flrcooTa2AKKKKQBRRRQBwmk2+l3XgK7g103C2cniDUFJtpZo3DnVJgnzREMBu285wO/FXL3wDBJod9pmn3KWqS2DWFpJIkkz28THL7naTc5z0+ZcVT0vR59f+Huoada3FvbvLrmosXubYzoQupzNgoHTOcY+93rE1P4aMPDN/aLpNtqV5DpqwQstrDHHdXCgrFKqNISpjQlMswOOnQUL+vu/pD/r8TqW+F/hKW4W6n0sve/ZWtXuluplldGOWy+/cSSTliS3JGeTT9Y8JeFiv/E1t7kpe3SqALq5K+a4KcBWwm7cQTwCTk5OK5c/B2d5Glj12GBJrCW2eyOloYUaRi3yAPuWNd2RGHI3KrZOKisfhzfL4z1e8+xWNrYs8HlIdMhIlijZT5UbLNuKsEwRIqheAARmq6rX+r/0ydeV2/rQ7b/hBdA8+6lNtcs94si3G6/nIkD53ZBfH8TY/u5O3GTVCX4VeDproXT6VILlYmhFwl9OsoVnLsN4fdyxPOc4JHQ4qlZfDuMWmnSIILJ4Wdmhns45XiUgLEEZW2pLGiqgcbsDdjOc1jxfBy/gsLK3HiDTrl7R3YSXeiA8NIj7VWOZAo/d4PXdvkP8AFS62GdPafDnwvDes8UGptJFkHz9VvXQ7lbPDyFW4kf1wWbuTWzo3hyw0Dculm5jhZceTJcySoDuLFvnJO4ljk9+K4iD4T3oislutZ01zZXVvcxNBpDRMGhVVU588nO1ApOcYJGOmPRrMXQsohqDQtdbR5pgUhC3faCSQPqaAJqKKKQBRRRQAVzfhf/kYvGf/AGGo/wD032ddJXN+F/8AkYvGf/Yaj/8ATfZ0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFc38OP+SWeFP+wLZ/8AohK6Sub+HH/JLPCn/YFs/wD0QlAHSUUUUAFcJpnizw5oPi3xha65r+l6bcPq0UixXl7HC7KbC0AYBiDjIIz7Gu7rmPDsscGueNppnCRx6wjMzHAAGn2mTSbsrgP/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8Aiqx9N8Ra5aW9hc3zx3y6wUNtDK6RvCGZiGOxMlcNCnRiCSSQKsRfEFXtFlmtbe1/ctMxmu9oITAkCZXLlTu6D+HnFN6AtdjQ/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4quY0f4jXqPFY63BDHcwKEuJJLtR+8KxkbwEAQDdIOO8eBnIqxYfEjUNUmhGm6RZzrMiMVN8VMSmHzmdj5f3QrRDp1en0uBv8A/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVM8LeKn8QrGPKgRvLWSVDcgyLuRXXChRlcOo3HGTn056ehprcL3Ob/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KrpKKQHnd54+8Ht8SdGul8WaGbePSb+N5RqUOxWaazKqTuwCQjEDvtPoa6D/hY/gj/ocvD/AP4NIP8A4qi+/wCSp6F/2BdS/wDR9jXJ3XxPtvD3ivUNOutasNSU6h5QiuNRghezT9yCqoseX5kf7xz+7xnqQLV2Dpc6z/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrIHxMjNxbwiytt73klrIGvSMFXC4TMeJHAYMyggKoY5O2sKL466e1v5ko0FG2Bgi+IEOTtVsf6serj6qB3O03VwO0/wCFj+CP+hy8P/8Ag0g/+Ko/4WP4I/6HLw//AODSD/4quQk+Mtqlm9/Athd4ihJtotVQqMvOJCrCLkgRZG4gMNuAp+90vjHX7S30nTbmLxZHolrPfiB76KW22kAPuXdMrrkFeeMgim01v6B/lctf8LH8Ef8AQ5eH/wDwaQf/ABVH/Cx/BH/Q5eH/APwaQf8AxVcfdfFqXQfJsLuzOpzNaT3UV5IWtxcxRs+JOIygBRAS2Ry6YXDZWa9+MJsdOuL2TTtPeG3t1mkeHU3lAVpnjDjZASYjsBDgchhxQ1YDqv8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KrKb4mW6XywS2kcCtLaqfOnZXRJ0ypZRGcNuGNuenJI6Vln4uxWumxTtFYTp9mWVpZdVRSSTywIiAMWcp5nGXwu0ZzRawLXY6n/hY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqrvhbX4fE/hu21a38nbNuBFvOJkDKxU7XAG4ZHBwOOwrXoas7BueTWHj3QbbwBqUWneKdHjv31bUHSMalarKYn1CZtyCVthJjbcpb5TkHoa4638ZXEGj2ekS6lo0mlW1nbeXGmt6X5kU0cqNkKXC7xtZs79mNoCgg16roGrQ6J4D1K9neNSmsaqsSvIqeZIdQuAiAsQMsxAGT3rnbb4u/2L4etk8QzafJqsN1cW1/Fd6jDbzRmN+DsQMpYoRwDjdxnkkJb/wBf1pf8h3sv69f0/MqWvxDd7FZJfHelJcmw80282o6dlbhQU2bkyhDZEn3uGXHCnFc/ovjK50/w1qVpY+LrfT5lYmyWTVNFbLyXEjvIQrkHCFMrlRy+3+HHZRfF+K4haZ4LNWtrqSM29lqazvcKLeWVWUeV8yOEUqVIOT7FTY0j4o3usWv9pWmkWkmnLbQ3D4u5RMEaWSNpEQwgug2AjIUkHseKrX+vvQbf18jlx4+dL+a4/wCErsZHeKQiRtV0ljAGMBKQEvkNhZQA+U3BScjBq1Z/FZrHxFbvqfiG0vNMESicR6npZTJj6gLKJCwbbnHGS+Mjbj2Cze4lsoXvYUguGQGWKOQyKjY5AYgZA9cD6VNRe2nYnoeQat460w/EOSTRfFOm2dheW8cNzqEGqaaVUqk2H2ySFyys0ePlwRuzniqVv8Srh9ehC+OtLeOWzS4ZJr2wW0hkPmKY2bCyk8RtgZIOc4BAr2yipKPD4vidfQ6lZbvE9tcWu9fNEmq6OPl3YbzCsgOQCxGwdAmedwNa38fam4097zx1EspkMcxg1TRsLGZVO6RSxBKoWUFBklM4wefeaKadhPU8GPxP11LFhP4k0xrlLqYIbTWdJkEkYC7C3mMm1C2cAZcKWyc4ND/ErUJLe4ltNfsbe9xEiTz6po26RUedsNtlOQVaJSMjBLFcc595ooTsHc5pfiR4IKgnxjoAJHIOqQcf+P1geHPH3g+DXvFkk/izQ40uNWjkhZ9ShAkX7DaruUluRuVhkd1I7V6JXN+F/wDkYvGf/Yaj/wDTfZ0gD/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qukooA5v/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKrpKKAOb/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiq6SigDm/+Fj+CP8AocvD/wD4NIP/AIqj4cf8ks8Kf9gWz/8ARCV0lc38OP8AklnhT/sC2f8A6ISgDpKKKKACuY8OPHFrnjaSdlWNdYRnZjgADT7TJNdPXnsSa3da943sdP0fS9QsLjUkSY3mqS2znOn2oZQqQPxjHO4Hk8cZINbmpN4z0m5vL6wuhJDZQpg3CmWJsBFZ8YUFcCSLkN/H7Grc/jLw3plrH5tw0MQxHGotJOpKLsChc5BkQEdQTg9DXGabbXF+ytp/h3SJjdJOxc+JL/DDeqyhy1pgHcgBDYJweOta8Wg61BcwTR+EfDoe3kMkIPiK5IjYkk4BtMDLHJ9SAeww+wjWm8d6RHqMUYcG0e2ad7hkcEHdhVVduWJxIT6eWc1atvGeg3V99jt55mn8824X7HKMuCQVBK4ONpzjoBk4FcxD4V1eC6W4h8KaKsyFdrjxTeZXaHCgf6NwAJGGB2NXY9M8Rwm3KeFtAAtZGljH/CR3O0OWLFiPsmC2WJyeeaNAfkdyAB0FFcw+qeM49u/QfDq7m2rnX5hk+g/0PrTv7Q8bf9C/4e/8H83/AMh0gOlorm/t3jf/AKF7w/8A+D6f/wCQ6Pt3jf8A6F7w/wD+D6f/AOQ6AC+/5KnoX/YF1L/0fY10led3l54x/wCFk6MzaFoYuBpN+EjGtTFGXzrPcS32XIIIXAwc5PIwAZl8deIW1AWQ0HSvPN4bEA398FMwTeRu+wYxtGd2duO9HkHmd9RXN/bvG/8A0L3h/wD8H0//AMh1VsPEHi7U4ZJbLQdBdYpngfdrVyhDoxVhhrIHqOvQ9RxQB11NjijhXbEiouScKMDJOSfxJzXKRa74vm1C4sY9A0E3FuiPIp1u4ACvnaQTZYP3T0JxjmrP27xv/wBC94f/APB9P/8AIdAGzqmmWus6XcadqCO9rcoUlVJWjLL6blII/A1aRQiKq5wowMnJ/M1zn27xv/0L3h//AMH0/wD8h0fbvG//AEL3h/8A8H0//wAh0AdJRXHweIvFd1qEtlb6J4fkmijWVguuXG3azMoIb7HtPKMCAcjHOOKsy6n42hjLv4d0IgEcJrdwx5OOgsyaAOnorm/t3jf/AKF7w/8A+D6f/wCQ6Pt3jf8A6F7w/wD+D6f/AOQ6ADwH/wAi7df9hrVf/ThcV0leX+H/ABD4m0Pwfe3suh6Q9rHq+ol2XU7l5N5v5twEcdm7MAxIBHUDcQvIG7o3ijxVr+mpfaZoGitA5wDNq13A3QH7slkrYIIIOOQcijcDs6gu7KC+SNbkOyxyCQKsjKCR03AEbh7HI9qwvt3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AOkorkn17xfHqkWnvoOgi5mieZF/tu4wUUqGO77FjILrxnPNMPiPxWNUTTv7E8Pm6dHcIuuXBAC7dwLCzwD86nBIJByBQB2FFc39u8b/8AQveH/wDwfT//ACHR9u8b/wDQveH/APwfT/8AyHQB0lFckdd8XjUxp50DQRctCZwv9t3GCgIUnd9ix1I4znmrP27xv/0L3h//AMH0/wD8h0AdJRXLz6r4ztreSefQfD0cUSl3c69PhVAyT/x51HYa54y1Kxiu7bw5ooilGVE+r3UL490eyDD8RQB1lc34X/5GLxn/ANhqP/032dH27xv/ANC94f8A/B9P/wDIdc1oureKrHVPGN1Jo2gqiaoj3LS63MqxEWNrwD9lO4bQpyQDkkY4BIB6TRXHaX4l8W6xbtNZeHtGCo21luNWu4HU4B5SSyVhwQelXft3jf8A6F7w/wD+D6f/AOQ6AOkorkrrXfF9lJbJc6BoKtdS+TFjWrhgXwTgkWRC8KeTgdupFSjVPGpuGhHh3QtyqGJOt3AXBJHDfY8E8HgHI4z1FAHUUVzf27xv/wBC94f/APB9P/8AIdVrzXfF9gsJutA0FBNMsCEa3cNl2OFBxZHGTxk8UAdbRXN/bvG//QveH/8AwfT/APyHR9u8b/8AQveH/wDwfT//ACHQB0lFcifEHi5dWTTDoOgi7eAzqn9tXGCgYKTu+xbeCw4znnpU82p+NYIXlfw7oRVBkhNbuHb8FFmSfwoA6eub+HH/ACSzwp/2BbP/ANEJR9u8b/8AQveH/wDwfT//ACHR8OP+SWeFP+wLZ/8AohKAOkooooAK5bQElk1jxultIsczaugR2XcFP9n2mDjjNdTXJaRJdQ3/AI8k06FZ7tNUUwRM2A7/ANnWm0E+5pPYa3IZPh9GQ8UF+Vt5JY3ktnQtGVWMqVwGBGWO/r96oz8L9KKiRSkV7JNNJc3UUCh5lk3/ALvnOFBcYA/u+vNZ0Wn+L11a/wBQjtbiOedXEbyC2Y5VY1izg9OZicdN2OcCr00Hju5ktoIbl7INLtuLgiCTZGHUhlG3klEfJwPmkGBgcPf5i9SO7+G0s8kDR6tFEyoUkX7JuDqRGrAfPkFlRwxJJPmE9hWhJ4Kf/hH7qwF4ha5ujdyOsHO77wC5b+/82GLDBK9KxPsfjWfWoLya2mSWK3Ft9qP2ZmTeWMjIu4cZjh69ixAHQa9la+MF1C3ku7+4khmu2aWEpbhYYAzbV3AZLEbM8HuAQeaf9fj/AExbL0KTfDpr5UuBNHpzrJPLBb/Z1Y2wkBwoKtgEF3zgkc4HTcY9U+E1pqbb2uYIXWAxJstjtUlJATgvk/NNIxBPPy88c+h0UhrQbFGIoUjXACKFGPanUUUBsc3ff8lT0L/sC6l/6PsayL34bm81241b7VpsN7PeSTG8h0vbdLC0Bh8oTeZnIB3ZxjI+7Wvff8lT0L/sC6l/6Psa5XVovEtn401LWZDPZokAhs5y1oIbjEyslsvBlzINwO4ZDE7SB1W8rd/6/Ee0b/1/VgtfhBcQ2mlRy+IkebTY7iNLiPTVhYCUOCECOAi4f7uCMqDxzRb/AAgmi+xn+2LG3aza5MJsNKNv5YnDhlT96cL8/Q5Hyr05zb1ZPiHbW91b6VJd3kiPA8F5mzG/CMZE2FV+UsFBOQ3z5HA5dYTfEZpbg6jaFEXVUESxXFsfMtTkM2dvyoAVIU5kJB+bBqtf6/rz/MT/AK/r+uhT1D4T319NEYda0vT447X7OFsdE8vYNsoIQecVVSZSSpU52jJNaV74U1ey+Fd/4bR4dbZdO8i2xAkLSTEsT8pYRqgym1QRtC4z0rmYrX4j6XJcNpWl6pNdTQBJ7m5n09RcSKpw+4Etu4CqSmMY3g4rejfx5JHbDU9LmuG/0OV1jks2SNwf3o+bBJGNxYd8bBgGi9/nb9QtbXt/wClffCGW9t7XyNS061kitpYCjaTuRBKXLqqrMMJl12qS20oCCcmrcvwpf+1dSurTWooIbsQfZ7QabGY7YxlTkcjeBt+QNkJk4zW14PufEw0V7TxPb3TamBJJHcXCwBWUn5EYwnbuGccAZ25riNO07x7YTazcRaPqa3l0s00dznTNzTMtuo2nd8ozFJ1GCu0sGanf3vlf/gBZPTz/AKZq3nwkuZpIls9Z0+wgiSRENvpBWZA5lyVfzsAkTEE7edvTnFTWPwsvLHTba3TXrWeSK3WF5JtJTa5W4EylVV12KvIVFwBnPOAKzkPxGa4P26w1u9t41tWWGVdJw7pIjStjdwxCkgZwCeDwKl025+K39oaYk+n3JtftSfbJL6axRhHtQOcRbtyjEmAu1tzKc7QVoWmif9f0weurOo8I+EbzwncXixXlpPaX9zJdzpHatCVkYKAVAcqM7SW4GScjFdXXIaJJ4w/tPTxq9vObbNxHcs8lvjAb93IQgzkjACr0GdxJrr6XRB1ZyXhO3lu/BWp29vKkMs2qauiSOhdUJv7gAlQRke2R9ayta+F8ut6dBBPqdjHcW+lx2Md0NKV3DowO8h3YFCAVMZByGb5ucVa0Y6mPh/qP9hrK15/bWp7RAYxJt/tKfds835N+3ON/y5xmqurt4+S4kOnJqTxBIdiwmwJK5Tf9/b+9/wBZu6R4xt5qf6/P/Nj/AK/Ff5IoSfCK++1pNFrelu6pEvn3OitJOxRI1DM4nUE5iVgdvB+grTtvhobXUILv7Vp1w1vdm6CS6b/rHCOqux8zmXc4ZpMfNsTgYzUcU/j9rBfPtL9Xazh80xvYiZJA+JNgOUMhX5ssdnQAA5qSOPxp/ae2C3urW3e+JeQiyPmJiMF5MclcCQKVAfcF3DbV3bf9eRO39eRe8YeC7/xfZwxtq8GnyLZvBJtshOrOzxPna7bSmYsFGByGPNYJ+El5FcQPaa1p37p4ZWludHMk8kiLEN5dZlGcwgj5eNzdanhm+IkUKrNbajOyllZg9gpYeQBvHb/WqSAQPvjOACBBZXPxRe50xJLCdIPPkW7lu5rNXVCqkMyx7gwBLhQpU5C7sjOUnroOWyv/AF/X9bkE3wluLKPU7qCfTr954rp4rddLCOs0yKpZGMwVfuA4woJLcjPFjwl4Bn0uz0/dpNpa31pau7XD2UEUdxMXLReZFE7YZGLMdrbRuG09l29HvfFtrc2kmuafeTWzWYSdVktnZJvNChiExklTubGFULwCao3+keKbDxF4huPD6zxwagBMhg+zYMnlRxhl8wZ8wFGJDfIVxzk8Hw/12/r8h77/ANXt/X3mv4m8JXPiOeOR72zjjW1ML289kZ45WMiP848xdyfJgpxnP3qzV+G80O4W+sRqPMtJUMliJGDwjazElvmZl4GeFwMA1jpD8QLWOK5tdLuor+Sa1l1KSE2O292xIso2s/BOCAQVwQvbpc0Wb4hPHCmq2uqpidS0jtp4dhsXhthZfK3Bt20eZ8w2+gFpt0/zv+Yt9/60NXxT4B/4STVJrv7Xax+baPbYuLLzmXcjLgNvX92d+5kxyyqcjFdRpln/AGfpNpZ/uR9nhSL9xF5UfygD5Uydo44GTj1rD8CSeK5NFuP+E4t0gvRcsIgs0cm6PA5zGqgAtuwMbguAxJyT01Gyt/X9ahuwrj9M08apf+OLQytCX1mIrIoBKMLCzZTg9cEDiuwri7T+0PO8ef2Nu+2/2vF5ezZu/wCPCzzt3/LuxnG75c4zxUvYa3JtT8HahrZ06bV9WtJ7mzkLMyaeVQZKkNEpkJjkG3G8s3DOMYPGPpXwo+xiX7deaXPmYSRiDSfKVAVdJAQZWyWjk254xtXggYpksnxOW+iSK2aSyNgxeUzWolWTccApt2mfbt5DeVnPHQ1kadbfEvR9OtbDTNIuobGK0fAWew81ZPOYgFD8m4gg8OEClhtDYxW39f12/Im/9f16/mdHZ/DebTrqQWGoWFvYtMri1j0wptjDTEIGWUDpNgHHAUcVXPwtuHtFgm1bT5VWGGII2kgRsIzLjcglAOBN8vTaUU5OMVT+0fE2TSbhIbTVI7tZY2hkuTp2WUeZuBCOQQwEQPQhmYrwMV6gpJUEjBI5B7UdB9TiPDHgbUvC2tXV7bajps0V24Esa6c8LlfNZyWfzW3P87DO0fzqzceCLiS7vpoNQtITeXsVy0w0/wDflUfdseUSAtjohwAo4w1dfRSDv5nmQ+Ec6XllPDqmmRi2mEjKNHPOHjY7cTYUt5XzHB3GSQ4G7AvaV8N7vRru1nstUsF+yTeZEi6ZtyBCItpPmHGQkeWAzwQMA8d/RTu7WA5PxL4KPii40y7u7i1jubOMq++1MqkkoxKZYFfmQAnnKMy8ZyOfl+ELBbVrHUNLtZbfTBYFhpBw/OXchZhnLBWAJJDAnPNemUUXtt/W/wDmByHgvwXeeFtQ1G5utRsblb7BMdnpzWwVvMkcscyvn/WFe3CqO1W/hx/ySzwp/wBgWz/9EJXSVzfw4/5JZ4U/7Atn/wCiEouB0lFFFIArm/C//IxeM/8AsNR/+m+zrpK4TTdGvtQ8WeMZrTxLqmlIurRKYbOO1ZGP2C0O4mWF2zzjg44HHXIB3dFeY6ZqGoXVutzf+NtbtraVpVieJLOYsUVn5AsQBmNd45PpzWtBG11DcTQfEXxA8Vs6xu4tbHBZjgKv+ifMScYAznI9RQB3FFeZafqk100v2nxz4jtwJjHFi0s2Mg3yKpx9iHLeU5wM9B6jM9xqdpbSQpN8SvEQM+DGVsLNgykEh8iz+7hWO7pgE5xzQB6NRXmsOoyPq1zay+PfEUccTxxRN9ksy8rsoYjZ9jyAA6c8j5u2DVrR7hNfkhTSviH4lmaaMSpu0+0TKEEhvmsxwcHnp2p2YHoFFc3/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i0gC+/5KnoX/AGBdS/8AR9jXSV53eeHNUHxJ0aI+NNcZ20m/YTGGx3oBNZgqP9G24O4E5BPyjBHOa8Q8Vvqt1Yy+I9Yje21AW/E1ixe3MRk88AWHXAxs9QRu45APTKK83tb9rqxtrhfiDrwEhjErG0tRHHviMmQ7WIyNo6kKOxweKdHqdrLNbQj4jeJ0kun8uNZNLtkIbcq4bdZDZy6fexnep6EU7O9gem56NRXl13qWp2d7rdlJ4v1/7XpjZiQx2QS5j8tHJ3/YdqsA/wBzJPGeh4stqtssixj4g+LHkZ9gSPRoHYtlxjAsSf8Alm//AHyaXS4dbHpFFeaxa1ZzwPJB8RvE52wiVQ+lW6lwSAoUGxyzHcpCqCxDKQCCM29KTUL3wbaeIL3xv4htIp7dZmiW3spCpPRQPsYZjk4A2gk8YzxRsB39FedXeoQWLAXfxD8VRMY1k2nSbfK5AIUj7Fw+DkofmA5IwM1E2tWSNKsvxG8UxyQnDRyaRbo+c8gKbLJx1OAdo5OBzR5AelUV5yt1PdakLLSvHuv3UsN6lpdq9vZRGHejMrLussODt4IOCCTnjB6L/hF9X/6HvxB/340//wCRaAMnSdZGgfDvU9RKxt5Ws6mAZZfKjUtqU67nfDbFGclsHABODWV4a+Jwm02wN9d2uozSizinkju0Yq8wcZ2RxA7iygY4GOfl5FVLKx8QaT8PdU1XS/EusTva6pqTNa5solZVvpg77jaOckAuRjGSQAowBpu+rWlxKdT8aa1BaCV1hniSzmMyJFvZgq2HBByu3OTtJGTxQuv9f1/XYH0Hx/FRpUjMem2Ls5mbyl1PMm2OPzGUL5eTKoyGT+FsDJzkYVn8aRY2qJf/AGLUJp3vZEnjvcwARMxVFlSHaVChcswUgMpw2TW3canbWi3DT/ETxSoto2ll/wCJTbnChUYniy54lQ8Z6n0OFgk1CfS9V1BfHGufZrGRBFKI7JlmR4o5Fc7bIso/eDPDYxn6OzC6sb+g+MYtU1O406/FnaXUSwtGkV4ZhKJELLglFBOFbgZOBniudvPiJe2/xAvrK3jtZ7Kxg/f2f2wfaEAlVWm8sRFhwwwu4hl+bg8GG41nTFMhufiL4mzas7Nu0e3JQoH3Ef6D28uQZHXaQKi1G9065htUuPiJ4pLSmWW3ibT4YhI8KlmRgLLPABOxgcjBCtxS6phZ2t1L/iH4qN4ZsNQbUtOso7yxa3V4G1BtmZVJGXEJx8ylR8p7E7RkimPjPHu1EPpcEY06ZoZnlvXRNwjkcAM0IBJ8okYJG1kOeSFr6u2l6jBHFq3xD8YxCGbiS3sUhCSKOcSpZrkANzzjacniry6nYW9uip8RvEiRpFuCrpdt8gDbdpH2L5WGD8p+YBScYBNNef8AX9aiunsWdR+J9paXM6+ZZRtazzx+W1+FEoSAyKSfKPBGCdpO3Kk5yRXWeGNb/wCEi8M2WqmBbZ7mPc8CyiURsCQy7xw2CCM1y+kGTXL57XTvHnil2S3S4Mj6dZxptZmUDLWgwwKEFTgj8DjNm1kab/an9u+PvEdl/ZsxWVksbWZfLyAr7lscdxuAztzycEEnl1Dz/rU9PorzqK4uEv5LPUPHniC3l+1m2h8u2spVcYQq7MLPEYJkUfNgZOASTXQ/8Ivq/wD0PfiD/vxp/wD8i0ulwudJXN+F/wDkYvGf/Yaj/wDTfZ0f8Ivq/wD0PfiD/vxp/wD8i1ylhpepafeeMrn/AITDXs2+rRIRFDY7rh2srTaTutiAfmVeMDCg4zkkGen0V52Rq2mGzg8VeM9c027vp/Itlt47O5ilbAIHmCxXae2GC5I4zVKHxJYSrFv+IXi6GWWBbhIZdFtxI0ZkEYIH2Ln5mUcZ6g9DmgD1GivOrbUYLzzltviF4qklguhaSQDSLfzUkwGwY/sW7GCDuxtA6mrlnDc3vh+TWk8c+KktIhIW8zTrMSYQkMRH9j3HocYBz2o2Vw62O5orzyC/gurOK7tfiL4mnt5rYXSSxaZasuxvugkWXDnoEOGPYGkm1CC3Mgn+IfiiMxxLI4fSrYFQcHaR9i++Aykp95QckAc0bAeiUV5uur2T27TD4keJtqlQwOl2wZc55KmyztG1tzYwu1txGDVO48QpZa1fWt54+8Rx2VmkQa+WxtXUyO7Jt4scbQVwXDFQcg4Ip2d7B0ueqUV5quqZuLlG8d+Ko0tmkR9+l23mSOkgTEaixPmDJ/hJPTj0uaVNHreoNZaZ8R/EU06x+Zg2NmisuFJIZrMBuJEPBP3hSWuwbOx31c38OP8AklnhT/sC2f8A6ISj/hF9X/6HvxB/340//wCRaPhx/wAks8Kf9gWz/wDRCUAdJRRRQAVy/h2JZ9b8bQuWCyawikqxU4On2nQjkV1Fc34X/wCRi8Z/9hqP/wBN9nRuBKPCNiLmzzl7SyCGGB2dtrIrKvJbG0K54xyepPSrCeF9Kj0ldNSGVbVJFkjQXEgMZU5G1t2VAx0BArXoo3A5+38D6Ba26QRWcnkoIwI3uZHXEeCmQWIOCoI/+vUi+DNBVXH2HdvtmtCWlcnymVVK5JyBhQB6c46nO5RQBgReCdDgeV4oLhXmEgkb7ZMS+8ANk7uemfY89a0INE0+2v47yGDbNFF5MZ3sRGhCgqozgDCL09Kv0UbAFFFFAHN33/JU9C/7Aupf+j7GtObStM/tk6jKipf3EH2MSiVlZ0GW2gA9R8xyORzzWZff8lT0L/sC6l/6Psaw/EnwwGvyX7Nd6aRdXX2mOO80kXCxEwtGxP7xSzfMCGyNuxeOKQ0bUXw88MweX5dlP+7WJBuvp23LGrKitl/mUB2GDkHPOaZ/wgPhi4mhIju5JLGQEY1W5JD5Rxv/AHnzEbYyN2cBV7AVh3HwojFy76XcaTYwSJiS2XRwY5GIi37gJACjmFSynqCwJOQQt18KY2v5L7Tp9ItLt5Efzf7GB+4ISF+WRflDwAgZ4DEdfmq+t7i33Oi1/QPDottT1bWYJlje3P2uSGaYHYAMsFjOQ21QCyjcQAM4GKrXfhDwxpkk/iCeO+jMCSTySRX92wAIcswjVyCcSSYwuRuOK50/CGRBDJa6lplpcpaT2zyW2jmMP5okDHAmyRh0+Uk/6sYIzXReIvB1zrlxHPHfWUUq2L2oe50/zzEzKQXiPmAx53EMOSwAGRjNS9hrfX+tv+D9wi/DXwhJcJfLpR+0fY47RLkXUwlESYKYffuDDAw+d3A5rRtfCOlWmiy6RGLptPkjWMQSXkr+WFOQUctvU55yGzkDHSuIT4QXmd0us6UWWC4gjWPRSiKkwk3qR553LucNgnqo6ZJqifhbq8fijTElltZ7O3Sci5ttNjiSAyl87C07SRsu8sCisGON2MAhvXT+uv8AXzFtqd/d+BdAvf8Aj4trkny1QlL+4QtjoxKuMvjgufmIJBJBIqjqfws8IazNcy6tp1xem5cvIs+o3LpksGyqmTavKj7oHHHTitDwV4am8JeFrfSLjUBqDws7ectsluvzMThY0+VQM9BW/Q9HoJbHP2vgbQLK6FxaWk0MgnW4Gy8mC71LkfLvxjMj/Ljbz06V0FFFIZzPgeNJvC97HKoZH1jVVZT0IN/cZFWB4U0Nrez05La5SHS42WBFuJ0ULIpU5YMBIcZ6liM54zWRoOjQ694Ev7GcR5bWtTeJ5IhII5F1GdkfaeuGAPakm+H0p1AXFpf2NsqTW00appoJDRBt5OXwS+8jOAVHr1o/r+vxDUtr8PvC11DbulhdRxwxokSC8uYdqoFC5XeOfkTqMnauc4FXYfBWhwaLeaTDBcpZ3gQTIL6fcQqqigNv3L8qKPlIyBzXLP8ACmaSxML6pp/mGya0Eg0sjaCpUKB53EQB3eXn74DZ7VdPhTV9P+G+uaBIbHVlmtLhbSG1tfs+XkMjbNskjKFBZQvzDAHNNvR/1caWqRDf/DfwzcNeaXp82pW2qTWjuktxqF9cRoH3rvKtLsfBkc7Sc/OSfvc6n/CAeHHhtLW9SaS6jgYeYuoXCSScYd8+ZuJ+cjJJIDYzXPJ8Lb+WLTXj1Ww0/wCzqXeKLSiGhd23OISJyIsjj+LkscnOKtH4UxG0hT7TpoljSVcDSh5GHaNtoj8zhD5R3ru+fzH5XNFu4rtmzJ8N/DctilnJHqRhR3cD+2bzcS6hWy3m5IwoGCcDn1NVB8LfBc948x0u6N3CjQG6e9uhKVZvMOJS+5slj8wJ6sueorB0r4XzDVNdW4jtrWCSMQW1w1mjG43QxqxOJSTEGTiJgOg+YitF/hneSanaXz6zZNLa3qXqMNL2sZFjijJ3LKMbhEQcDB3njgULfX+v6X+QdP69fz/zOl03wdpOjyQPpn22Aw46380nmDLth97HcN0rnn1HoKpXfw28MX1/PeXlteyzXDO0m7VLrad33sJ5m0A+gAGOOldLaC5FnCL4xNc7B5xhBCF8c7QcnGemaloe9w6GCngvQ0vFuhbTmZZvP3NeTMGbCgZBfDKNikKcqCoOM81vUUUgCuV0K1gvtX8b2t5EssEurorow4Yf2faV1VcVbaWdal8e6csywm41eNd7x+Yn/HhZnDJkblOMEZGQSMik9hrcs6boHhfWbexuLSK+uFtT50E9xcXYcnzB955G3OQ0I+ViSu0cAEZkk+HPhqS4imNrdrJEQUMepXKYwQQMCQDGVXjp8q+gxg6d8Lryxtoov7X05TCbcxNb6R5YTypZXGFMzDpKyj+7gGpR8LENwjS3tm6LcNMf+Jd87ExuqyFvMI87LhjJj5iicDGap+Ql5/1/X6mtp3hfwteyXb2EF1vhvm88m6uUKzKSWHLD5TvPA+RgccjFaa+FtNWyvbI/ams7xCklu13IVUFmYlPmyhJc/dI6DGMCuC/4U1d7bYJ4gsYEgmmk+z2+iqsDCRFXbsaQlclTuKsNwYqeua67wv4OHhm/lmguLXyZbSGF4LeyEIMiDDSZ3E/N/d7cnJJzQtha3/ruTf8ACC+HxGYxaThDF5RAvZ+m4sD9/wC8CTh/vLngikn8CeH7lZRLb3X76MRyFNQuELYx82Q4O87QC/3mAwSRXRUUhnLQfDfwzbq4S2vn8wgsZtVupCcFjjLSE4O98jo245BzSXfw18LXt7NdXFjcmSYtvVdQuETndnCCQKud79AOWJ711VFO7A56fwNoNxdS3EkF35sobJXULhQhZg5ZAHARtyg7lwfenaX4J0LRtY/tTTre4iuthjG6+neNVIUECNnKDhE6D+Eelb9FJabAFc38OP8AklnhT/sC2f8A6ISukrm/hx/ySzwp/wBgWz/9EJQB0lFFFABXN+F/+Ri8Z/8AYaj/APTfZ10lc34X/wCRi8Z/9hqP/wBN9nQB0lFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Guc1w+IFubx/D9hd3WrJdT+Y8C2uYkMRFuwNwR8vP8GR/rM810d9/wAlT0L/ALAupf8Ao+xrkPEHxY/4R/xTq6zG3e00+22mzNzlw4lVTLIqRNJGuG4xvBGDhaX2rB0v6f5EzxeN9U0S9tta0rUpt1vKsMDvYASHzGMZk2txIF2EbWCcNnkDMfiW08e3+n6xpiWuoXlncpJEjA6flkLS4ChsDBDRK24Z2o2PmwWtW/xXa4S+Y6XZwi2AOZdSKiDLKFNz+6/cAhwcnd0b0yZbz4mBby3tFgt7W6lSCWKCe9CPIJInYKR5Z/iXbgEMRk8YwXLa7CL1bRnfaPHthfRmy0XVILJJ1eYH+zdjpmIHdiTecIsoyOfucnmrHg7XPFOvfDzUL03Fzd6i11thMU1jIwiyobynQeVvxvIWTO1sKxOMnY0Xx8NQ0nUri8iso59OsIr1/Iu2kiZXjL53eX8oyCONxxzjtWCnxqtVNmLqysI5J4S728eqrJMrgzKVRAnzjdEMNkcOOOxp3Xuv+v6sKKVk1/X9XNG8Hjw3E4tjqKxEQhDGbEkDfHkruA+fb5u/I2/d2Vk38/xWhmuo9Hsr26Rbj91LfTafFuQSPgqUB4KmMsGUMQrBSrcnU0Tx/K/gZ9ZurrTLyRtUltRKdQUWsQ3nYGnWL7oXADbMklc9c1JJ8S2+3vaQ2OniT7alpGtxqZiYMzMoDr5RKMdu5V53Id3HSktGv67D6P8Ara4mj23i2bxXBceIbC4mt4dQme3nc2v+jQNE67cowZlLBSPl3YYZ6V39eVQ/HKwe8trZrSzlkmu47cmyvzcqNxIHKRffypIU4BUZ3A8VreFPiB/wlXiS2hWWC1UxXStZxXKTLLsMDRyhtqvykp4wMcgjIppOWi/qyFa39ev+R39FFFSM85Oq3Wi/CXW7/TphDdRavqfluZIo8E6lMPvy/InB+8wIHUg4xWbajxvNZW2o6Pb332u7jsnu73NgRc7BJ5ikZwQcqoZMdVIJGa3tJ1kaB8O9T1ErG3lazqYBll8qNS2pTrud8NsUZyWwcAE4NZXhf4majqXh+O5jh0zWY7GGA6ldW+p7plLjk+VHDtyCGyMrwMgdgR6/L+v8wa0XzL9tJ47EnkXUOptEtygNwrWAd0G4EjsEJCM3y7sN8vPyipqMnxJjs5DZw6jLP5zYWL7Bj/VvjbvYfud/l4z+8xvz/DWzqvjq50rxJo2gTaTGdT1W2aRE+0SeWJApOwOIiCoI+ZjtIDAhW5AoxfFJYvEGl6dq+lrp8epRu6TPO52BFPmE5iCgIysGJYfLtYZyQGtf6/rsG39f13GaZfePY9YtLnUtP1M6bCk/2mCX7CzzD940ZAjfIcYjXAODu5xgk7WuP4nfVC2ix3K2xsi0IVrcR+cc5EocF92Nuzb8uc7uMVn+IfHUfh3xzBYPcfaY7rTvOjs1ZBhlZjuGAWJYDaAflJwOCeci3+MgvtHW/wBP0/TZAbU3Bjm1N4S377yhtDQZ2lioDsFHJzjHKvdff+o7Wf3fjYddah4206a2n1VtQh0pYf8AS7m5bTlSJSZRulO7O8Awk7AUyDgEZBb5/j+CzhSwtNUnt3hiMTWq6fGIwRAxASQrgAeeuCO6/UWrP4pzXE8W7TrHyrmWMQD+0MSFXiifaBsw0p83hARkIxz8vMH/AAt5109bmXS7An7bHausWrblXO7zPmMQHmIELGM4O0g5ycVVmn/X9dSdG7/1/WhLAnj+90z/AImC6xaXMf2Y4t5LAb1V08z1/eEByRkR7cADORTk0/xkfDN1Ay3u6TTyYrNo9P4m2uhhKhdhDEpITnHBGQPlqlpnxRu5/FD6Wz6PdXtypih0+PVFHkzL552n91v+YRoGyDtLLgHNeg6Bqk2taSl/Lai1SY5iTeWYr6sCq7TnPHPGDnnAOg72ZxDW/ji1ub6S1t9SuJdsr28kzWGBmZGWFG+8qlAQdwIGOOcV6DZXT3cDPJbTWzK7IUmAydpxuGCcqeoPp6VYopdLCtrcK5vwv/yMXjP/ALDUf/pvs66Sub8L/wDIxeM/+w1H/wCm+zpDOkooooAKKKKACiiigAooooAKKKKACub+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISgDpKKKKACub8L/8jF4z/wCw1H/6b7OukrhNNufEUHizxiNE0vS7u3/taItJeanJbMG+wWmQFWCQEYxzkdTxxkgHd0Vxlp4n8V3s6xW2g6G2+Myo51m5COoIGQxssEZIxzyORkVbm1XxnBBJNLoHh9Y41LMf7enOAOf+fOjZXYdbHUUVyVlrvjDULWO5tdA0ExyKGUtrdwhIIBHBswehFWP7Q8bbSf8AhH/D2B1P9vTf/IdD03Ba7HS0VyGneIvFuq2iXNjoWgvFIAVZtbuEyDyODZg1a/tDxsenh/w9/wCD6b/5DoA6WiuRtNf8XXrXAttB0Bvs8phkzrlwoDAAkDNnzwRyOKsi/wDG56eH/D//AIPpv/kOgBb7/kqehf8AYF1L/wBH2NSXvjjQNPuJ4Lq6n8yGRY2EdlPJuYsFwhVDvwxCnbnBIBwSBXN3l54x/wCFk6MzaFoYuBpN+EjGtTFGXzrPcS32XIIIXAwc5PIwAec1OPU/EmtXek6ZpGlWGqNeJJctJq+pRq/lOskiQt9lRVZsKS0TZ5DHPBoWskgeiudxpvijwlpk15Dp93dGW4A1KSMw3MzSiXGGjBBLZOBsTp6CrE3j/SLTUfsd4t4rM7qrxWFxIqbfLB8zEf7vmQcn5cYO7nFcre+HLu1uoGn8J6PBLdsttC0Hie/XawVSuClriM4hX5uOVHOTzYuPC3iYQ3H9neHNBgmufMWR5/Ed5OuyQIsihGt8cqigdlIBweQWrf1+H4A9/wCvn+J2uma7Fqd9LBFFIiCNZoJXVl85CSpO1gCMMp7YIKkEg1qVxVpb+NbPUpbv+wvD5XyUt4IhrkwWGNe3/HnySTnPoAMcZNuDWPGVyCYNA0B0wCHGuT7WBGQVb7HhhjuM0gOqorm/t3jf/oXvD/8A4Pp//kOqVx4j8W2uoQWMvh/RTcXCsyLHq91IAq9SxWyIUdgWIyeBzQB2NFec2nxJ1q9tJ7mHQdOEcO0ES3WoRvIWLACNW08NIcq3CAng1Yfx5ryPCh0bRS0wLYXVLxjGASuZMWP7sZVhl9uSCKAO+orm/t3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6ADwH/yLt1/2GtV/wDThcVu3dlBfJGtyHZY5BIFWRlBI6bgCNw9jke1cF4LvPGK6Dci10LQ5E/tbUiWk1qZCG+3T7hgWp4DZAOeQAcDOB0H27xv/wBC94f/APB9P/8AIdAHQzRLPA8TlwsilSUcowB9GBBB9wc0yKzghsltEjHkKmzY3zAr6HPX8etYP27xv/0L3h//AMH0/wD8h0fbvG//AEL3h/8A8H0//wAh0AdGAFUBQAAMADtS1zf27xv/ANC94f8A/B9P/wDIdH27xv8A9C94f/8AB9P/APIdAHSEZBFU9K0q00XTYrDTlkS3izsWWZ5WGSSfmcljyT1NY/27xv8A9C94f/8AB9P/APIdH27xv/0L3h//AMH0/wD8h0Ab9zbpd2stvKZFSVCjGKRo2APoykMp9wQRToIY7a3jhgQJHGoVFHYDgCue+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOgDpKK5v7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q6AOkrm/C//ACMXjP8A7DUf/pvs6Pt3jf8A6F7w/wD+D6f/AOQ65Sw8QeJ9EuvGeo3OiaOYYdVje626pcuYz9itRhQlmzONu05wMEkYwNxAPT6K4zT/ABP4r1S4u4bPw/opks3WOcS6tdxbWKhgAXsRn5WB4zjNXX1LxrFG0kmgeHkRQSzNr8wAA7k/Y6A3OmorjrjxJ4stb20tJNA0Np7zPkrFrF1JkDGWYrZEKvI+ZsDJAzk0p8R+LV1RNPbw/oi3EgYoG1e6CttCk4f7FtPDjv6jscAHYUVzf27xv/0L3h//AMH0/wD8h0fbvG//AEL3h/8A8H0//wAh0AdJRXN/bvG//QveH/8AwfT/APyHTI9T8aSgmLQfDrhWKkrr8xwRwR/x59aAOnorkrPXfF9+Jja6BoLeRM0Mm7W7hCHXqMGyGfqOD2qx9v8AG46+HvD/AP4Pp/8A5DoA6Wub+HH/ACSzwp/2BbP/ANEJTItT8aTRJLDoPh2SN1DK6a/MQwPQg/Y+RT/hx/ySzwp/2BbP/wBEJQB0lFFFABXKaLarfal47tHdkWfVVjLIeVDadaDI9+a6uub8L/8AIxeM/wDsNR/+m+zpNXVmNOzuhuq+G9S1PRbewTUba2ECbB/opkRv3ZQMVLjoSGA5AI78Ywf+FTwxaa9tZ3tvC9xHLFdObPcJFbaFAXeNu1AVHJ+8x4JzXolFVd3uLol2PP7v4aXVzE0SazDEjTm4ytkdyMXkcbD5ny/M6HI5Pljn02dU8KXN7oMVhY3lpYOC7SGKyzE7MhUHy9/VcgjJIyoOOmOnopdLBs7nBj4albfyodSit9pco9va7CuYhGo++egSIgjBBTg8mnS/DSCW+mvjdQi6Oz7OPs37u3AcF1ChhwyKqdQfvH+I13VFO7vcVlax5+nwuD2U9re6jDcRzo6sRalShkdjIUAfCllkYdMgnI44rodC8KW2g6pd3Vr5KRzqEjgih2iIAnoSSckbAcYB2A4ya36KLjObvv8Akqehf9gXUv8A0fY1j6n8MLbV7rUrzUJbO6u7u/S6ga5tZJYrdF2AqImm2byseDIoUnPII4rYvv8Akqehf9gXUv8A0fY1zt9p0C+OY7XVNIxd31zIy63IyBJ7YjH2Tdu35wceXjacFxyKS+L+vIH8P9eZcPw4kS+uZrPVILVLi48xvKsishT5+GcSAM678I+PlVQuD1rNm+FV3G1hNY6lpcMllIZVSPSGVc+ZG+IsTjygfKweuTJIeN2BLoPhvUPDujoNC8PyaNLcapMbtLEWiSPB5sjQk5LJsCsAcfOF4UcCn+LpPG8OvXjeFdM1B43RNlxB/Z4RyI3+UmVw+0OU6jON+O1PbYN2Ynhf4T3p0uxOqm0sZrTUGuyr6XEskhOwYJimZfuoy5ydwbLLuGTr23wna3s47UahpqQxPGUSHSfLC7Y1QyAeacTfKCsg+7k8HNVtQX4nWt/INLjvrm0ma6fc9xZB4SQTEqqy/MBlAuWGCH3ZG2tW9svG8Gn3cdjqep3MzxpJBKy2IeN2wrR42BTs+Z+evA3Gjmdr+n9fgFvet6/1+JLoXw+udIGvJLqtt5WrxNGBY2Jt2hJeRt5Jlbcf3uOg4Val8OeAjoGtw6isulkx2b24W30vyShZ9+Iz5h2Rj+5zySc81l6ZZarJ4mjPiSwm09b63UvcRtEA975Ea7h5bNhgBKAWwMgYzxWvo2i/8I9qWlaXaXlxeT29jKtzNMSd0e7Me7sMMWCjqBu96Hpr/XX+vQN1/XkU9I8AahpMUjwajo8V79o+1R3FrozRb5T5gZpl88+ZkSMOCrdOeKvat4Q1TUWZoPEDWrXaRJfNFDJGziNiwMTxyo0R+YjkuMYyDyTW0bw0NUh0rVH1O/tLq2tpoLyCKTbuuH4kY/7QbJ98IRwBmxomijw9quk6XbXlxeS29lIt1NKSd0e4GPd2GGLBR1A3e9HkDOtVQiBRnAGBkkn8zS0UUgOb8B/8i7df9hrVf/ThcV0lc34D/wCRduv+w1qv/pwuK6SgAooooAKKKKACiiigAooooAKKKKACuHj0mTXV+IOlQzQwNeaokRkngMyAHT7MHKbl3cZHUf0ruK4G4tr290/4j2ulLcNeTaiscK2zRrIWOnWgwDJ8o/Ht70nsNble++FDT2pttM1Sz0a3Gpx38cOn6SiJHiNUZQpYgMdu4OACpJPNQ2nweijvbx7670u7troXLeU2kYaOWZVUupMpUfcViAoySx4zxHFpviy2u3sBotzNoCPEtrZ+VpyrCgjkVxgFcA5Q8DIO4A7epCnxAsrS1sbe01ZIRFDGrwtpx+zjEGR87c4AnX+L+Hr1qt7r+tv+AibtNP8Arf8A4LNbxF8Nk16Oxi8zSYYrbT/sDK+k+ZlSyEhP3g8tcIQAMkbjg1Ui+GF8tm1tNrOnzIfmBbSmz5ghijRzmY5IMKse5zwR1rW8I3Xi6K/v7XxfZyNE10y2VykkMgaMAnc2xV2KflwGBbO7JxishYfiC+o2hFxqS20j3QuVmFhiND5iwkbBuDDEbZy2ctkDGKLtfP8A4f8AP8RpL7v+G/Qr3Hwinu9M1C3k1fTYbieKKG2ubfRVBhRJGfa6vI6yKdwBHyj5F9BW/r/gu68SeCD4d1HUICqsircvbGVnRVwGYbhiTPzblI5A9xVDwafHsUeqw+JreZo4rZPsEs1zbNLLJtPH7tcKegJYsC2SOOKytNuPihFd2sd7aajOE3LJJN/Z6wyZMu1nCPvBAaHO0YyhwMdTbT0/r8A8zU1L4Y/2mt4ZrzTWnuJS4uZNKDy4aN42V3MmXADkL02jg7qZpvwuk07xXp+tQ6xBCLWaaae3ttNSMXDSZJO8szLyTnB+ZQgP3c1FomneKrLwneRpa6pZ6jdayJnkP2AzNC5TzJCATF039BuyAcHnNPR18W6bZpp0jXmig3KxWNtcGxPmo+8OEEe84jG2XnHRgfl4DV9Pl+S/z/Bieqs9tf1Jdf8AhNqWu6lqVyPEdnZi9l8z91o4d8BgVDl5WV9oBx8owx3DBFTy/CVLnxNLqV7eade2tzMktzbXWlb2m2I6KS3mbd2JCC2w5wuRwc5a2PjvSdcmntbDXdQkYPBLfF9M3XEYecxn5mUgL5iEAqOdwIxgV0Xgy58avrRTxPZ6klmYG/eXf2HaHyhXHkOWzzIORjATvkmYpW5V/X9WHPdnT+HdHTQPDlhpMZhK2cKxAwQ+UrY7hMnGep565rN+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISm227sNjpKKKKQBXN+F/+Ri8Z/8AYaj/APTfZ10lc34X/wCRi8Z/9hqP/wBN9nQB0lFFFABRRRQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gukrm77/AJKnoX/YF1L/ANH2NdJQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+A/+Rduv+w1qv8A6cLiukrm/Af/ACLt1/2GtV/9OFxXSUAFFFFABRRRQAUUUUAFFFFABRRRQAVxVtqw0OTx7qTIri31eNsPJsUf6BZjLNg7VGclsHABOK7WuT0W+t9O1Xxvd3jlIY9ZjLFULE/6BZgAKoJYk4AABJJwKT2GtzmPDnxR36dC9/fWeoPi3SaSK+jZVMk80e4BIgSfkQdMNlThOc6Q+KDvcJFFptm7tcNEE/tL5wFjd2Ur5efOAjOYuxZPm+bjobrxxoNiwW7uLmFjGshDWM4KggEKfk4fB3FD8wGSQACaoah8SNHs7rTFh864t7wSSTSrbT5t40jkfJURn5sxMNhw3BODg1W/9f12YkcfY/GhbVdt8bO+e7vbhYZIb3fDCqorKnmpDggBssXCkLk/ORz2nh3xvFrF+bO+Sys5mt4LiIRXvnCRZgSmCUUZOOByTg44GTYufHeh29pPcK95OtvHLLIsFhO5QRllbdhMLkqwG7G7BxkUknjHRN+y/dlIuNkam0mZkICkFwYx5ZywAJ4JIAJJxQrLRie/9epkeJfiV/YA1fy7OxuX010QW76gYppCRkkr5ZCAj7hLfOQRxWNrXxWf+wbe9s59KsoJ9QMMd8uqI8bRRzIrjLRFSzK2dgPC7m3DaM9xb+MdFvNBn1e0unktIGCMfs0ocswUqoj27yWDrgBTncMZqjonjyx1OwtJ71fsT3UULCILK+1pFZsEmNQFwp+Y98g7TwVqlr0sP0Obt/i9EPLi8ixuEawFx9sOqL5ayF1UrIRENsYD7vMAIwrfLkGvR7K4+12EFwfL/exq/wC6csvIz8rEAkehwM+lYY8feHSFP2q5+YOebC4G0IFJLfJ8ow6kE43BgRkGqOm/EzRLjS1utSaWxkPnsYfs88hVI5HTJ/dgqxEbNsYBsK3B2k0+n9f1/wAMB2NFUNK1qy1lJWsGmPksEkE1tJCVJGcYdQe/4HI6g1fpAFc38OP+SWeFP+wLZ/8AohK6Sub+HH/JLPCn/YFs/wD0QlAHSUUUUAFc34X/AORi8Z/9hqP/ANN9nXSVzfhf/kYvGf8A2Go//TfZ0AdJRRRQAUUUUAFFFFABRRRQBzd9/wAlT0L/ALAupf8Ao+xrpK5u+/5KnoX/AGBdS/8AR9jXSUAFFFFABRRRQAUUUUAFFFFABRRRQBzfgP8A5F26/wCw1qv/AKcLiukrm/Af/Iu3X/Ya1X/04XFdJQAUUUUAFFFFABRRRQAUUUUAFFFFABXJaPp9tqup+OLK+QvBNrEYYK7If+PCzIIZSCpBAIIIIPSutri7TR7fX5vHumXio0dxq0YBeMOEYafZlWweCQQD+FA1uaV54E8P34Iube6OYxGxTULhC2P4iVcEvjgufmIJBOCRVaL4e+FI54US3uGltUYhG1O4c4feCXBkO7O+QAtk4JArC1r4Tzalqv2201q2tla0MMttJpaSRvIX3tJw6sAWJbYGxu2tnIqKL4PobqwmvpdBvfs0YjkWbQd29QZdqLmY7ExKBtO77i9OlHT+vP8Ar5iX9f1/Wx01n4F8N/Z2lgtLwJdQskizXtyC6uDncrvnPzMRkZUsxGCTTIvCnhi91C8RIrx7m3uN9wXvLoEuyIRyX+ZcBCAMqGXIwwrJj+GLLaQxT3um3EkFrbQwzy6SGeNoSpXaTJkRnYD5YIO4k7u1U5PhRqE1jaW82uaa32CeGa0I0dh5ZiACf8t89FwcEAgkY6Ybtf8Arb+ugHV2XgXQNP0a50q1t7oWl06SSB7+4dwyBQrLIzl0ICLgqRjaPSqFz4I8I6NpRe7tbprOJ4CVlvLq4CmNv3fyl24BY54x3PAqpffDVbv4f6f4ZhurG2NpIsrTxadhHdQcOqCQFGBKtkMfu46GqDfCUm3ytzoS3jRXCvcLoZG55ZQ+7Hn5G1QUA3ZwTzjijr/XyA6Y+CfDdrbs8sEqQpFKjtLfzlQjhQ2cv0ARQCfuhRtxismz+G/gPVlW7g0yeaS3Nxai4lu7oTLmRhKN7PvOWL85/iODhuc9PhbBdWcmmanb2UqixeJrsafGsMshZvJKxF2b9yruBlh1GDxxXk+EmpzPOZNX8PtHcOryRHw8+w7WcgY+09AJGXH93j1yXsx6WO5i0HTbPXvtlsLuK7uD5srrLKyTbE2BXySuAHyF4yeeSCa2a8zs/hTfw29xBdazpM8M1tJblF0Vl3eZ5W4tunbdnyQT0JLscg4x3Xh3SToPhvT9Jaf7R9it0gEu0rvCjAOCT2A7mm7W3/r+rEo0q5v4cf8AJLPCn/YFs/8A0QldJXN/Dj/klnhT/sC2f/ohKkZ0lFFFABXN+F/+Ri8Z/wDYaj/9N9nXSVweneE/Dmu+K/GN1rmg6XqM6atHGs15ZRzOqCwtDtBZScZJOPc0PQDvKK8VTTfCmk+HrHVNS8LaHcSXFjJNHb3WmWtuJyCDnIhznLoqgADG5jmtOK28ET3UttH4E8KJIrP5TzW8Kxyhdp+VhEckh0IAz1bOCME2A9XorxFbnwLqC6bND4N8N2YMqtPH9it2EgMSEpuMfyqHnhy3oG9K2tB07wnrt8wg+HHhn7BCjSXF2ltC20B5VXavkjcT5YbGRgMPxbVtwPVKK8QR/Bt14ilay8HeGJbSO03paC1tQzvt3YyYvvEyQr97AJPXBrSmXwcYofsPw18PXU08ixRwiyiUlmKAE5iyq/PwSATtPGBmizA9dorxORvBz6xaqvgjwzH5cTi4tFtbYjzixVQ7tENoBjlwcjPyZA3YGpBYeGJLyKOX4aeGI4Zrw2kUqwQsX2na77fJztEmEz6nJwOaEm9gem52l9/yVPQv+wLqX/o+xrpK87vPAPg9fiTo1qvhPQxbyaTfyPENNh2MyzWYViNuCQHYA9tx9TXHS6Doi+NJLO00nwjcWf8AbUlrHFJFZJI7C2MgtmQWhKrvGN+8v2waS1dv66f5h0v/AFs3+h7rRXjLSeFodT0y3uvhj4Vii1IfuVKRC4Yq6JKqxG3G5lZycBuVRm46VlW/iDwfq9hPJovw48HrNBHNJKt/GsGxYmQMdptsnHmYPQAo43EAEtJvYD3uivBZfFfw6hmuI5vAPhOA2109vKLmOKE/LgnbvgG9sZ4GRynzfMdutczeAYryWP8A4QvwqJLeS5iaDybcBjH5ZDNmD7u19zMpOwA/e7Lpf+v61BanslFeOaZd/D++8Uabos3gfwhFJfqpUxrbyPkrKQVTyhvQ+Vw+RkSIcc4rv/8AhXHgj/oTfD//AIK4P/iabTQrnSUVzf8AwrjwR/0Jvh//AMFcH/xNH/CuPBH/AEJvh/8A8FcH/wATSGdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAB4D/5F26/7DWq/wDpwuK6SvGLjwn4Us/hbq2of2PoFjdRavfxRXdxY2oCgajLGiF5YnVV2gKPlOABgcCk0jRtFijvTP4L8J6vN/aj2bRwx27pZuY1MUe5LVSVLEgsy5XP8VC1/r0/zB6K57RRXhT6/wCBrXTkur74beGBuvEtGNpBHcIjncDGWW34lBXhCAPmXLLmlv8AVvCGm6VHq9z8PfBbafJbvKjwKkxO2ZYi2Vtj8oJOSAcZX14P6/C4HulFeHw6/wDDqY6hjwL4RH2OLzigWAyKgdVbzEEO5GAcfLhiWBXjGTf06HwfcRyvF4B8MXsWbl4XhhgkeUQyyB1VVtwPlVUIBOTvAJz8xbVlcNz2GivIrCTwDqPgrTtfg8C+Fo1vro2ym5tEht1ILc+Y0G7B24X5BliF4zmqE1z4Khu7qWXwR4NFtbRXZRYmt28zyJkRmdTbZTAYsNpP8QIPBos72BantlFeR2Q+HLawLa48K+FRbS3c0JuGt7ciEpEkmMCEY4JJ3kbTxk5AHb/8K58Dnp4N8P8A/grg/wDiaLOyYro6Wiub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mkM6SuIh/tEnx+NE80X51aMQGEx71b7BZ8jzPkJHXDcHGK0/+FceCP+hN8P8A/grg/wDia5/w54B8Hz694sjn8J6HIlvq0ccKvpsJEa/YbVtqgrwNzMcDuxPek1dWApi5+Jyywo9lqMhNoiXDqdPEYk8r53T5927cPlDfLljnjGNPRbHxHpfgfQ7G3sr61liuXF1FG9mJlj3sVJ+9EFORuCcgH5RkYrZ/4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJqr63FY5lT8R21e8jxqCW5mnltXf7B5aqFPlxOR85BZQQQoOHwxyMjLsdM8dWGkXMOlaZqdneSfaGju5RphdXkuVcMQrFTlSxZQApxxhsGu6/4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJpLQp6/mVdNl8Vtp+ryahb3i3n2fNpF5lqI9+35REQCQ2eGMpK7h8uVrAgi+I0sdsl3caxDJGIUlkhTTQsv79w7kHcQfK2NgcZ6A8iup/4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJp31uLpY5yyPxKk0949Shkjn+3vGGhuLUloCmBJnYAqhuVXBfoGJGa7jQY7uLw9YR6k07Xa26Cc3JQyF9ozuKfKTn04rK/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4ml0+78AerudJRXN/8K48Ef9Cb4f8A/BXB/wDE0f8ACuPBH/Qm+H//AAVwf/E0AdJXN/Dj/klnhT/sC2f/AKISj/hXHgj/AKE3w/8A+CuD/wCJo+HH/JLPCn/YFs//AEQlAHSUUUUAFc34X/5GLxn/ANhqP/032ddJXN+F/wDkYvGf/Yaj/wDTfZ0AdHtHHA46cUbR6D8qWigBNq+g/KlAA6DFFFACbFxjaPyowM5wM0tFACbR6D8qMDjgcdOKWigDm77/AJKnoX/YF1L/ANH2NdDNEs8DxOXCyKVJRyjAH0YEEH3BzXPX3/JU9C/7Aupf+j7GukoAzodC0+DUba+iikWe1t2tYj58m0RkgkFd20klQdxBPHWtGiigAooooAKKKKACiiigAooooA4/wvqCaX4Ou7qX7o13Uk5DEZbUplGdqsRyeuMeuBzV6fXNGvr2Dyjc3N3DJMkMaxXAQOowxfau0LngSMMc/Keao+F9LtdY8G3lnfiVoH1vU2IineJsrqM7D5kIPUDvzWiPBGgLqE18lrNHczyPLLJHeTIZGYAHdh+R8qkA8AgEYIzSeozH8NeMfC1h4asILaW4tVMZY27pc3DRMVEjKXZSxHzjaTw2QFzwK0o/HuhXUTmwuZJXXadstpPGMF1TOTH/ALanp0ZScKc1h3vw5+H+n31kl7pl3JdnzZLRzdXk8gKxAMFcOxBCKNq5z8o2jIq/a/D7wmkzJbJqbsykMf7XvXUbWTK7jKQpyiccHC46A1ejZLukbq+JdMbS59RElx9lgfyy/wBkmzIcgDy125lBJABQMCemap3PjrQLOd4J7m5EyBN0a2E7Nl9uFwEJ3fOmV6rvXIGRmwvhPR00mfTVgmFrO4kZftcu5CDuGx926MA8gIQFPTFUX+HHhV9cOsf2WU1FhErXMdzKjuIiCmSGGeVXOeuBnOKStfUZA3xH0c6vZ28LPJZ3KyhrryZgY3VowAU8v7jCQESZC8d85q0fH/h5YUla4uwj7sZ064zxxyPLyMkFRn7zAqMkYpll8OPCemljp+kJbF7lrp/KmkXdI2N2cNypwDsPy5A44FW7fwdols1kYrecmyz5RkvJnzli/wA+5z5mGJI37tp5GKXRD0ILjxr4cLWtteXEgXUCUhE1jMI5f3YkIyU2/cOcE88jqCBM/jLRY443Mt2UkiWXcmnzsI1YgLvIT5Dk9GwcZOMAmhvBehM1ifski/YARbhbqVQgLBsEBvm5AxnOBwOOKhi8BeHYLcwQ2c0cRgMBVL2cAqSTk/Py+WbD/eGTginoTqQS/EHSLW9AvWaCxlW3+z3Xkyne8zyIEdNmY8NHjLHHPOO+5pWsWetQSzae0zRxStCxlt5IvnU4YDeozg5GRkZBHasNvht4YeVJHtbxmQbVzqd0QBl2xjzPWR/pn2Fb2l6Xa6PZfZLBZFh8x5MSzPK252LMdzknkknrRoN76Fyub8L/APIxeM/+w1H/AOm+zrpK5vwv/wAjF4z/AOw1H/6b7OkB0lFFFABRRRQAUUUUAFFFFABRRRQAVzfw4/5JZ4U/7Atn/wCiErpK5v4cf8ks8Kf9gWz/APRCUAdJRRRQAVwmmeJbHRvFvjC3vINUkdtWicGz0m6ukx9gtBy8UbKDx0Jz0OORXd1y/h6UQa342lcMVj1dGIVSxONPtOgHJpN2VwJP+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYrmdCv/E1lcIjw3pkvdjE3iz3EUIP7zPqrfvSm3hR5POM5q2/izxLJqH2e2sogwMknlNYylmi3qIzncCuVZicgYMbAA8Zb0A2/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYrDtfEfi6KCK4utPAtWWNHAsJ3mWRovNc7d2doJEY4+8eSAOW2PifxhKsr3GmfOYl8uP7BKimQRxkrycgF5WG4nAER4znDtq12A3v+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKyrTxF4pgmtJdbisYra7t5LlkjtJA9nGjoT5pLnkxs3AAwwxzXcg5GRRbQDm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYrpKKQHnd5400tviTo1wLXXNkek36EHQL4OS01mRhPJ3EfKckDA4BI3DPQf8J5pH/Pn4g/8JzUP/jFF9/yVPQv+wLqX/o+xrpKAOb/AOE80j/nz8Qf+E5qH/xij/hPNI/58/EH/hOah/8AGK6SigDm/wDhPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukooA5v8A4TzSP+fPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/wAYrpKKAOb/AOE80j/nz8Qf+E5qH/xij/hPNI/58/EH/hOah/8AGK6SigDm/wDhPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukooA8n07XdM1XwHqGltFq6NNq+oSZfw1fXMLA6hM4SRFiAZSPlZMgjJU4IIFHV9L0vUriSaJ76NnSEKJvA2oSBfLKfJhVX91+7ysfG0sTk5rfYSn4S60LZr9Jzq+p+U2nrO0qv8A2lPggQESEeoBHGcnFQaX4g1zS59J0ixea+hkiaWVrvStQM5HnMGYtM5eNQpBAkyTt2qWyCED2uczN4ftZYrdTfXrNFYPYmSTwHqLMEaMxhUP8KAENs5+YE55wLsmlaUbi7eL7UkV15jyRHwJqBEzvKsh87geYnykbeDg9eOdyDxP4t+zaekVhcQIkNtLMX0a5lYhom3xkvIG3b1A55UEFic1APG/jNbXTXvtKaNZhKl60Hh++kaMh28t1UNuCuqjI5Kkg8g8U9HftcLaW+ZgxaDZQzXxS+1Ly7q1MAz4H1EvnEW1nYjEmDCDjA+83rXpFv440qG1ijkt/EEjogVn/wCEavxuIHXAg4qHwz4lvZ5ltNasrm1V4rYWrvZToGd4izIzyEksCjZJAxkAkk1y+qeNfFOh6hrFvo+h6rqkS3TPDv0i6lKDeAQruyrIpJ4CkBRlvmAxTd0+T+v61Fuub+tf+GOy/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GK5iz8d+KJdcS2n0efymuDHs/sC9jwu91AMxzGONh3/AHevr8qW/jXxfJren2L2MA+1FjtbSLmN2VXiD9XxGFEjDe3ysY+PvgBJX2Bux1H/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFYmm6z42+xbb02M1x9ia6Df2VNGwK7lMTR+aWLb9hBAAZQwA5BpdK8V65LJHPNpN7HFcahHHOkumXKukbW6EkBnKoFfcCwyvy4wWOSf1+Nhm1/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xW/aXUV9Zw3VsxaGdBJGWUqSpGRwQCPoealpbAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFc/4c8aaXDr3ix3tdcIm1aN1CaBfMQPsNqvzAQkqcqeGwcYOMEE+iV57qAlOk/EkWpvRcf2ivkmwExmEn9n2e3aIfn+9jOO2c8ZpPYaV3Y3v+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYrktO8ReKNBtdE0iDRtW1OV7t4tQuLi1nlWMFwVKyyPkR7CWDMZCNoRsMciW38b+KbjVY7KWwEZ+x+dNEdGuRIPmmQuCJDtH7tGVT8zgkDnpT0VxLX+vkdR/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFcpD4x8X/wBjQ3NppjsBdwwfZ59Cvlk8oRK0rFmbdnJZVcqQSvOd3D5vFvjays3zYfapkjmYEaHdHeVZ9pG1scbUXb1cPvBwDQ1ZiTujqP8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xik0a88RvrU9lq81hNDBEJvPtrGSHerj5F2tKxDArJuz1G3GOa4Oy8S+LLG3nSWz1C+huIZZppX0bUkkExkIRYwXJVCi42rt2khuQaLa2H0ud7/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXKr4p8SaQsiRWd/NaNcXBjefRb25lUebPtyQclf9RgYHyk445XQ0Dxl4hk8SNY+JdHmt7BraGSO+TTpYY2kkKBUyzsc5dlKlQV2ZJw2FEruyCXuuxtf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFdJRSA5v/hPNI/58/EH/hOah/8AGKPhx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohKAOkooooAK5TQ7lLLVPHV1LgJBqqyNk44GnWh/pXV1zHh2RIdc8bSSnCJrCMxxngafaZ4pS2GtznNN+IuonUVN/ZwtFeRoIUS5UJG48oMQduSu6cKzE8bDgGp4fHka6lcX7aDaW0TMLV9TkuNhkYK0gU/u8ldg3Dn+NQBknG1bfEXwpeKTBqOQELnfbSpxhD3Uc4kU49DnpS6l4406z1DT7WFTOLtyHdkkURDKrz8h53SIpBxjJz0NU12JRmx/EOS70u2uorS2jeV4UkgF4GmjL7WOF2HI2liCcbtvHUGtOXxpBBocOpz/ZBFcyiOBku96fcLne4XAICsMDOSAB1q0PGGhmYRrcSGQuEUC2k+Yldwx8vI2ndkdBz0qivxF8O/Z1mnlmhhdQyb7SXccoH+6F4+Rlb6N2waT2dhrzMGx+JcRvI5bnQ7SzGoKv+kfbB+8YLD947BlVabaTnjacA9K63wfqNxrHhyLU7mYSi8kkmh24ISIudi8AfwgdRnnmo28WWE99a2elr9qmnnjjO5WjUIyu/mKxXDDbGxGOvHPIz0A46U9OwvIKKKKQzm77/kqehf8AYF1L/wBH2NdJXN33/JU9C/7Aupf+j7GukoAKKKKACiiigAooooAKKKKACiiigDgdP19vDHw6v9VENvKsWvagj/abnyI1V9UmQsz7WwBuz06CseX4qaTba411daNpQ1MaeT5kN6sl0UEZl2YEe8x/KTkZ4KsFOcDpfDGk2mteD7q01BJHh/t7UpcRzPEdyalOynKEHhgDjPauxo6f12GeX/8AC6rNNMW9uLbTrZJbU3EAuNTMRmGwlcB4gcMUcKcZOFOOSFdb/Ga0uop/s8WkyyROF3R6yrRD55FJZxH8ufLGzj5jIg+XOa9Oop6XEtjzUfFuzuPEQ0Yvp1tP9sjgRRqsZlYmRVKtGYztPzDKjnh8EbQS/R/ic1xJCNSXT/OkmtYJorXUPNW3MpcD5REH35UAqeB1yMHPo9FCslqJp3bCq7afZvqKag9pA17HGYkuTEDIqE5KhsZAJGcdKsUUhkUdpbw3E08MEUc0+DLIqANJgYG49Tgcc1LRRQAUUUUAFcKNabw6PHuqpDDN9m1iFmWefyU2/YbIEl9rYwCT07dutd1XH6ZpVprWoeN7DUVke3l1qEusUzxMcWFmR8yEMOQOhoGjCf4yW9vdxW9zY2ZkktmmEVtqQlkchJmGxNgLofJ4YdRIhxziqUPxb0cIuvPpOkWlxd2nyXc975LzoomKrueFWKF4SFyP41O3PFetDgUU9BHmNt8ZbS6ScQporyRjIZNcVolG8qWkcR/IuNuGwcs2OOCUn+MNmdaGly/YrKVpoVAbVIxMNzwblaNoztOJjxyT5b4Ixken0UKyeoHn+meP7Z/BGseIrLStPgngvNjxJeAR3TsECO0ojyCyug+ZeMYOMZFa6+LqRW8csFhY/vPIIFzqZiCrNA8i5bymUEshQLkk5B4zivSap32k2mpXFlNdpI0ljP8AaICkzoFfaVyQpAbhiMHI56UafkH/AAf+B9xwY+KRF/rFvBDpszafG00kc+rBHixsARlWElBucAlidp3ZOAKhtvitLPNBLc2tnbxyxCaG0j1BTO+bbzWDoY/uq2RuU/w9Dgg+nUUugrHn1j8Vbe58Q6Vpc8WlxtqG0Bo9WWRmJaVQ0S7B5iExjDZGQ4OOx9Boop6D6hXN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCUgOkooooAK5XQ7SK/1XxzaXKloZ9WWOQKxUlTp1oDyORx6V1VedjXbay1nx1pzHVobm41FfLuLHSLq7WItp9qobdFGy5BGduQenqKBrc2V8OeFZdaaCOCVb21YSZSWZPLZy75DAgZ+90PAwOBgVYl8CeHJrpp5bSRnYsSDdy7fnYsRt3YwWYnGMZNcCtlpvnXUkkurbrlZQxi8H6ihXeIlGCEyCqwgD6855zJLYaBdyWyX516e1hm3tCPCl+nnLvVwjEQ9F8uNQAAAqkYOeDsLudn/wAIx4Yg1H+z3iuGuLtXuSr3M7htqrGXLFiAQCoHIPp3qebwL4cuIJYJrN2SZdj5upc4/d8A7sj/AFMfT+79a8+j0/ThcI0tzrMkKpHEYf8AhENRUPGvmZDEJkkl1PoCi4GAAL9lB4bsr+3u47bWfOW7a6nceFL8NMxdmC/6rAVd3AwcYBBzT0/r+uwvTod1p3hDRtKvI7qzgmWaM5VnupX/AIBH0ZiD8qgVt1zf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMUhnSUVzf/AAnmkf8APn4g/wDCc1D/AOMUf8J5pH/Pn4g/8JzUP/jFABff8lT0L/sC6l/6Psa6SvO7zxppbfEnRrgWuubI9Jv0IOgXwclprMjCeTuI+U5IGBwCRuGeg/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKAOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKADwH/yLt1/2GtV/9OFxXSV534L8aaXbaDcpJa64SdW1JwY9AvnGGvp2HKwkZwRkdQcggEEV0H/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lc34X/5GLxn/ANhqP/032dH/AAnmkf8APn4g/wDCc1D/AOMVz/hzxppcOveLHe11wibVo3UJoF8xA+w2q/MBCSpyp4bBxg4wQSAeiUVzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQB0lFc3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUAdJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFAHSUVzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQB0lFc3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUAdJXN/Dj/klnhT/ALAtn/6ISj/hPNI/58/EH/hOah/8Yo+HH/JLPCn/AGBbP/0QlAHSUUUUAFcpor3EepeO3soxLcrqqmJCcBn/ALOtMD866uuV0K6hsdW8c3V1II4INWSSRz0VRp1oSaT2GtzNk1W+065s5bS01K8b7KBc3TLPIBI4LMDCBgsPLwMY2bwOAah/4SnxZJa2zPp7Ql/JaV4tMmbb8jPKu0tkHMbKOD/rE5zV1fHpXV79ZrOYWVsrEBYlaQeWiGQnDnoZUHA42uD0qxc/ETTreO3KWN9cNcv5cMcCxu0jh0RgPnwdrSAE5x8rYJxVb/MSM2bxD42s9Jf7XpdvNfrAsnl2lpKyEtGSRnd/CwC4Byc9BjNRP4i8ZJMbdLD92XCROunzM5QTFdxYsQCURzz03ITwcC+3xCifV7aO3tJ3tpLXzTCIg00kjE7AuGwBtjlJz1wMHnm9a+Oba7vEgXStRjWS7NpHPIsYjkkVmVsHf0BQ/XoMnijrdf10F01Mi48U+K1077RBpivI1vLKI10+ctGwTMaENjOWVwSOeU4IOap3finxlpsM00GmPfpDIBIDp04klAkEfyKDxlUlfIGBuQ4+avSqKL63H0OK0jU9Z1rxPbJfwXNva2sk0qSJazW6SgRxqA4bggtJIQD/AHBxkHHa0UUdEI5u+/5KnoX/AGBdS/8AR9jXN6/qGvT+MTJaW+qDR57e40oLAlyjCcqGWbYIwEXcNom3454wBmukvv8Akqehf9gXUv8A0fY1nXfjmePxXNYQWrixi8uPz2hVi8puUifH70HaN+DlQQeRvHFTa8lHvcq9lf0Ofu9e8XyaTocM1peqRfwebcW2m3YkmjSSLcrAMTGMGTc0mVcIcAbhiW48deMLbyTJpLgMzeYE8PX0hUhkzH8hPQFx5n3XxlRjg7EfxRs54TJbaBrM4QyCQILcbFQoC2TMAykSoQVJyG+tTW/jxorm+tNS0u7N3FNtt4YUiUzAsoEYJlI3qWAYkhT2PYXe/wA9fyJ0itemn5/1/WnOXfjvxPAiT22l3jXEtrHuz4c1F0LDz92EBwhLCI884fBJwCNHTvE2u6xq0Q1HTdQtLaPUoTatFp13AWjZZVZZgcggFQdxwuGUkA1LL8Y/DixXrW8N7dPZRJNJDD5RlKkAsRGZA3yggnIGRkruwa6nXNfj0PS475rO6vUkdUWO1CbuQSD87KMcY69/TJCvb3mN66eX6HGX/jLxckmvR6XZQXb2MzQ2zLpFyyh/MUKGKv8AvAVY5Mf3NuSOcCBfHviCDVo0XRr828lypuA+g6gxVCYgdrn5VwrSnpj930+atW18daDp97d22leH7uISFLuSW1ggRLhpU3b8+YMvkBW3YbLLnjmp9S+Kfh/SZki1DzrdneJVEjwoWWRNwcAyAkDkY+8SDtDURurddhSaevz+R19pdRX1nDdWzFoZ0EkZZSpKkZHBAI+h5qWsbw54ntfE0d81pb3NubK5NtItwF+c7QwdSrMGUhgQc/lWzQxhRRRSA4bRzeL8P9QOniYyf23qW/7OP3nl/wBpzeZs/wBrZuxjnPTmlXVNQ09tMg0C01SfTrqX5m1O2upZiuVUruc74cDc+6UHJUgdQam8OarFongbUdQuIpJYoNY1QssW3dj+0Zxn5iAAM5JJHFSx+P7Y3z28mlXwUXPkrMjQuhQlFWXh87S0irgAnnJAHNC3sD2OVTX/ABLBpyJYRamqRRIsrXmj380kg8mc7eWDFt6pl1wfmXJ6V2Hh/wAR3VzfS2erWs9tueNLNmspoxIDEXKlnySw2nJIUAkLyapxfEuzltmmOiavHiIyKrrADIdisEX97jcwbgZ6qRkZGYJfiWrwx3Nnot+1q9ulykjiIeaGt5JhHgyAxt+7xkhhnI75D7sLNtJeZkvr3i9/iNcW9rHPawzstrH9o0W9ntoVVpcSFxIsRJ/dksCowwU8rmtyXX/Ett4VvL+eK3ku7e6S2VLXTJ59+2QJLII45GcqRkgdV2856Vd0zxhFe30NjfWVxazXUrxJHMIgIysavsYiRt5IYkbewOQMZNfW/En/AAjWraToWg6QZY9yiWG2ijVY4ikhREzIgVmMRxwVwDnbkGlskmF+ZuSMS18ceK7nSnkXSJPtCSRjL6DexA5Q/JschuXXHmAlUDDcDjJZqPifxZNbXNvPa3FssMuyeS00S7ZnjJnU+WVYnPyxEMmcb88ituT4l6dFZ/a30zUfJMDzxt+4/ehFBdVHm5LD5gR2KN7ZiHxEWPVD9p0+5js2hICMsSyW8yNMHWRjLsIPk4XbxnqcHIJLS39f1/Xq49+xa8C+JLrVdMjtdZhuodQj3BfP064tvNjUJ82JRknLgE5+YgkDsOtrhpvilYGCwFrpOqPcahbzTRwlIFeHy94YOrzKSQUbO0kDjJG4Z29C8WWuuatfabFb3MU9ikTvJIiiOYPnlCrN0KsCDggiqfvMhKyN6iiipKCvO9S8/wDsj4kfYheG5/tJPJFkZhKX+wWe3aYfnHOM7e2e2a9ErjLLUDpVx49vlVmMGrRt8qB8f6BZ87Sy5x1xkUbhe2pg3Wr+M/B9nZ2sVq+oJLHPLJi0vdSa3yrGFBMMO+GChg6hsPnIwcWU8beKJtMaZdNmhmjiuGTd4dvW+0MpbYAhZWj42n5s78kLgjFXrv4m2OiahLp2sI0975lw0MdoI0LxxltoCySAsxCkZXIyMnbkVt6X4vstV1NLFLa5t5ZFlKmcxgN5chRgMOSTxngcAjODxTWqugfunGX3jfx3btqlvb+HXlltoontbg6RP5M5YZ2jbKX55HQeWQN2c8S6l4g8XpqV4LdZl2eY8DjQbuRYY99ucEK4WYlGk6DdlSBjkV0uveNI/D+qTwXGn3t2kcMcgFtHHn5hMxO5pRkYhIxgYPcg/LRtvijpUmsRaZd2V1aXNxJMturyQnzlQsAyqH3HcVYYAOCPmwCCRBZrcXQfFOorNpsOsWdzFa3NmhMx065TbcGXZtcyEsu7cMKQSACS2Ko6v4x8UWmueILXStOTUYtMXMcUGnTNIMxxuDv8wJK3zv8AulKscDkdaszfEuMXUPkaPfNaG3+0NMht5Mny5mMPEw2uPIbn5lyCDjINRv430q0eQ6VostjqWq/aN08ltEVE8KPt+0bJNxyIztOTkDGQeKUtPxHHp8jLHirxrqMEc/8AZ8tnJkhLdtEu1dHNozhmYSbGUSfLtIIyQM7lzVufxh4ttreYtYGQx+SN66DeMVyygttViX3KWfC8x7drZJBr0G0ma4sYJnADSRq5A6ZIzU1N7kp3ijydfFviu70973+z722jdWM9qdEvy7v5EOFT5gyfOZRuUbflz1OT3Gg6/cXt5dWeq20tvcLcyrb5s5IkmiXaQwLZzw4GeMkHA4roKKbdxhXN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCVIHSUUUUAFcv4dgiudb8bQXEaSxSawiPG65VgdPtAQQeorqK5vwv/AMjF4z/7DUf/AKb7OgDQTwzoUX+r0awTr922QdcZ7ew/IVYTSNNinE0dhbJKG3h1hUENgjOcdfmb8z61cooAy18M6EkhddF08OWDFhbJkkZwenbc35mrS6XYJJE6WVurQ58phEMpk5OPTk5q1RQAUUUUAFFFFAHN33/JU9C/7Aupf+j7Gq95B8PJr661PUIvDMl1GzG5u51ty6mJlDb3PIKsUByeDt6cVYvv+Sp6F/2BdS/9H2NT3vhS1vJLyRbu7tpbmVJ1khKE28i4+ZAykc7VyGDA46UdQ6GUunfDNrt4Fs/CZuJAkLxiK23vkgqhGMnJ24Hriq/nfDZr+4D2Hhtb29Vjdh0tN8sRZiXds4dSYixGSeMkDHCL8KrKO8Se38QaxCkbKUgRbUoAPK4yYC3/ACwj7549zVmX4cRPCFj8R6zC+cvIgtSznfK3O6Aj/ls44A4x9aHtoPrqTzv8PplimuW8MyDUJFt45JDbn7S8Z2qgJ++VzgDnGab4sTwboeiRr4k0zTZ7O4vE8u1ukhZWlYhNypKQMgHJ284BwKw5fhhe2uqaRJpeuXssFncNPLLcTwxvnEYCmNLfbKg8pflJTB+bOQMdLrfg4a9aWAvdXvo7qzQK1xbCJDcYZHO5WRlALxqflAPGOnFPS1xK99StFb/DowqIIfC5imRCuxbfbIoXcnTqAIsj2TI+7Sw/8K8nhgNv/wAIzJEzAQlPs5UmBcjbjvGvPH3R6UDwcZdIi8yRrW+S5kvfLtbg+WZGz+6Lsm4x/dHAXOOmOKxNM+E8MGn6VdX2oXsms2MK+YIrzZb3DqiqiOFjXdGpRcfKDxk7jnKu9Qsb1pd+B7ZBqGkT6Gpj86ZXs54U3FV/eHIIBIBGSTxkZxW7Y6vp+pTTw2N9bXE9ttFxDFOjvAWGQHCk7SRXH6P8NBb+H7CHUNWvotRigMdxNaSxYcmEQ45iAZVUDaCvYFtxrc0Hwha6Bq13qMV9eXdxdxRxSNcmM/Kmdv3UU8bm6+uBwBimkm0LojoKKKKkZx/hr+zf+EF1P+3fsn9nf2tq32j7bt8nZ/aFxnfu+XH1q1cS+BI7lZLuTw6s6BLpXkaAMocCNZATyNw2qG7jAqn4b0tNY8FXto9xNbE65qUiT25XfG6alOysNwK5BA4II9RUuo/D611GaSU6zqkDyMkhaMwNiVdgMnzxN8zCNQR93jgA80f1/X9f8A/r+v6/4NR9L+FemQi7Om+ErdGSMiVLa2GUlO1DkD7rdAeh5qeC4+Hd00cxHhlZ7a38xVZrVnghCk5yCdqBXJyDjD+9LZ+AbCKFI7fXNTka3jjh3iSHKtHIsisyiPaX4Ucj7vbnNZun/D2Vda1GC91W/NqttGtnMjIJMlHRpGIgVQ4DMAoZlwQWXJBL3X9fIEXI/wDhXNxOul2Nv4elacGUx2ot1wskTEyjBBIZExlcnGO3I0Jp/BfiLULJ1vNDvNU8vdp1wj281xH94h4S248bGPAI+U+hrPh+G2kNbx2kOrX7WluPKa2RoAh+SRMHEeVwkxGAR0X8WnwHawa3Bdp4l1c3sbo7KI7Z97/vNskgEGQDuYcFV49aHa4dC34m0nwouhxaT4g1Cy097qJ7S3urmSBLht/+sEZkUgls8gDnPSqstr8L302G/uLfwrdW9tasYrgw20mIYzhtpA+6pOCF4BOO9Hi7wtqOq6lol+NRlih0pWe6mhl8t5MbTkxCF/MGUzsBTBwQcgUmmfDvSG0eE2er6pJbXEEpD7okMwnTBZgIxk8lhkfeYkg0LZ/16B2X9ef6GZf2vwwvb621V7/Qp9PtbeQNDCbKS3VQ2WJ+UyDLSchCAc4YHNdLpFr4PvJY30iz0iOcuZYxaeTvcROUDgxk5UFfw6EA5FQ/8IDE1okE2vatLtNwzSMLYM7TEEscQgZBGRgAeoI4p9r4I+w3kV5aa7qQuY2lJaQQlZBJN5rBlWMA8lgPQMe+DQhPU6miiikMK4uz/sc3XjlfEv2H+zW1qFZhqGzyTmxs9obf8v3sYz3xXaV57e2N5qVj8QrTTSouZNXh2MxYbcWNkSRtRySADgbGye1A1ubG/wCH8LR3e7w1GXje6jmzbjckhCPIG9GJClu5wDms6xvPh5dancafZWWiQLGy2yXMRto1lkkVX8qPa28thVJ4AOBgnBwtx8KNLuLxLtdY1mCcQmN/KuI9kjlizStGYym87mGQoADHAHGNG48CWt1qs99Nquos085leP8Ac7CpCAx/6vO0+VGc53ZXhuTl7P8Ar+tv66E7r+v6/r5lLVrn4X6xNNqGst4U1OeKAvJNOLe4kESDJPOWwM/rVyyk8C+ZaT20fh+CQvMtnIpt9z7RiQxlSeNqgHHIA5AxVCT4faVdz20M2tarcy28E8IbEJC794fJWLar4n6cZ2qcHaaur8P7b7QZ5dZ1SWRpTLIz+R853b0yBEANj/MMYz0bcOKW2w2SxeG/AniKzing0bw7qttbqYYpEtYJkiH3toIBAHzZwPX3rH0SX4aanautnpXhy2gUTGFHjswJolOJJVVSSEyCCWAPHIra8MeDf+EVDR2et391bycyR3aQEsRGkaEFI1xtWMD3zzWZdfC3Tr+OBL/WtYuPIikjRjJCjLv35IKRDaf3nVcfdXOcU3boHTU3x4k8M6faRIus6Ta28dqs8ai6iRFt+FVwM4CdAD06Vb03V4NUlvEtlcC0mERclSsmY0kDKQTlSrjrg9eK5u1+GtlZ6RJpkGt6z9lmRRMsk8chmcEEyOzRksWAwwPykE/Lnmtjw34Zg8MWstva3l1dJIY/+Pny/k2RJEANiL/Ci9c809Lu4lsjaoooqRhXN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJQB0lFFFABXN+F/wDkYvGf/Yaj/wDTfZ10lc34X/5GLxn/ANhqP/032dAHSUUUUAFFFFABRRRQAUUUUAc3ff8AJU9C/wCwLqX/AKPsa6Subvv+Sp6F/wBgXUv/AEfY10lABRRRQAUUUUAFFFFABRRRQAUUUUAecnTLvWfhLren6dEZri41fU1VBHHJ/wAxKYn5JGVH4B+VmCnoeDVSy+EsxsopHu7Gyn/skaf5aaaMLgqwZwsu1sMgbbyAWYbiMVdhtLq9+Gl/Fp9jNfXI8QX0kccBi3qU1WVty+aypkbcjJ61QuZ/iobfzbKzut/9nKjwTy2Ks1wGTLo43BXK+YMMGTJU4HIAtL/10f8Aww+39dUaI+FUJ12+1F59M3XUEqCSPSQtwJHCAu0u/DfdbjaOHYZ5qhf/AAguruIRQ6poscJjCtE+hs6oR52PLH2gbFAnYKvOAqjJ5ySXXxNS7RmsNUf5Ii6WzacYN+yMuFLuJMbxIDkZw3HYi3OvxCkRlD6pFmZyzWw08sAI3OE35Hll/LC7hv5fdxg03ordv6/UUd/UR/hRI+vWmpLrUNuYrhp7iO301FNwWRVbLliyklTlgclW2nPUtm+FE5itzb6jo/2mK3SBprjQw+VXzRtULKu1dsu3GTwo65qnJb+PLLU5pdO07V2kvbWMXV0G01czeX9/BblkOFA27SBznhqo3niH4gtr0Gj2k7tqkOjpJPaxz2KeZc7fmJRgzqDyRIP3YbapB5oe3L/XX/L8UEe6/rb/ADNey+E97avp0jazppk06eSe3MOkNGELqqsB+/JwQGLDOCWzjI59A0eyk03RLKxmmWeS1t0haVI9gcqoGQuTjOOmT9ai8Ptqb+HbBtfjWLUjAv2lFdW2vjkZUAE/QY9K0abbV0SknZhRRRUlBRRRQAVw8Wkya4fH2mwTQwSXGrxKss0BmVP9AsznYGXJ445GDg13Fc34X/5GLxn/ANhqP/032dAHNp8K7satdXcmp6O8Vxcee9qdEJjkPmSOPMBmIcjzGKnAwwU4OCCmq/CeTUIbpI9T04G4uDMWudKMu7KyLufEq7pP3uN/HCKNvFek0UdLB1ueaX3wnubm5ea31DRI2mbfOZtDMjTMWhcliJ1z80AIz0DEdeaox/Be/jkZ28S2c4MMEQt59GDQjymUjgShyuEACl8LufH3jXrNFO4bHmlz8Jru60GbT2161WeS2t4BenSEkk/dBRtbe7Bojsz5Z6MScnoPQ9PtWstNtrV5nuGgiWMzSfekIAG4+5xmrFFF2xWV7hRRRSGFFFFABXN/Dj/klnhT/sC2f/ohK6Sub+HH/JLPCn/YFs//AEQlAHSUUUUAFcFp/hXw3rXirxlea/oOl6hNFqsaCe9s45WVBYWhxuYEgZJOPc13tcv4ehiuNb8bQ3CLJFJrCK6OMhgdPtMg0ne2gI4axs/C3nWJ1HwN4c2TWxmeGHQIxLIZGPkKgJPVEkZs5+7xjpWi0Pw4i1UadP8AD/TIZ3Z1i36XaYkZER3AIJxtD8k4HytzxXSDUPCN1qlzYNbae/lLGHlcRFG2qSoHOfkDDtx5g9aSG08GafpzJqF7pl4kkpuHuL94WLtIxYEnAGP3uBx0YetNgcva/wDCublZpP8AhXumRxxQrOd+lWu7aUR2yB0wJYxjOSWwBwTVZY/BMb3qXXgLQ18uWZ4ZRo9vsa3RZSHPO7kwnsPvLxzmu1W88IWmqQ29vbaaoEJujcxLEI4gDGq5OeCfl28fwewqVZPBV2zWavoc7KxiaEGJsF/l2lffbtx3xim0nsC8zjrKz8DJarHqfgTQ5b2OaK3mW20m2CiRiIyRuP3fM8zvkBGyOObOh2Pw/wBcuYoU+HFhafaESS3a50m0AnjYE71CknA285A9s13DeGdCeQO+jWBcMWDG2TIJYsT065JP1Jqe20m3tb17tQXlKCKIsqjyIuP3aYAwuRnnJ9+AAX11FrbQyP8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JrpKKQzzu88A+D1+JOjWq+E9DFvJpN/I8Q02HYzLNZhWI24JAdgD23H1NdB/wrjwR/0Jvh//AMFcH/xNF9/yVPQv+wLqX/o+xrpKAOb/AOFceCP+hN8P/wDgrg/+Jo/4Vx4I/wChN8P/APgrg/8Aia6SigDm/wDhXHgj/oTfD/8A4K4P/iaP+FceCP8AoTfD/wD4K4P/AImukooA5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJrpKKAOb/AOFceCP+hN8P/wDgrg/+Jo/4Vx4I/wChN8P/APgrg/8Aia6SigDm/wDhXHgj/oTfD/8A4K4P/iaP+FceCP8AoTfD/wD4K4P/AImukooA8q0jwn4StPBV5eyeEdAuJxrV9bRvc6dEVQHUZYk3HbnYg28dlXAxSz6D4Y0LWrKy13wh4UvYrgGOSfT9Ehj8qTfCilldjtBMuNo3H7p9a63wTDFceFr2G4jSWKTWNVV0dQysDqFxkEHqKut4M8LuLQP4b0hhZDFrmxiP2fnPyfL8vPPGOaFowex59c/8K+itoNRPgbRLbT13tOLnSLbe8fkmSORGB2gMF6NgjPO3FQBvA00Rv7HwNoF3YSRCWBIdJtS5xDO7Iz79md0Bwy7h25BDV6b/AMIvoG0L/Yem7RJJKB9kjxvkGHbp1YEgnuOtMXwh4aSWOVPD2lLJEgSNxZRgooBUAHbwACRj0JFMFvdnnVtb+DiLiLUPh7ottPHcRBT/AGNalRE8sabT+8+8vmAMwO3nIDYK1PB/wrm80uO5h+HunwSTrciOO40izDB4QTtxuAYsBuXaxBHJI612qfD/AMGxMTH4S0JC3UrpsIzzn+76gH8KtDwl4cFqtsPD+li3UMFi+xR7BuXa2BjHK8H1HFHSwLR6nO6F4X8Aa4lwIfBWhpJayCKRZNKtgScAhgoyQDnjOD/OtX/hXHgj/oTfD/8A4K4P/ia2bDStO0pZF0uwtbJZCC4t4Vj3kAKCdoGcAAfQCrdDt0Er21Ob/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mukopDOb/AOFceCP+hN8P/wDgrg/+Jo/4Vx4I/wChN8P/APgrg/8Aia6SigDm/wDhXHgj/oTfD/8A4K4P/ia5/wAOeAfB8+veLI5/CehyJb6tHHCr6bCRGv2G1baoK8DczHA7sT3r0Sub8L/8jF4z/wCw1H/6b7OgA/4Vx4I/6E3w/wD+CuD/AOJo/wCFceCP+hN8P/8Agrg/+JrpKKAOb/4Vx4I/6E3w/wD+CuD/AOJo/wCFceCP+hN8P/8Agrg/+JrpKKAOb/4Vx4I/6E3w/wD+CuD/AOJo/wCFceCP+hN8P/8Agrg/+JrpKKAOb/4Vx4I/6E3w/wD+CuD/AOJo/wCFceCP+hN8P/8Agrg/+JrpKKAOb/4Vx4I/6E3w/wD+CuD/AOJo/wCFceCP+hN8P/8Agrg/+JrpKKAOb/4Vx4I/6E3w/wD+CuD/AOJo+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISgDpKKKKACvO1j8QXmteOrDSNO0+4tLnUUjknn1SS1lRm0+1B2hbeQcDBBz1J4459ErldCNwNW8c/Ylja5/tZPKWUkIX/s60xuI5xnrQ9hrc4uLRdWuLuW3/wCJHc3F35qPE3iTLPvVCwCiw/uwjGOgXjpxop4S8QTTWs8ui6Pdx285njSTxFK6Fi4c5/0LLfOqHk8bFAwM5tXPgvXheW76bNbw2do0n2e1N1JE6IyjCebGN2EYEgZ+6xXpV7QfC2vaVq0Vzc6rJPElu8YikvZZFVvLiRDtIw2SjsScHL8d6af4C8jAj8C+JkuY5m03TZPK2KiSa8zIFXzPlwbDBB81s55JwetW4NG8QWuqWcaaRoIu4JZL4R/8JBJ5krMx3O3+hbiMvt44wQKJvB3jK7upZp9X8j9yiqkOq3ADv8m5iAoC9ZD8o/uDgA56LwxomsWeq3WoeIJYZZ5beKFDFcPIAQWZzhlAXczDgdlUdskE9V/X9bD/ALd43/6F7w//AOD6f/5Do+3eN/8AoXvD/wD4Pp//AJDrpKKQzm/t3jf/AKF7w/8A+D6f/wCQ6Pt3jf8A6F7w/wD+D6f/AOQ66SigDzu8vPGP/CydGZtC0MXA0m/CRjWpijL51nuJb7LkEELgYOcnkYANpfHOrNfTWSp4MN1BII5YB4qfzI3LBQrL9lyCWIGD3OK1r7/kqehf9gXUv/R9jXP6t4E1m/u9X1HzYpbmW9Eun2rX5ihjj/dBnLrB5iSERdMuBkYx1o6h0Og+3eN/+he8P/8Ag+n/APkOj7d43/6F7w//AOD6f/5Drmz4M8W3umNbalqabn01rZjHq1ywLeWVCkbBnLYczff6rgirS+FvFkUsskGpqCLqKRFl1S5dXQOSQwK/LtQ7dqnDlQzYJNPr/X9f121Dpc2vt3jf/oXvD/8A4Pp//kOozqvjJbhIG0Lw4JnUskZ8QTbmUYyQPsfIG4Z+o9a5OLwf8RobhHm1i0u/LvHlRhrF5B+73xsNybXDEhGynCLuIAwSK0Lzwf4pvVe3uL2OS23ysoGsXSM4M0UkYYheDhHGRjaHwBgUl0DqbJ1rxcLR7o6N4a+zxhi83/CRS7FC53Zb7JgYwc+mDUwv/G5GR4e8Pkf9h6f/AOQ6wm8IeKH0m4U6i6Xk1vIqquu3ZWKUNIIiH2g42yLu+XrGvB6iXTPC17Z+JFEl5qCCa4lurpY9Qu5IGjLh4wCxCIwcbSq/eTOeDinpewPRXNn7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q66SikBzf27xv8A9C94f/8AB9P/APIdH27xv/0L3h//AMH0/wD8h10lFAHmPhvX/EWi+E7y8vNP8N2timr6j5lzfeIJIFRzfzbgSbUjG8lQc8jBwCcDeTxL4lk0n+1U07wq2nbPM+2DxLIYdn97f9kxj3zVGw06/wBW+Guq2OkNGl3NrOpBHkmMQTGpTEsG2PggDIypGcZqrqvgHXom8nw9qAktHs7mKdb3UJI/tM04kLu8aRmPO9kIKqpHzDGMULzHodGL/wAbkZHh7w+R/wBh6f8A+Q6X7d43/wChe8P/APg+n/8AkOuUh8LeP01I3Hm2iI0zSbD4lvJEUFnOAhhAICvtxkfdB4wMXvDHg7xTZPMmt67dRBYPLtrq21eW6kB81n+aOeLyyQrBNxDEhQeD0a1JNebWfF9tJClxovhqJ538uFZPEMymR8E7VzacnAJwOwNTfbvG/wD0L3h//wAH0/8A8h1yeg6F4pvLGe5WSUg6g/lR6tfXQcIjzASYePKEq0YCrwQu7dk1Hp/grx3BcW0V5qSTWsYaN5H8Q3bu0bGXgoYgGYCVQGJz+7U5zjC6FHYfbvG//QveH/8AwfT/APyHR9u8b/8AQveH/wDwfT//ACHXKWXgfxfbalbiS+xpv+jJLCniK9zGsagMUymSWywI3KDhTwenp9NpE31Ob+3eN/8AoXvD/wD4Pp//AJDo+3eN/wDoXvD/AP4Pp/8A5DrpKKQzm/t3jf8A6F7w/wD+D6f/AOQ6Pt3jf/oXvD//AIPp/wD5DrpKKAOb+3eN/wDoXvD/AP4Pp/8A5Drl9L1zxJpOo+ML2903w5awR6tG11Nd6/JDHC32K1AAc2uCMbDk7eWIxwCfTK4KbTbzWbL4jabpohNzd6ksKefM0SDdp9mCSyqxGBk8D8utJjW5f07xD4o1eyW80nS/C19auSFntvEcsiNjg4ZbQg0ln4j8T6i7Lp+meFrpkUOwg8SSuVUkgE4tOhKsPwPpWJaeCvFVjbpJa3UUUpvGma2/tq7dVTdCwDTFN0zfumGXXhZNvIGC9vB/ixvPMcljbeZtBW21SeJnAmuH5kWIMuPORsDIYoVPBzVtIleZ0f27xv8A9C94f/8AB9P/APIdQza14ut7iCCfRvDUU1wxWGN/EMoaUgZIUG0ySACeOwrIuPC/jFLy5+xalG8TMHikn1W5BJDq/wA0YXAGTJ8qtjG1fu8Cbxf4V8Taz4mtb7R763git4nETy3kyeQ7Qyx7hCqlHOZFO4kMApA61PS492zX+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOuStPBfjlNLI1DUYrm+VYAnk+IL6CLCys0i/dY8oUQMdzHBJwerrPwh49IsVvtTiQW9wkszRa7dSGVdkaOpBiUEMFkbaejMCCOcsDpZNa8XRLO0ujeGkW3XdMW8QygRDGct/onAxzz2qUX/jcjI8PeHyP+w9P/wDIdciPAPiqPSI7aK4jWa1j2WzDxFe/Kxt/LL7tmRhwGC8jk9O/ceHrHV7KfUjq80csc9z5tsFuJJWRSoyp3ABQDnAUYx7k0WQFb7d43/6F7w//AOD6f/5Do+3eN/8AoXvD/wD4Pp//AJDrpKKQHN/bvG//AEL3h/8A8H0//wAh0fDj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJQB0lFFFABXLaDN9n1jxxNtZvL1dG2ohcnGn2nQDk/QV1Ncv4emS21rxvPJwkWro7fQadaGk9FqNbmMni7xXHMsV1ojyFoA7eRYzYVgsxcB8kHPloFPB/eDI7VHZ6x4s0rw7NZtC1xd2Nrut7iXT55jfEA5zhsqcr3OTuBAHQ7Fh49iu1hafTbuDz5I4VRgmUdoxLhm34+6w465BAycVEPibowVTPb3sIdEZNyIS27zPlwGJDDynyCARjHWq2uK+lygPF/iRr9XfSrmG12uCo0yZjne4VjznOIunH+tQngVXi8YeNke1a60aMxTrglNPuAYztiyzAEkDe8gAxkhc/Xqr7xba6foQ1G6triBmjlkW3lVRIFjzliN2AOB1OfmA6nFZNh8QFh0qwfXbWZbu6Z4sQRqqtKjBGVcueS+QozkgE9jQt7A+5HqHiXxVaeUItKExSaOKcpZSsNuYw0i4bvufAGcBck9q0/DOt61q92DqVj9jtzaJLta2kjZZGPKEueqj0Bz6jGDEPiDYNqQs49Pv5G3bHkRYykb+Y8YUnf3eNgMcdzgZIoad8SYp9NuLuawu7lFuTHGbSJcYaRUiXJfDMwdG4OCG46Ghf1+QPTQ7qisnRdfj1qS5jSyurSS1KCVLkIGVmXdjCsegxz0PYnnGtSA5u+/wCSp6F/2BdS/wDR9jWDqPi7xbZaggtNFl1C1fVms/3OkzK0cQx87F5ANpBP70Ar8nQ7vl3r7/kqehf9gXUv/R9jVDWfH8Ol61b2ojKxpem0uY5FXzJC0TNGyHfhQWXblwB1PAGaFq/67oG7L+uz/r5GZpni3xffxiK501rKZpJhHKdEuSJBsVowQXAiI3HLMWUlCByRUemeKfFYEQksJpnkuEEs0mj3kYl/cw/KEZj5PJk/efcBjwRls1v2/jmH7fbWdzYXu65uZIROscaxxlZ2iAb96T1UDIBzuBwOQsWq/ErSdE1j7Bqtrd2ubsWi3EjQLG7YViVzJuIAkTgLu+bgHDYa/r5A92hng/xhqGq3U9rr9pPbStIqWrnSLq0WThyR+9BzgJnOQPmA69c+38VeMG1ixjbT0ltLiW5SUnRrqAxKpdYmLsxHJRSQVGQ4x0JrRl8flmtfs2i3whuozMlyzQOFj8yNQ5QTA7WEoI6MO69qLn4l6da2zXD6XqjRKSwZUiO6LY7iUfvPulYn4OG+XlRkZLP+vuDuZWieKddn8ZWK3enakkGoQRJdLLpV0kUTqJsurElIgSIwQSSdwzgg1X1Dx34ws0vzHoskpivZEtgmg3rmWEIxUEKSAxdAu8EqQ4bArsJPFUD6fqctrC3n2E4tvLmZRukYhUPBJCksOSAcc4qgnjuKzvEstVsrsyGZonuYoY1iQq5TJHms2CQMYBOGHAw2C6uGyv0MzQdb8Q3Wt+KLyewvSY7ONrGzmtLiCLepl+VWkO12I8slkxnIGMgms3WPEfitrWwndLtI2ZWU2eg3uZGWdPneNSXjXy92Y3+969K6N/HLx3lpK+m3AsrqHKxfujMrGRFRyRKV2MJFOPvDIJHYUrn4jPLrNjFpljMbGa2Ek0skKMyu3klVH75fupMC3BHI2kkFSWbs+36XFe91/XQy4vHvjW71GK2Xw3cWUcsNqwuZ9GuJI0aQoJM4kDcbpMqQu0RjLHeMeoDO0biCcckDFcVdfFHTbTTZLufSdUVknSAQHyFdywbBBMoXkoygbskgAA5Ge1UlkBKlSRkqeo9uKbd1sHU4Gz1TUtF+Geq3+iWEmoXkOs6mUgigMzkHUpwxEYZS5AJO0MM4xkUy28TeM7qJro2dtZorwQtZXWlzLIHmiXBEplCuElbDbQeARkEc6HhzVYtE8DajqFxFJLFBrGqFli27sf2jOM/MQABnJJI4pbzxpp5ut8vh2/u57GdUR1W2ZojJtWN1Jl4EgfgjsGzipVrlPY5i98UeLdI8QTmWO9vJVaWFhD4evpLfZ5h8tlCMUJAO4sDkr8vXmtseKPFsZXdpa3BNj9o2JpdxH8xj3BtxYgENhDCf3h+9wOKZ/wALPWfWbb+z9Lu7rS5bLztyRxiV5WeBVVS0oGAJxuyB2wTyK0Lr4j2dszr/AGNq0pWR0Xy1gPmbA+8jMo4Vo2XnBzyMjmnZqKT/AK3/AOHE9ZN/1/XQxPCer+MF00QTlZi/2u4je9065jlCpLJhSkkm/Db4dgwcLuHJAqO/8eeM4IzNZeGrq4hOmpMU/secTRzbk3YUyBXG1nPl7lbK4J5FbcPj7w7Hr9nBJZyWWo6tKbYNMsKSNsOE3fPuYHeMBdxG7kLzWrrnimHSdZs9I8ic3WoRyeRcBFeGJ1RmAkG8MM7GxgYOCMilJ6X/AK6gtWcnf+J/Fl3prCfTLzTlKwPOINLuJpBHJC++NWjbcXDgDcg+TIznBrNj8eeLINJeWHQdUvby1ttv/IDvU3/PH82yR0WRsFuMhvlYjAOK6ZPiVbx2tp52k6hc3E6RKDaLFsklYRhlXfICMNKg+bA+YYJwcFv8V9BvNQbT7KK6nvvJjljtVaESSFwhCANINpHmLy21Tk4Y4OKs+Z2Ffmin/X9f5eRTufFviPzFM+iXkTxS7wkOmXMgANq7BSyOBIRIFU5wuWAHzDcOq8J6jqWq+Gba61y2Frfkus0awSRLlXKhlST5gCACM+tZp8dWtvfW9tdWl2Td3/2OMxpGRD8qYZ8SElSZFG5R1YAgdT1dG6v/AF/Wodl2/wAwoooqRhXN+F/+Ri8Z/wDYaj/9N9nXSVzfhf8A5GLxn/2Go/8A032dAHSUUUUAFFFFABRRRQAUUUUAFFFFABXN/Dj/AJJZ4U/7Atn/AOiErpK5v4cf8ks8Kf8AYFs//RCUAdJRRRQAVzHhyKOfXPG0M6LJFJrCK6OMhgdPtAQR3FdPXG21v4s0zxJ4kl0zRdLubO/1CO4hlvNVeB2AtLeM4RIJON0bDJIPB4xgkA6AeHdFAIGkWIDDBH2dMEYA9PQAfQUkvhnQp5N82jWEj7du57ZCcYIxnH+035n1rO+3eN/+he8P/wDg+n/+Q6Pt3jf/AKF7w/8A+D6f/wCQ6ANW60LSb21itrzTLOe3hUrHFLArKgIwQARgDFNTw9o0aBY9JskVRgBbdQByT6erE/ifWsz7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q6ANZ9F0t7drd9NtGhbZujMC7Ts+7xjHHb0plr4e0axKmy0mytypUgxW6Lgr93oO1Zn27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdAG7bWVrZhxaW8UAdtzeWgXcfU4qeub+3eN/+he8P/8Ag+n/APkOj7d43/6F7w//AOD6f/5DoAL7/kqehf8AYF1L/wBH2NRajH4Bubm8m1dPDcs9vMqXb3QgZopHG1RIW5DEcDPJHFZtzH46l8aabqg8O6HsttPu7cka5LszJJbsMn7LuB/dHACkdclcANlS+DfFj+ILjWorOygvp5Vk8yPxAfkC7wFGdPOVxI45yQDwRgYFuHQ31svhqLsXK23hQXFlOqiUR22+CVpDtGeqsZA2O+4HvV3xHF4V8O6Rda3rGmaascEv21neGFWknAwGDPgGU9ASQegzXn+pfC/xLq9xPLfKredK0m2LxKYtm5mLKGTTwxUiR1IYnIb6Gt/WtB8ba/op0+/s9LjKzSPFcW+usskaMrJs+axZSNjlckE9855o+zpv/wAMPTm12NNZfhteL9jceF2aHfcPaSfZi0JLAuzJ/CdwG4+oGelP12w8EQMLbUtA0e9eS7jeaD7Jbu0bzNsE7q3OCRgtyTjvisSw8MeMLG3to5bDS79oL37Z511rrB2Ozbt/dWKLt4U8g9PpiPxL4O8U+KbiaS90+wt0nSNZIbbxC4jbY4YEhrA85AGfQYGOabtdEq9nf+v63OlW+8GSR3enRXOkWYv5BGfIuYY2umKR7WXY24sA8YGcN93HBUm1F4E8KR3SXjeG9IlvlcSG8fT4fOaTOfMLBc7iec+tcFceAPGdzefaJbhWYsrsDrsZDMojGSTpmefJTPPY+prsbO58fQWqx3Wj6DdSgnMra3Kpbk44FnjgcfhRpug8jUHhLw2sYRfD+lhApQKLKPAUuHIxjoWAb6jPWq9x4D8IXZjN14V0ScxoI0MmnQtsQdFGV4A9Ki+3eN/+he8P/wDg+n/+Q6Pt3jf/AKF7w/8A+D6f/wCQ6QyrqPwv8J3ttHBa6Np+mxrMsrrZ6dbATEAgBg8TA8McEAMMnBFdYiLHGqIMKoAAz2rnft3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6AIfB1nbah4RvrW/t4rq2l1jVVkhmQOjj+0LjgqeCK05fC2k3lvcQatZwapDPIrmK9t45EQL9xQu3GFycZBPJ5Nc34aj8daVpM1vJ4d0MF9QvbgeZrkoOJbqWUfdtWGMOMHOSMEhTlRr/bvG/8A0L3h/wD8H0//AMh0ASnwH4QaaKVvCuiGSEKI3OnQ5QL90A7eMdvSp73wf4a1J5X1Hw7pN200gllaexjcyOBgM2V5IHGT2qn9u8b/APQveH//AAfT/wDyHR9u8b/9C94f/wDB9P8A/IdAFuDwd4ZtYY4rXw7pVukTM8aw2UaeWzLtZlwOCRwSOSKsS+HtGuDAbnSrOdraLyYXmgV2jTGNoLAkDFZn27xv/wBC94f/APB9P/8AIdH27xv/ANC94f8A/B9P/wDIdABq3gHw7qtitodNtbSLdB5gtrSEedHCwZIXDIQY+B8uOnTFaM/hnQbozG50TTpjPEsEpktI28yNfuo2Ryo7A8Cs77d43/6F7w//AOD6f/5Do+3eN/8AoXvD/wD4Pp//AJDouBfHhbw+swlXQtMEgmM4cWce4SHGXzj73yrz1+Uelatc39u8b/8AQveH/wDwfT//ACHR9u8b/wDQveH/APwfT/8AyHQB0lFc39u8b/8AQveH/wDwfT//ACHR9u8b/wDQveH/APwfT/8AyHQB0lc34X/5GLxn/wBhqP8A9N9nR9u8b/8AQveH/wDwfT//ACHWRo0fjqx1bxBcP4d0PGoaglwu/XJQMC1gi+XFqSRmI8sFOcjGAGYA7uiub+3eN/8AoXvD/wD4Pp//AJDo+3eN/wDoXvD/AP4Pp/8A5DoA6Siub+3eN/8AoXvD/wD4Pp//AJDo+3eN/wDoXvD/AP4Pp/8A5DoA6Siub+3eN/8AoXvD/wD4Pp//AJDo+3eN/wDoXvD/AP4Pp/8A5DoA6Siub+3eN/8AoXvD/wD4Pp//AJDo+3eN/wDoXvD/AP4Pp/8A5DoA6Siub+3eN/8AoXvD/wD4Pp//AJDo+3eN/wDoXvD/AP4Pp/8A5DoA6Sub+HH/ACSzwp/2BbP/ANEJR9u8b/8AQveH/wDwfT//ACHVnwVp91pHgHw/puoReTd2emW0E8e4NsdIlVhkEg4IPIOKANuiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z" alt="" width="388" height="505" vspace="0" hspace="0" border="0" style="width:388px;height:505px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM0MQAAkpIAAgAAAAM0MQAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNCAxMToyODowNwAyMDIxOjA2OjI0IDExOjI4OjA3AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjRUMTE6Mjg6MDcuNDEzPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAIIBeAMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APoPWNYstB0x7/U3kS3R44/3ULzOzO6oiqiAsxLMoAAPWsn/AITzSP8Anz8Qf+E5qH/xijx5/wAi7a/9hrSv/Thb10lAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMV0lFAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUActbfEXQby1iurOLXJ7eZBJFLF4ev2SRSMhlIhwQQcgipf+E80j/nz8Qf+E5qH/wAYrnbK31W8+APhy10SGaeWfRbOOWODyfMaM26ghfP/AHfpnd2zjnFUtMj+JMV3bWM1nd2OlxpaRrLbT2TvGoQCQbXBxj5tx3Pk7dvG4Ejq2glornX/APCeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxXIQ3XxMV5Few1x1KSBWkbS1wSjhSCrnkMIiMjGS+eMYDp3xAnWD7Y+pS3LQbWlH2BY4ZBBOnmKMlkcuYz8uRhiOmQDpca3sdf/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWJpMni7TrmOa503UprRZpmuVlNkJpkEKbHPlH5mLqVAG08/NwBTPFmr+IX8ZQaX4ZvbsTNp32prKH7H8gDlSzCb5skHAwSu4LnAzkelvP8AyuJaq7/rWxvf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFcxeL8RLSKNLVtavjLEjs4GmBoXZfmTB2ghWXHfhurdQt7p/i9dRleC31We2W4ceWBpwF0N1vtkkU4B4WUA8OMDpxTt71hX0udN/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWVa3WsWurW8uqWl3NfQzXAdYzGzzWf8BKphR85XaCd2A3JO6o/FVx45i8TSDw7ZalPpzQBQYWsVRXMcmWUytv3B/KxkFeG7YpdB9WjZ/wCE80j/AJ8/EH/hOah/8YqKX4i6DBJDHPFrkb3DmOFX8PX4MjbS21QYeTtVjgdlJ7VgaPY+K59c0ifxFpFxNNazRGa/dbNM4gnjdwI33YJdDjnBY4GK6TxR/wAjF4M/7DUn/pvvKbVhB/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRSGc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUActP8RdBtYxJdRa5CjOkYaTw9fqCzsFVcmHqWYADuSB3qX/AITzSP8Anz8Qf+E5qH/xijx5/wAi7a/9hrSv/Thb10lAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMV0lFAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBiaX4u0rV9VGm2w1CG7aF51jvdLubXeiMqsVMsahsGRMgHPzCiq19/yVPQv+wLqX/o+xooAPHn/ACLtr/2GtK/9OFvXSVy3xFiefwlFFFPJbPJq2mKs0QUvGTfwAMu4FcjqMgj1BrM8QR33hyOF7rxn4onEu84gt9MJUIpZiQ1uOwxxkkkDHNAHeUVw86RWqsbr4palBsOG806am04JIObbg8H8j6U26jlgkSKD4ha7eTtPFCYLZNNZ0LttDEfZuFGGJP8Asn0o62Dpc7qiuKubcWVw0F58UNTglX70cp01WHIHQ23qw/MVCFeS/sbS0+Imt3bXiNKjwLpjKkaqG3n/AEb7vKjIz94etAHd0Vw8ggiiikl+Kt+kc2PKZn0wB8jIwfs3OabamK7CiH4o6kXaPzdm7TCwTAbdgW3TDKc+hHrQB3VFcIsto93Fap8Wb5riZtkcIk0ze7ZxgD7NknIIxWpD4d1K4gSa38f67LFIoZHSHTyrA9CCLXkUAYFl4gfw18AfDl7E8MUraLZxRzTziGOFjbrh2cqwGMcZUgkgd6bovxPjktrfznh1FpnWLfBdI7M/2SObaiInViX4J4IPzYwoz9Bg1TR/hN4Wv4/EniadLjT7GKOzsItM/dmSNAqgzQj5QSF5YnpnPJrS03VtO1PTPtsfxX1CFFIWaOd9LV4HJ27HH2f5WzxjuemaI9Qdrr+v62C3+KrXAuNtnpTLb2rXMjxaxvXaGC7gfK5jBYBnONpWTg7ecPRPjXm2hsLlbO+vhGrG6kvfLilLTiPIkWHZtG7AIwWKkbV6100ctrNvEXxV1FnSWWEpu0wMZIxmRQDbDlRyfQc9KSKa2k2q/wAVr6KUhS0LzaVvQsAQDi3IzyOhPtT0v/XmJ6f16f18zo9A8QDWrnU7aSKKG4025+zypFMZADtBBJ2rgkHOOeMZ9K2q8/e7sxexWkfxXvpZ3BYok+k7kQR+YXKmAHbtwcgHhgemSNWz0S91Gziu9P8AiJrV1bTLujmgTTnRx6hha4IoGdXRXN/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDItIDpKK5v/hF9X/6HvxB/340//wCRaP8AhF9X/wCh78Qf9+NP/wDkWgDpK5vxR/yMXgz/ALDUn/pvvKP+EX1f/oe/EH/fjT//AJFrn/EfhzVI9e8Jq/jTXJTJq0iq7w2OYj9hujuXFsBnAK/NkYY8ZwQAeiUV51cTapa65NYXHiPxilvBLHDJqPkaSYFaQDbkCHzACWAzswD145q0j2kvl+V8Wrx/NTfHtl0s71+bkf6NyPkfn/Zb0NHS4Hd0V59e31jY2hnm+LN5gqTGv2jSVMpAB2qWgAz8y9SB8w9a0rLS59RkuI7D4kavcyWr+XcJCNNcwv8A3WAtjtPsadgOvorz+2nSaG7e5+JWsWLWU5guI7s6WjRHzCilsW5wHKnbnr9eKniFvNdm1h+K99JcBzGYUk0svvG7K7fs2c/I/H+y3oaQHc0V56uo6W09tCvxfume6Utb4m0siUBtp2n7Ng4IIwPQ+lP+0WrTJFB8Vb+difn8ubST5S7GfcwNvnG1SeMnHPQEgDrY7+iuOGnyNpA1UfEzVTpxTzBeD+zfJK/3t/2bbj3zVR5rKONpJPi3dqiBWZmm0sBQyllJP2fuASPUAmgNzvKK4OfMdyLe3+I2tXk6zwwzQ2o0x3g804RnX7PkKcj354FbH/CL6v8A9D34g/78af8A/ItAdbB48/5F21/7DWlf+nC3rpK878aeHNUh0G2aTxprk4OraaoSSGxABN9AA3y2wOVJDDtkDIIyDau7bVrfVPsVv4p8XXpTb581tbaYUgLfdDbrcEk5z8obA5OBQB3VFee6fe2t/Y2twfihqlq9zwLe4fSllR8KTGQLcjcNy5AJ6j1FSmexEcUh+Ll2EmQyRN52l4kQZyyn7PyPlbkf3T6UAd7RXAXd1YWMU8l38W72JLcxicmTTP3XmfcLf6N8obOQTxjnpSSXlhHCXHxbu3+QyKq3GlZcBQ/GbcD7rKc5xhgehoA9AorjrHTptSmnhsfiTq9xPbbRcQxDTXeAsMgOFtjtJFVrh7S0lnju/izeQSW8gjmWWXS1MTlS21gbbg7QTg9gTQB3VFcJLJaQMRN8WryMqxQh5dLGGBII/wCPbrlWGPUH0qTToDqtx9ms/iXqsl1sMptkbS5JBHuKh8Jbn5SR1/Dg8UBsdvRXN/8ACL6v/wBD34g/78af/wDItH/CL6v/AND34g/78af/APItABff8lT0L/sC6l/6PsaKzbbS7vTfinpH2zXdQ1fzNF1Db9tjt18rE9lnb5MSdc85z0GMc5KANLx5/wAi7a/9hrSv/Thb1L4h0LT76ZdT1W+a2js4v3blkVYD5iP5mSODmNRzxjI71F48/wCRdtf+w1pX/pwt6h8U6Jrms30cdpLb/wBnAws8b3MkTHbIWcEKpDBgEHJ6bhjnNLqg6Mhf4d6Rd6Qtkb26kiVJUSRTFuBdQhbOzlgoZcnJwzZzxibTfAllpV5aXf8AaV9O1n5ewTmLGEjkRQcIO0rH68+uaFp4Z8T24tjJqKyCKGOOaI30pErAEsd23I3PtJyCcAgEbiKqP4M8WQ6dP5OvSXd7OkkbeffTJEg8tUjZQAcHKlyPVupA5rXWwb7mnD4H0rUWi1CPVru8t5P3sGHieLl3kDKQnPzuGzk5KLnOKseHfAVl4b2C01G/nEVtJbRCcxny1dgxI2oOcgc+gA7DGZB4L1poYbe41SaCCKU/LaahLHmFVcRxqFUbPvJk8/cz1NdN4d06903T5I9SuGuJ3meTc0zSbVJ+VctjoOOAPXGSTRZapf1/V2F76syNO+HWmaagC3d5OUjZImmZCYi0SRB1wowwWPj03N603/hXGmJcQTwXt7DLCwcMhj+YjywuQUI+UQoB+NdfRRd3uBx8Pw/tbOwNjbTSyieaKW4vp5B9oXymVkC7UAOWUknjBYnnNdbFEkEKRQqEjjUKqjsB0FPopXA4Xw34dtPFHwZ8I6fqLN9lGm6fNJEI43WbZEjBHWRGBUkDPAPHWtO48C2M4uBFfXlqJZ1miW3WFVtgIvKKIvlkbShIIYMeeCOKwNN0vWNW+CPhC38PuqXI0yyZi2ozWXyfZwCN8Ssx69Me+cgVjar4f8fWt1HLqGpPeRXctrDHb6ffX0ZV9u2QySRqRHGPmO8IM7gWwQCBa6ef+Q3pr5HTy/DvQ9UvIZrPWtSjbTbiUCOzu02I7Yby3XaQ21sOA2SCecjiqq/DbS9NvIGu/FmredJhLdZ3tELFBG3ygQAsQtunrwpPqaoyeDvHA1Scx3dq9tcGITTLrl1bySbRAC+xIsKxETg4bnzME4HOh/wifieO98wXcN1FHdNIgn1S4LEeTMgcEoxib94g2qcDYWzk4p7LQSSuS2vgbTI4Lawj8XanLJKv2i3xNaiRo1g8gMm2IEqqOPmHcqSeed/wtocOhacLfTtSkvNOwTAjLFhCXdmIZFUEEtjHQbR71xH/AAhPjO3W1ltHs5LuObzpZpdfu1LMRDkZ8k5UmJwV4BBBI7VYXwj45JaQ6pHE39m/ZhENaunRpQysrklMg/KQXGGIbB6ZLb/r+vuEtbX/AK1PSI5opWkEUiOY22OFYHa2AcH0OCDj3p9cfp2i+KYtft7u8urf7Ml1K0sQ1CeQNE0agYQqBu3qTgkhQTjrXYUuiAKKKKQwrm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8oAjn0PT5/F8v2jxFdPNcGO7bRTLAqMI9oV9oQSlQwB+9gnr6VXsdA07UJ9raikN/DfNfzW+nXgfZlipQkru2FkbIAXLBh61neJPCPiW/1XVrnQrmOya7kt3inGsXMbDy0brGqFFG4rlRuDDOcGo5PCni+cs7zW0coL+W8etXIYq08jbCwjBIEcmB1wVGAMAhdF/X9dBvr/XkX4vhlbQxTxL4h1kwzWz23lt9mwivGkZIPk5ztjUckjjpzWnpXg9dF1a41Cz1e9klvJVe6FwsTeaq78LkICOZOucgKo6Vyo8I+PXuLS7XVre1nW/jkuIjq93cRtAqIDtBCDduDnaVKnzOfurjS8XQa7qt54dgskvLC7n837Qbe8uFgtsKCGd4l2uQR8qvtDcjIyavW+4t1qVde+HegkXcmu+LtUs1vZHlVjd29t5RBeV9jLGpxtaTOS3yk56ZE8fgHTLDVLOY+LtURp591tbu9oBMctLsU+Tvb+I8NnA68VFd+EvFUtxM/2q1u1NxJIi3OoTEMGhmQMAY2ER/eoNi/LhC2cnFZd/4I8ez6h51pqFikXmxSrHJqtwywFIpIyIx5WU3CQA7SuNuRgniYpaIctd/M6Kw+Hel29q9tZa1qDGKT946tblhJvjly2IsbtyA9Od5z1GC1+H1lBZjS4/EurNJDJ9ozvthMoaA26/diGAEBwcZyvU4qpe+HPGT6hJd2c8GPtJdLd9dulQx74mAOIzjO2UEYIAcdegz5PBHjVdL+z2mqeTM8VuzzP4hvZWWaPzNxUsh+ViYwVxhgpyM4NUthK6uzqbXwTHaeGbzw/Fq14NOuImjQCOEPDvd2cqRHt534wVIAHFZ9/wDC2wvdYu9Tj1zW7We7ZGZYp4njQjGSiSRsq7iFJwOqjGOa6+ylupbUNfW62025gY0l8wYDEKc4HUYOMcZxViperuxLaxxtn8NbKyvYrtNZ1V5YxbrufyDuWEqUUnys4yucDH3mxjPHZUUU7thZI5vx5/yLtr/2GtK/9OFvV640ATawb+31K+s/MA8+C3ZBHOQMKzblLAj/AGSucYORxVHx5/yLtr/2GtK/9OFvXSUhnD2Pwus7Ris+v6ze27RvG1vP9mCMGi8rOUhVgQvoeo5zT7r4aw3UkUv/AAkmsxSodzyIloTK+8PvbdARnIXoAPlHHXPa0UBvozjbD4a2GnyGVdW1SaXy4IxJKYCyrCyMgyIhxlOh4+ZsYyMLbfDm2tJ5pIde1cLJbyW4jP2crGHRUyv7nOQqKBkkccg5OexooeujBaO6OY0nwUmi6y+pWer30k04jS5+0LC3mxoG2pkICOXJznjoOOKoat8MLPVdWvNQOu6vay3h/eiD7MQQA4C5eFjgCRwOeN3sMdtRQ9dwWmxyKfD2CPVbe+TXdWBhlSUw/wCjlJCu3hv3OcEpk4I5JxgYAk0TwFaaLry6uNV1G9uUSWNftRhwqyMHYDZGpA3AHGf5nPVUU7sVkFFFFIZzd9/yVPQv+wLqX/o+xoovv+Sp6F/2BdS/9H2NFAB48/5F21/7DWlf+nC3rpK5b4i20F54SitbyGOe3m1bTI5YpUDJIpv4AVYHggg4INZWp+EPBdvqL2kXhDw5ClvaNeXM8mjxPtQEgBVCjJ4JJ7Y6c8K9h2O+oryhY/h9b6fBJceAtKvHJETz22iQRxvKFJcKJMEAbHzn7u05wOalaP4dm1jnt/hxZ3KyyJEix6Na5aQ9UGcZK4bd6bTnjBLEepUV5d/Z/gbULy0s9I8C6Gk1xLblZLjSLco0T73ONvIby4nIz6r1zimX2n+B1162tNO8D6BNbsdssn9k25JJlWJSvIIXPmEkjkRkj3dnewHqlFeXFfhktnLdP4E0pY4cedu0m1BjJYqAR2O5XBHUbCTgYJpXjeAltbF4Ph9pVq9xdpDJHd6Nbb0BXeV2g/eKlQOwMi568LcHoevUV5hPbfD63llWb4bWapBAk88p0e1Cwq5YDd3BwhYjHA5OK6eH4e+CJreOU+CtBTeobY2l25K5HQ4Uj8iaAJPhx/ySzwp/2BbP/wBEJXSV5X4e8J+ELX4NaJq9x4Q0W8vG0W1k3PpKTPNK0KYJCoXcljzjJP1qtCfAsPg3TdUvvh5osl7d2csrQRaXbRKJogfMi/eYYNlWwMEgKc0bgeu0V44118PdIsbyTxN4D0W3kt7gopXS7ONHUySKoBZ8blEZ3ZIBP3c5ArQig+Ht5K0dv4A0yEJcRx+bNo9oUkRpWj3LhuBlOp5G4HB5AAem56nRXBeHPDngDxNoZ1Kz8A6VbhZHjNvc6TbLIGU4/hypB4IIbBBBrktOufCP2ZE1L4Y6ZLf3ES3MMFvpFkiiNpUQRlzKwLgSK2TtBBHA6U7O9gPaqK8jll+H1pNFay/DiwurqSCa5ZINJsUMaRtIGBV5MnHlkErkZK8jcBVqyPwtvfE1toP/AAhejQX9yZAiTabaDlGcdASxz5TkEAgYAYqSARJvYOlz1KivOdU0r4faTr/9l3Pw+0xsRJK10ul2YhUPv2gkkMMmNh93AyMnGSMmCX4f3Fot7F8NbQxMu37OdFs1lWQSSRkEl8cGPHp8wOSM4Q7NHrlc34o/5GLwZ/2GpP8A033lQWXgPwHf2FvdweDdA8q4iWVN2lQA7WGR/D71jeI/APg+DXvCccHhPQ40uNWkjmVNNhAkX7DdNtYBeRuVTg91B7U2mnZkppq6DXfGviLTPE93Z2unzT2cMiiMp4fvpty7Yyf3qZQ5zIuRwCAT0wWv4k8UtZ30Wn2k9vKkV5JA8ujXUpmcSybMF3GzChCFOd+8BAAMVj3+iaRY+ObnT7f4eaDqlhAA7QWnhtFkVDEWz9odhCW3ADYQpIYHtS3l98M7G2lu7n4daelkkaSJeNp+nrFKHYquGaQY+ZWHzYHHuMpPRFPc1R4u8XreLp8tuouHmSJbseGr1oSC7gucSYUbPKbl/wC8M/3YtP8AEXik3mn+dZ3M8TIrLb/2TeQkP5M2S0ruQoMioNsmcblPoaq4+HtzqDWdj8PdN+VrZvtT6PZtE0czxqjAbwxBEnXGVxkjoG2fDnh/4feJY75rXwJpFubK5NtItxpNt8xChg6ldwZSGBBz+VVZ2FfW/Qq2njbxT/bWnW93pksltPKqSSx+H72PcpfaWySRFjJzvzkJno4xZ1vxb4m07XLmwt7FnTzglvOmh3dwm0tDgs0bbT8ry5OQMx/hW3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0l0A4u4+InjOJtU+yaDJqJtL5beGO30eZTLHlwZFLS4kQlUXeMbCxJVgBuv2fjjxTczXMMulTwKlwiJcnw/eYRC8o+4WBkJCRfMrAL5uTwprpf8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoT01Bk/h691q7vL+LWPsuy0k8kNBA0fmN94MMyNxsZAR/eDc4xW7XN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNIDpKK5v/hXHgj/AKE3w/8A+CuD/wCJo/4Vx4I/6E3w/wD+CuD/AOJoAPHn/Iu2v/Ya0r/04W9dJXnfjTwD4PtdBtpLXwnocLtq2mxlo9NhUlXvoFZchehViCO4JHeqmp6B4W0XxBfR3PgXQL6xSO38iCy0S3E4eQyD5ndwpGY+wH3hngE0Aen0V5RDJ8N5ruCEfDe0VZiuZW0izCxqxjCs3zZwfOjPAJ+bkcHEUUvw+udstt8OLF0BkjaD+xrLezCSFVKt5gXaROrDGcg5yMYLsw0Z65RXi2r6r8OF0vWk0LwNoc+rabvX7PJpdm4UqHLM4VxhV8twQSG4yFYFc6+uaf4E8Na26av4I0E6b9jScTQ6Pb5hfErNvJIyCI8DC8HOTjkFrDsz1KivHLm9+HF1o6zaJ4H0R57ixuLm3mk0q0mgSSIOTHIY26nynwVJU7ThjWnHZeAY9Tjsbv4e6buluGhEy6PaCNMSFBn5ixyccgfxDgYOCzTsxbK56hRXn3hTQvh94u02a+sfAWkW8McxhBuNMtDvIAJI8ssOM4IOCCCCAQa3f+FceCP+hN8P/wDgrg/+JotYDpKK5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJpAF9/wAlT0L/ALAupf8Ao+xorNtvDmh+H/inpH9g6Np+mefouoeb9itUh8zbPZY3bQM4ycZ9TRQBpePP+Rdtf+w1pX/pwt60dYOiKI/7dezQODGn2plXeGIBXnqCdox0Jx7VnePP+Rdtf+w1pX/pwt6l1vwnBrN99rm1G8tiBFlIWTafLcup+ZTjk569h6CkMp3upeDItLvtSjTSr8BWaVLbyXeZmT7vXBZlbGCeQ3vWisXhvTb2NDFplldt+9VCI0kyEbJ/Bd/4bu2axLb4Z6RBdG5stRvo4H+zEQRtEY9sOwooyhO07ATzzV3UfAtrqWpteyanqEbGfz1jRo9iv8nPKEniMDBJGCR0NVoIq6dq3gOC7meEaLp01pOyo7mCNmKKwLpg5wB5i54PDj1qyG8CvePuTQlnllKZYQ7pWyfxPLMPruqm/wALdHlhZLi7vZnKuBNIYy43BwTnZjP72Q5I6uSc8UkHgvQrqFrq11meXy3Ym5jlibZh5WYZ24HzyEnvlF/u0mHoXnv/AAV5EDzvo6i4ULGr+US6uM9s5BDk56YYk8GluJ/At8ft91JoNwZgT9odoXL7VOfm74VT+Cn0qCT4d6dKysL+/QrH5Y8to148p4gcBMZCSEBuvC88Ut78OtMu/NRLu8tbaRWAtoPLEaZh8njKE/czjnjJ9TTdgLkN74Tu7MkHTBbM643+WFZhGoHHqFZV5wRnFa2n6pp+qQtJpd7bXkcZCs1vKrhTgEA4PHBB/GufuPh9p9zDdRyX1/8A6WSZWDoCf3jSLj5eNrMMeuxQcgYrY0PQLPw/bzwafuEU0okCEKBGAioFXAHAVABnJo06gc74ROjQfCHwhe+ITYx29npVjNHPfbAkEnkoFYM/CtzgHrzVjUB4D0jT9RmmtNAVbFWuLmFUt1ZTKuCW3YAaQcZYjd0zVfwno0et/B/wjA9zcWkkelWUsU9vs3xsIFGQHVlOQSOQevrzUbfCfR1vLi5s9T1i0eWNEiWO5V47baoUmNHVlBYABsg+owanWzHpdBa2vwwt9PaX+zvC2npPFE9xDNBbRMqsPMQSDsfl3AH+6SOlWoNL+G0mpRfZrHwq17dzsYvLhtjJNKh3NjAyzKTk45FZ6fCLTobgz23iDXoZSkSg+dC6rsAGQjxMiliqlsKOVGMc1a074Y2Wn3djO2t6tdmxnWeFJxbbQyoiDhYVx8iBcjBwTzzV6XI1sdHY+HNG0xidN0qzswYzEVt4VjUoccFQAOw7dqgh8HeGLaMpb+HNJiQp5ZWOxiUbc528L0z2rZoqSjl0+Hfh2HxBDqlvYW0AghMUdrFZ26xKDuyQRHvGd7ZAYKcnINX18H+Go1YQ6BpkO6N4sxWiIQjjDqCACAQADjritmigOtzDbwjpcvic65cxC4nFmtlHHNFG6RRgsTtJXcCdxB+bBGOKjm8AeDbgqZ/CWhylRtUvpsJwPTla6CigCnpuk6fo8Lw6VZw2cTsGMcCBFyFCjAHAwqqMD0rH8Uf8jF4M/wCw1J/6b7yukrm/FH/IxeDP+w1J/wCm+8o3A1m0e0R76exijsL2+UCe9toYxM5AwrElSGKjpuBHtVc+FdBe3aK40exuQ8C28rXFskjSxqchXJHzAHnB4zzWtRQBjT+D/DN1dJdXPh3SZriN96TSWMbOrccglcg8Dn2FXrDStO0sSDTLC1sxK2+QW8Kx729TgDJq3RQAUUUUAFFFFABRRRQAUUUUAc348/5F21/7DWlf+nC3q5qHg/w1q91Jc6r4d0m+nl2+ZLc2McjPtGBkspJwOnpVPx5/yLtr/wBhrSv/AE4W9dJQBzFt8O/DNl4gtNV0/SbKza0jdYra3soEiDuVzLgJuD4UDII44q03gbwk0kcjeFtFZ4m3RsdPiyh45B28HgfkK3aKLgZN14U8O3y3C3ug6ZcrdSiacTWcbiWQDAdsj5mA4yeaLrwp4dvr6K9vdA0u4uoUEcc81nG7oo6KGIyAM9K1qKAMd/B/hqSGOKTw7pLRxReTGjWMZVI+fkA28L8zcdPmPrVb/hAPCAuPtEfhbRYrndvWePToRIrddwbbkHPOa6GigDE8LeFNP8I6Y9lpY+R5PMdvJhiLHpysSIucADOMnuTW3RRTvcAooopAc3ff8lT0L/sC6l/6PsaKL7/kqehf9gXUv/R9jRQBF8RbhLXwlFcSiRkh1bTHYRRtI5Av4CdqKCzH0ABJ6AVzvinxJLqs4Okf29bItrLGB/YuqR7ndSAxCW/BUhSDk8FuOhrp/Hn/ACLtr/2GtK/9OFvVXxbd6umtWCaHFO8sCGQjEnku7ukah9pAKhWkc5PG0HFHVBtqcrpGqSWmvGe8PiA2TXDzGOLSNUzwxCBgbf5hsEY25ABDdQSKsT+IrmZnfbrvmG4kZsaTqqrNEd/lrtFt8m0mPIXrtOTyc6S+JfGSWkVw+lRyxvHFIzCxlQoGkkQgoWLblHluQAeN3saddeI/FKSLGtmQoeLdNDpszggKzSDBII5jKg4wRIhyDQ9h21OStr/XLGVXW+169LIyzfaNK1ZVYlm24UW5xjEZJBBOXHTFQWKXVvaWsEh13Ee4PjTdXOCxhUsD9nHPlpKf96Q+prq7Pxh4hM8dsYYH8lUWci0mdnJEYZowGywR3cOOcbVXqSQ2PxR4unKTtpkrJtD/AGYafNEzfJLJgsScH5YkI55ZuOlUrp3J3MPVb/VNQLNFf+IoCEmO2LSNVQSyEOEztg+RRvXgDjZ1JOR0fh3xTFYSXkmqp4hmMzJ5af2JqcojAXBGTbgdcnOM88k4FOl8UeLItWKHTFOnxzRoZxp07NMp3FiqqxKgbG5IPVOu7jq/D11qF7okFxrEKwXb58yNEKhSDjjJJIOMgnGQRwKS2Bu7M7/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukopDPO/APjTS7X4beGreW11xnh0m1RjFoF9IhIhUHa6wlWHoQSD1BroP+E80j/nz8Qf+E5qH/wAYrkis7/ADwmtpLqMM5sNNCyafFdSOo8uPeWW2ZZCuzdkbh25zitGwExOlw38viKQCziWzlgS8jDzDcJTMH+YHpj7QcYxjJ5oWquD0Nz/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABisnwndaofESW91Z6oZfsjPqdxezXCwrcZX5YUaMxMvHBicADORnrQsWbUNVu9PnvNeTUI4HfWohNcIijOYzBjgZ2kDycErnd82KHorj62Ol/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8YrF8J3Gq6Zpfhu1I1R1voBLeyalb3V1KJdqhoy7sDByC2XyvUKORVa98Za/Y+KpLGz0y7mtjf8AlvI2iXzqULxKGWX7gAVpDkfKfLzgbqdve5Sb6XOj/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GK42Lxr48gnjsbnRpnbyImN/wD2FcNFvaVVbKrJuyAWGMD7u/O1sDW1TxF410vRpZFsre9vYLnyWWDSLgpMAXYsoWRiAYwgB+YBzg+xa42bn/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxVjwjLNLospuReBhfXQX7akiybPPcp/rBu27SuO2MYrcoegHN/8J5pH/Pn4g/8JzUP/jFc/wCI/Gmlza94TdLXXAIdWkdg+gXykj7DdL8oMILHLDhcnGTjAJHolc34o/5GLwZ/2GpP/TfeUgD/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrlvEviLV/DvijVJdCstXvZJPLzHLpmoXdudsLHEWz92hLbFJXj5snoa0v8AhJ/E8+pxxW1kY1kvHjMU2iXP7uJUZlJm3hCX2rhsALvwQSpFHS4Gv/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFcppnjnxvff2cZvDc1oJjOtwtzpM6FcK3luNruFG8BSG5YEMCM4Gx4c8W+ItV8VQ2Oo+H7u1sJNPW4N1LYtCok4yCzOdpzkeWVyAASxzgOwrmn/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMVzlzq/iTWJLO1vobqxt21WKOY2unXkbCPDlozIjg4BVP34Ijbd0wCDP4h8Y+KtKvbiHTvDt1qCR6hHCrwafI4MTLnqZBu5HMgG1Mj5WwaX9fl/mN6f16/wCRuf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MVzMnjDxha2MF3cWgmS5RmRIPDd7vh2uUw6hy2TlWAIXjOM/eF/wf4w1zWNXe21nTp4YVt3k8z+xLy1AYbCBulGDkMwwOcxk/xAAWoPQ1/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK4jUNW1prjXf7UttfWy1aGK40z+zoL9pINsjKVby4laBioUlM9iSfmxW7qKQ694j0C6tm8U20E0kkTBTfWqKsaEq0icBcuRzKBux3FNK4m7G1/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWR4l8V+JdK8RXttp2mNPp8VmJIpV0m5nbztyfLmMkOpVm6AFSvOR1z9F8S+Ita8Y6EdQstQs7ZVmWVV0q8gjlO1gJHLnYikqMI43A8hsHlLUb0J/GnjTS7nQbZI7XXARq2muTJoF8gwt9Ax5aEDOAcDqTgAEkCug/4TzSP+fPxB/wCE5qH/AMYo8ef8i7a/9hrSv/Thb1zPivXtW0DxdfzaHbarcyyQQrsfTL+9tchJSdixkRq2RCCR6n3IBpXOm/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8YrHHinxLc6jBHb2bW6TXaxGKfQrpvKjKM24zb1X5iF5wAmSrc1maZ468b3stgLrwzNZiS6liuVuNLnHyAKFZWV3C4dsZbh1UsNvQOwvM6v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8Yrm4vHHi972GH/hFrxo30152mbTpI185dw5zISuSBiLBYhs7uMV0Pw9nv5/B8b6s12119puNzXdvNA7L5zlCEmJdV2lcAk4GBniiwr/1+I//AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrpKKQzm/wDhPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukooA5v8A4TzSP+fPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/wAYrpKKAOJttetNb+KekfYodQi8nRdQ3fbdNuLTOZ7LG3zkXd05xnHGeoorSvv+Sp6F/wBgXUv/AEfY0UAHjz/kXbX/ALDWlf8Apwt66Sub8ef8i7a/9hrSv/Thb10lABRRRQBXhsLO2uJJ7e0gimlOZJI4wrP9SOTViiigAooooAKKKKAOF8Ma8vh/4QeDp2sLu/M2mWUKxWnl7txt1I++6jHGOvcduasr8SLBwXTSdUMIw3nbYdpj2LI0mPM3YVZEJGN3zcA4OKvhrw3ZeJ/hB4LtNTLNbQafYXDQ+XG6T7YVwjq6sCv0weOorqD4b0NiS2i6eSbgXRJtU5mAwJOn3wBjd1oj5/1t/wAEH5f1v/wDnV+ISWVvcDUrG4upreS48x7GNFRVSWVIwQ8gO5hE3TIyOSoIpk/xA0Qalpbz6LeG9uHnhjZ0t/MtwjYkOTJkjA3ER7jgcgdK6GTwl4cmGJtA0uQESA7rKM/6w5k7fxH73r3rMb4ceG11ewvrPTrWxWwYtHa2tlbpGWzndnyyyHIGSjLnAByOKOoPrYyoPilZ62dK/wCEahadbm+jhunfypFgjZtoyyS/ePBG3fjkMFPTv6x/+EQ8N5tT/wAI9pX+hyGW2/0KP9w5O4sny/KSRnI781sU9Lf15C1v/XmFFFFIYUUUUAFc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033lAEWseLJtN8daNo0dsz2l4WS4nNvIRG5VjGPMA2KcpgqTk7lx3rIvPFPiYaNqk9tNpMF3ZETiOeylkUwFnC4KzBXztB3hh3BQGrt/qPhCS51y2v9Fs57vT7hLm6tpILdpbhgiEXCqWy21XA3HBGCB2zduB4GFjqcN2PDwtWuEj1FJfI2GbjYsoPG/hcBuelC2V/62B72NC61K50Pw219rEYvZrdc3BsYxGGGcFwsj8ADkgsSMHGe/Oj4saEFtGnt7q3W7ujaxtLJAB5gbaw/wBbyQSvC5JDAgEA414tR8P3HijUdBiit5rlrJZL1Q0bx+WPlCOu4kfK3QqAQepqo9/8PGtYvMu/DJgRzeRbpLfarLlTKvbI2kbh/dIzxRvqHl/W2n6Gbe/Ery7VrWzsLhtT/sx9QDyxxCONVBOHQTb+o25XcuSPmrY03xtBqFxcA6bd21ta2j3M1xM0eEKSPG0ZVXJyDGxyMj3rn7rRPhnaa493eXWhKkccdodOaO08mHzAdgI2b1DAkhS2w5LYzzWxpeoeB9Psd2jR6FavHa7zaWklqjpG+1ivyttAJdD12kspycina60/rf8A4AO35foZVn8WLC2m8jxJE9jNPdzRwIRGrJEoUruUStuY7gP3e71IUZxf1L4mWOj27zaro+o2kccUcjvLNaBV3sVRS3n7QTtzycYI5zxU9nb/AA7s4xJYQ+GLdLW52hoVt1EU8nyYyPuu2NvqcYpLu18A6RJcafqNh4d0+IwRxyrOltGjoS7rGVPOBsZsEY6kZwcHRC7/ANdRv/Cy9INzcRra3pigjglF1iIQyRy4+YMX4C5G4NgjIwDkZzbz4r2F3oFzdeGYmurqKcxbG8p1VVKlpG2yjC7WHGd4J5Tgitm7bwBBqE8V8fDcd47ok6TeQJGbAKBgeScICAeyjHSmm2+HupRRWTQ+GbuO7lkuo4Clu4mkXIklC/xMMHc3Uc5o0/r+u39djW39f1udXRWZH4i0Joz5OsaeVjthdHbdJhYO0nXhP9rpTtB1u28RaHbarYBhb3IJTeVJwGI6qSpHHUEgikMzPHn/ACLtr/2GtK/9OFvUN94yOkeIdQsb+0kmhihE1u8CoucRlmjYvIMsdpIOAMcEjjM3jz/kXbX/ALDWlf8Apwt6i1Sx8Atrd1Nrdr4bOqLCGuXu44PPEbfuwXLfNtOQvPBzikMzrf4taFdSGKC1vjci0W7NqwiWYAlcqUMgIZQwJONvBAJIxVkfEmw8l2fSdUSSP5mhZItwQb97/wCswQnlPkZydvyhsjKsvw2uoyjL4VmSWLyypFsweMDztvuoGZMdP4veoNMtfh0m6CLRvD2mySSuy28lvbRtN5BJ81Qv3lH3g3YHJxVaC6Cz/EW3k1i4tLO2mjh025VL64nRGUoUc4QLJvVvkz86DK9Bhgaa3xEYa5axNpd2lrLGyTRNHGZreXfEqFmEpQowmT7uSMjPfE2k+GPB3/CSXV3DLp2p6jdEX6pJHbPJGpJxKpRA7DJOHcsRkgEDirFpL4Gkgt7SOPQIRbebNBa5t/3Q+YPIqqSFBAYkjtnPcUlotQer0F8O+N4NbvLaxayvIpprZZhcSRxpE58uNyABI7A4lHBz0PJ4Jp3fxT0KyuYLaaK4F1PJLElv5kAk3IcY2mQctlcAZI3AsFGSIrey+FMIaaxh8I252KTNbfZo2CvgA7lwQDuXHPOR61qPbeBb2ZreSDw9cSR3TwtEyQOVuJFO9SOzsoOR1Izmm9XoBV/4WLbJDLJc6Fq1v5cLThH+zlnQJvBG2U9VzgHB4OccZ1NB8Uwa/c3EEVje2kluMsLpUGcSPGQNrN0aNgfwxmsPW2+HTW2nve6XoGqJcXMWm2qJDbSkMH8sIoY8hCxyq5KjPHWuj0nwvoGgTSS6Foem6ZJKu2R7O0jhLjrglQMijTfoLW1upq0UUUhnN33/ACVPQv8AsC6l/wCj7Gii+/5KnoX/AGBdS/8AR9jRQAePP+Rdtf8AsNaV/wCnC3rpK5b4i3CWvhKK4lEjJDq2mOwijaRyBfwE7UUFmPoACT0AqX/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAOkorm/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigDpKK5v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAD4cf8ks8Kf8AYFs//RCV0led+AfGml2vw28NW8trrjPDpNqjGLQL6RCRCoO11hKsPQgkHqDXQf8ACeaR/wA+fiD/AMJzUP8A4xQB0lFc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFAHSUVzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMUAdJRXN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xQB0lFc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFAHSVzfij/kYvBn/AGGpP/TfeUf8J5pH/Pn4g/8ACc1D/wCMVz/iPxppc2veE3S11wCHVpHYPoF8pI+w3S/KDCCxyw4XJxk4wCQAb+qeB7HVL2/umvb23e+jKuITHhGKqhddyH5iiqvOVwMgA5NQP8PLB/MYajqCSs+6KVTFugT95mNcxkFT5smdwY/NwRgYsf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAR2ngOws9Su7mO+vmt7q1ktTZM0flRo5BbaQm/OR3Y4yfbEGofDyDVbNoNQ8Qa1KTbLbrMssUUkZWQSLIrJGCrgqo4+XA5BJJq3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUf1/X3h/X9fcjPs/hjp2nzCWy1XVY5EjhijcvC7RrFt2AFoySPlP3s/fbGOMVYvhRbxRlB4p15lMBtxkWfCbFT/n3/uoo59PU1tf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFO7Awbn4PabfQzpf+IdenaZw7SLNDCw+aRmGYol4bzpAwOchscYFaviHwBD4h1Brp9d1ayDQpCYbUW5TChwD+8hds4lfv39hVn/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YpPVWY7vchj8B26eSja1qklvDP54t2MOwsUZXziMHDbiTzkH7u0cVR0z4U6Tpb2TJqmr3X2OR5U+2XCTbmZShyWQnhDt4I4AznGa1P8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xijzJsZUHwo0q3vJLoaxrjzPb+VmS7DKrbgRKEK7d42qOm3Cgba6fQNGTw/osWnR3dxeLEzt51zs3sWYsc7FVepPQCs3/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABigYePP+Rdtf+w1pX/pwt6h1zwDaa7rE+pSapqNrcTW5th5HkkRoSpYLvjbqUXIOR1wBk1i+NPGml3Og2yR2uuAjVtNcmTQL5Bhb6Bjy0IGcA4HUnAAJIFdB/wnmkf8+fiD/wAJzUP/AIxQBmW3w7FhIETU7zUYp545J3vXiRolR3k+QQwpu3GR1YMQNrnr0q1cfDyxvNUS+utT1GZo55p44n8kohkDBgB5ecYdh1yRjJOBVn/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABigCDRPh9p+h+IItXh1PVrm4jtRbFLm63xucAeaUAA3kKBnpgDis5/hTaTXYnufEmuTYYsEb7KoBPmd1gB4M0hHPf2FbH/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MU7sClqnw4tdZsbq31LXtble5aJzcJPFFLGYwy/KyRrjcHYMDkYOAFFEXw102G6mnTU9U3zTxTMfNjB/dsxVNwTcVwxU5JO0AZ4q7/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFIDGsfhHpOnRwpZ6zra+XcrcFpLlJi4Vo2SMmRGwi+UgAXBwMEmu9rm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYp3drB1udJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFIAvv8Akqehf9gXUv8A0fY0Vm22vWmt/FPSPsUOoReTouobvtum3FpnM9ljb5yLu6c4zjjPUUUAdtXn3i+7uYvix4NgiuJUikM2+NXIVvl7jvRRQviQPZi+I9PspNB8cmSzgcq4uV3RKcSrbRlZBx94EDDdRis34pfvtT0y2m/eQSQhXiflWDSoGBHQ5HB9RRRSn8C+X/pKKX8Rf19o63wKzSeHYpJCWcxW4LMcnH2eM9fqT+ZrpaKK0qfEzKn8COcvI0HxN0mQIu86VdqWxyR5tvxn8a0tFlklgujK7OVvJlBY5wA5AH0ooqV8Mfn/AOlMt7v5fkZuqWdsvjzQbxbeIXTR3EbThBvKhAdpbrjPaujoopdF/XUDL0oCW91CaUB5Yrp4o3blkTah2g9hnnFO1OWSPUtIWN2VZLplcKcBh5MhwfUZAP4UUUL4ULqyrcRoPH9hIEXedNuVLY5I8yHjP41H4oije+8Ou6KzR6qpRiMlSYpBx6cUUU1tD1/9uYdZ+n/tpwVxp1lc31nLc2dvNJqWpXsF88kSsbqJJ8IkhI+dVAAAbIGOK6v4W2NpYeB7OKxtYbaN4YJGSGMIGdreIsxA7k8k96KKKfwv0X5jnv8AP9Dj7rSNNm1a81aXT7V9SQu63rQKZlYX+wEPjdkIAoOenHSvYqKKUf4a+YS/iy+RxniOWSXVb60ldntntWDQMco37iU8r06gflWheOyeOdKCMVEmm3O8A43bWi259cZOPTJooo/4P5MOn9d0ZGrXVxJ8DdQuXnlac6TKxlLksTsPOetcnrNjaQ31hbw2sMcJWyszGsYCmBlUtFjpsJ6r0PpRRQ93/XSQ/wCX1/WJ6Z4OJPgzSsnP+jKOfTFbVFFVP4mTHZBRRRUjCucsI0T4la2yoqs+m2RYgcsd9wOfwoopoOj/AK6ov+IAE00XCALNHLGqSDhlDSKGAPUZHB9awo7W3b4R31q0ERtxZ3SiIoNmAXwMdMUUVPcuHxIxPiJ97SZP44LUSRN3jYz26FlPY7WZcjsxHQ1e+FsaR6LHFGirHCkqxIowIx9pl4Udh8o6eg9KKK0js/X/ADMvsx+R0F5Gn/CwdKk2L5n9nXa7sc48y34zW5IqvE6uoZWUggjIIoorOf8ACXo/zZovi+4wPAKqnw80FUAVVsIgABgAbRXQ0UVrV/iS9SFsZWggTWklzKN8/wBouI/NbltgnfC564HYVJdSyL4h0+NXYRvFMWUHhiNmMj8TRRWa2H1ZmeMoIryLSLK7iSe1utSjinglUMkqbHO1lPDDIHB9K860fRtMu9V0+6utOtJ7i1uLyOCWSBWeJIpk8tVJGVCZO0DpnjFFFOn8XzX5Cnt8n+Z197o+mXPxgS9uNOtJbuG0tWjneBWkQ5ueQxGR0H5Cu6oopR+BerHL+I/RGIkUa+PJpVRRI+mxhnA5YCR8An2yfzNbdFFC+FfP82OXxP5fkjLvwJddsLeUb4JIpmeJuVYqUIJHQ4PStSiigQUUUUAf/9k=" alt="" width="376" height="130" vspace="0" hspace="0" border="0" style="width:376px;height:130px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>* 13.4% vandetanib patients had QTc (Bazett&rsquo;s) &ge; 500 ms compared with 1.0% placebo patients. QTcF prolongation<br />was &gt; 20 ms in over 91% of patients, &gt; 60 ms in 35%, &gt; 100 ms in 1.7%. Eight percent of patients had a dose<br />reduction due to QTc prolongation.<br />** including two deaths in patients with QTc &gt; 550 ms (one due to sepsis and one due to heart failure)<br />Events such as Torsades de pointes, Stevens-Johnson syndrome, erythema multiforme, interstitial lung<br />disease (sometimes fatal) and PRES (RPLS) have occurred in patients treated with vandetanib<br />monotherapy. It is expected that these would be uncommon adverse reactions in patients receiving<br />vandetanib for MTC.<br />Ocular events such as blurred vision are common in patients who received vandetanib for MTC.<br />Scheduled slit lamp examinations have revealed corneal opacities (vortex keratopathies) in treated<br />patients; however routine slit lamp examinations are not required for patients receiving vandetanib.<br />At various exposure durations, median haemoglobin levels in patients treated with vandetanib were<br />increased by 0.5-1.5 g/dl compared to baseline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose with vandetanib and possible symptoms of<br />overdose have not been established. An increase in the frequency and severity of some adverse reactions,<br />like rash, diarrhoea and hypertension was observed at multiple doses at and above 300 mg in healthy<br />volunteer studies and in patients. In addition, the possibility of QTc prolongation and Torsades de pointes<br />should be considered.<br />Adverse reactions associated with overdose are to be treated symptomatically; in particular, severe<br />diarrhoea must be managed appropriately. In the event of an overdose, further doses must be interrupted,<br />and appropriate measures taken to assure that an adverse event has not occurred, i.e. ECG within 24 hours<br />to determine QTc prolongation. Adverse reactions associated with overdose may be prolonged due to the<br />long half-life of vandetanib (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic Group: antineoplastic agent, protein kinase inhibitor, ATC Code: L01XE12<br /><u>Mechanism of action:</u><br />Vandetanib is a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2 also known<br />as kinase insert domain containing receptor [KDR]), epidermal growth factor receptor (EGFR) and RET<br />tyrosine kinases. Vandetanib is also a sub-micromolar inhibitor of vascular endothelial receptor-3 tyrosine<br />kinase.<br />Vandetanib inhibits VEGF-stimulated endothelial cell migration, proliferation, survival and new blood<br />vessel formation in in vitro models of angiogenesis. In addition, vandetanib inhibits epidermal growth</p><p>factor (EGF)-stimulated EGF receptor tyrosine kinase in tumour cells and endothelial cells. Vandetanib<br />inhibits EGFR-dependent cell proliferation and cell survival in vitro. Vandetanib also inhibits both wild<br />type and the majority of mutated, activated forms of RET, and significantly inhibits the proliferation of<br />MTC cell lines in vitro.<br />In vivo vandetanib administration reduced tumour cell-induced angiogenesis, tumour vessel permeability,<br />tumour microvessel density, and inhibited tumour growth of a range of human xenograft tumour models<br />in athymic mice. Vandetanib also inhibited the growth of MTC xenograft tumours in vivo.<br />The precise mechanism of action of vandetanib in locally advanced or metastatic MTC is unknown.<br />Clinical data from MTC:<br />A randomized, double-blind, placebo--controlled study (Study 58) was conducted to demonstrate safety<br />and efficacy of vandetanib 300 mg versus placebo. This study included 331 patients with unresectable<br />locally advanced or metastatic MTC. Only patients with CTN &ge; 500 pg/mL (conventional units) or<br />&ge; 146.3 pmol/L (international standard units) were enrolled. Of the patients enrolled in the study<br />10 patients on vandetanib and 4 on placebo (4% of all patients) had a world health organization<br />performance status (WHO PS) score of &ge; 2 and 28 (12.1%) patients on vandetanib and 10 (10.1%) on<br />placebo had cardiac impairment. Cardiac impairment was defined as patients with previous<br />cardiovascular abnormality.<br />The primary objective of this study was to demonstrate an improvement in progression-free survival<br />(PFS) with vandetanib compared to placebo. The secondary endpoints were evaluation of overall<br />objective response rate (ORR), disease control rate (DCR) defined as, partial response (PR) or complete<br />response (CR) or stable disease (SD) lasting at least 24 weeks, duration of response (DOR), time to<br />worsening of pain based on Brief Pain Inventory (BPI) worst pain scale, and overall survival (OS). The<br />PFS primary endpoint, ORR and DCR were based on centralized, independent blinded review of the<br />imaging data. Biochemical response with vandetanib as compared to placebo as measured by CTN and<br />CEA was also assessed as secondary endpoints.<br />Patients were treated with vandetanib or placebo until they reached objective disease progression. Upon<br />objective disease progression based on the investigator&rsquo;s assessment, patients were discontinued from<br />blinded study treatment and given the option to receive open-label vandetanib. Twenty-eight of the<br />231 patients (12.1%) on vandetanib and 3 of the 99 (3.0%) on placebo discontinued treatment because of<br />an adverse event. Fourteen of the 28 patients (50%) who stopped vandetanib for an adverse event<br />discontinued without a dose reduction. Five out of 6 patients (83%) with moderate renal failure who were<br />treated with vandetanib had a dose reduction to 200 mg for adverse reaction; 1 patient required a further<br />reduction to 100 mg.<br />The result of the primary analysis of PFS showed a statistically significant improvement in PFS for<br />patients randomized to vandetanib compared to placebo (Hazard Ratio (HR) = 0.46; 95% Confidence<br />Interval (CI) = 0.31-0.69; p=0.0001).<br />The median PFS for patients randomized to vandetanib has not been reached; however, based on<br />statistical modeling of data observed up to the 43rd percentile, the median PFS is predicted to be<br />30.5 months with 95% confidence interval 25.5 to 36.5 months. The median PFS for patients randomized<br />to placebo was 19.3 months. At 12 months, the proportion of patients alive and progression-free was 192<br />(83%) for patients randomized to vandetanib and 63 (63%) for patients randomized to placebo. In the<br />vandetanib arm, a total of 73 (32%) patients progressed: 64 (28%) by response evaluation criteria in solid<br />tumours (RECIST) progression and 9 (4%) by death in the absence of progression. The remaining</p><p>158 patients (68%) were censored in the analysis of PFS. In the placebo arm, a total of 51 (51%) of<br />patients had progressed: 46 (46%) by RECIST progression and 5 (5%) by death in the absence of<br />progression. The remaining 49 patients (49%) were censored in the analysis of PFS.</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM0MQAAkpIAAgAAAAM0MQAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNCAxMToyODowNwAyMDIxOjA2OjI0IDExOjI4OjA3AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjRUMTE6Mjg6MDcuNDEzPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAIIBeAMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APoPWNYstB0x7/U3kS3R44/3ULzOzO6oiqiAsxLMoAAPWsn/AITzSP8Anz8Qf+E5qH/xijx5/wAi7a/9hrSv/Thb10lAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMV0lFAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUActbfEXQby1iurOLXJ7eZBJFLF4ev2SRSMhlIhwQQcgipf+E80j/nz8Qf+E5qH/wAYrnbK31W8+APhy10SGaeWfRbOOWODyfMaM26ghfP/AHfpnd2zjnFUtMj+JMV3bWM1nd2OlxpaRrLbT2TvGoQCQbXBxj5tx3Pk7dvG4Ejq2glornX/APCeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxXIQ3XxMV5Few1x1KSBWkbS1wSjhSCrnkMIiMjGS+eMYDp3xAnWD7Y+pS3LQbWlH2BY4ZBBOnmKMlkcuYz8uRhiOmQDpca3sdf/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWJpMni7TrmOa503UprRZpmuVlNkJpkEKbHPlH5mLqVAG08/NwBTPFmr+IX8ZQaX4ZvbsTNp32prKH7H8gDlSzCb5skHAwSu4LnAzkelvP8AyuJaq7/rWxvf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFcxeL8RLSKNLVtavjLEjs4GmBoXZfmTB2ghWXHfhurdQt7p/i9dRleC31We2W4ceWBpwF0N1vtkkU4B4WUA8OMDpxTt71hX0udN/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWVa3WsWurW8uqWl3NfQzXAdYzGzzWf8BKphR85XaCd2A3JO6o/FVx45i8TSDw7ZalPpzQBQYWsVRXMcmWUytv3B/KxkFeG7YpdB9WjZ/wCE80j/AJ8/EH/hOah/8YqKX4i6DBJDHPFrkb3DmOFX8PX4MjbS21QYeTtVjgdlJ7VgaPY+K59c0ifxFpFxNNazRGa/dbNM4gnjdwI33YJdDjnBY4GK6TxR/wAjF4M/7DUn/pvvKbVhB/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRSGc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUActP8RdBtYxJdRa5CjOkYaTw9fqCzsFVcmHqWYADuSB3qX/AITzSP8Anz8Qf+E5qH/xijx5/wAi7a/9hrSv/Thb10lAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMV0lFAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBiaX4u0rV9VGm2w1CG7aF51jvdLubXeiMqsVMsahsGRMgHPzCiq19/yVPQv+wLqX/o+xooAPHn/ACLtr/2GtK/9OFvXSVy3xFiefwlFFFPJbPJq2mKs0QUvGTfwAMu4FcjqMgj1BrM8QR33hyOF7rxn4onEu84gt9MJUIpZiQ1uOwxxkkkDHNAHeUVw86RWqsbr4palBsOG806am04JIObbg8H8j6U26jlgkSKD4ha7eTtPFCYLZNNZ0LttDEfZuFGGJP8Asn0o62Dpc7qiuKubcWVw0F58UNTglX70cp01WHIHQ23qw/MVCFeS/sbS0+Imt3bXiNKjwLpjKkaqG3n/AEb7vKjIz94etAHd0Vw8ggiiikl+Kt+kc2PKZn0wB8jIwfs3OabamK7CiH4o6kXaPzdm7TCwTAbdgW3TDKc+hHrQB3VFcIsto93Fap8Wb5riZtkcIk0ze7ZxgD7NknIIxWpD4d1K4gSa38f67LFIoZHSHTyrA9CCLXkUAYFl4gfw18AfDl7E8MUraLZxRzTziGOFjbrh2cqwGMcZUgkgd6bovxPjktrfznh1FpnWLfBdI7M/2SObaiInViX4J4IPzYwoz9Bg1TR/hN4Wv4/EniadLjT7GKOzsItM/dmSNAqgzQj5QSF5YnpnPJrS03VtO1PTPtsfxX1CFFIWaOd9LV4HJ27HH2f5WzxjuemaI9Qdrr+v62C3+KrXAuNtnpTLb2rXMjxaxvXaGC7gfK5jBYBnONpWTg7ecPRPjXm2hsLlbO+vhGrG6kvfLilLTiPIkWHZtG7AIwWKkbV6100ctrNvEXxV1FnSWWEpu0wMZIxmRQDbDlRyfQc9KSKa2k2q/wAVr6KUhS0LzaVvQsAQDi3IzyOhPtT0v/XmJ6f16f18zo9A8QDWrnU7aSKKG4025+zypFMZADtBBJ2rgkHOOeMZ9K2q8/e7sxexWkfxXvpZ3BYok+k7kQR+YXKmAHbtwcgHhgemSNWz0S91Gziu9P8AiJrV1bTLujmgTTnRx6hha4IoGdXRXN/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDItIDpKK5v/hF9X/6HvxB/340//wCRaP8AhF9X/wCh78Qf9+NP/wDkWgDpK5vxR/yMXgz/ALDUn/pvvKP+EX1f/oe/EH/fjT//AJFrn/EfhzVI9e8Jq/jTXJTJq0iq7w2OYj9hujuXFsBnAK/NkYY8ZwQAeiUV51cTapa65NYXHiPxilvBLHDJqPkaSYFaQDbkCHzACWAzswD145q0j2kvl+V8Wrx/NTfHtl0s71+bkf6NyPkfn/Zb0NHS4Hd0V59e31jY2hnm+LN5gqTGv2jSVMpAB2qWgAz8y9SB8w9a0rLS59RkuI7D4kavcyWr+XcJCNNcwv8A3WAtjtPsadgOvorz+2nSaG7e5+JWsWLWU5guI7s6WjRHzCilsW5wHKnbnr9eKniFvNdm1h+K99JcBzGYUk0svvG7K7fs2c/I/H+y3oaQHc0V56uo6W09tCvxfume6Utb4m0siUBtp2n7Ng4IIwPQ+lP+0WrTJFB8Vb+difn8ubST5S7GfcwNvnG1SeMnHPQEgDrY7+iuOGnyNpA1UfEzVTpxTzBeD+zfJK/3t/2bbj3zVR5rKONpJPi3dqiBWZmm0sBQyllJP2fuASPUAmgNzvKK4OfMdyLe3+I2tXk6zwwzQ2o0x3g804RnX7PkKcj354FbH/CL6v8A9D34g/78af8A/ItAdbB48/5F21/7DWlf+nC3rpK878aeHNUh0G2aTxprk4OraaoSSGxABN9AA3y2wOVJDDtkDIIyDau7bVrfVPsVv4p8XXpTb581tbaYUgLfdDbrcEk5z8obA5OBQB3VFee6fe2t/Y2twfihqlq9zwLe4fSllR8KTGQLcjcNy5AJ6j1FSmexEcUh+Ll2EmQyRN52l4kQZyyn7PyPlbkf3T6UAd7RXAXd1YWMU8l38W72JLcxicmTTP3XmfcLf6N8obOQTxjnpSSXlhHCXHxbu3+QyKq3GlZcBQ/GbcD7rKc5xhgehoA9AorjrHTptSmnhsfiTq9xPbbRcQxDTXeAsMgOFtjtJFVrh7S0lnju/izeQSW8gjmWWXS1MTlS21gbbg7QTg9gTQB3VFcJLJaQMRN8WryMqxQh5dLGGBII/wCPbrlWGPUH0qTToDqtx9ms/iXqsl1sMptkbS5JBHuKh8Jbn5SR1/Dg8UBsdvRXN/8ACL6v/wBD34g/78af/wDItH/CL6v/AND34g/78af/APItABff8lT0L/sC6l/6PsaKzbbS7vTfinpH2zXdQ1fzNF1Db9tjt18rE9lnb5MSdc85z0GMc5KANLx5/wAi7a/9hrSv/Thb1L4h0LT76ZdT1W+a2js4v3blkVYD5iP5mSODmNRzxjI71F48/wCRdtf+w1pX/pwt6h8U6Jrms30cdpLb/wBnAws8b3MkTHbIWcEKpDBgEHJ6bhjnNLqg6Mhf4d6Rd6Qtkb26kiVJUSRTFuBdQhbOzlgoZcnJwzZzxibTfAllpV5aXf8AaV9O1n5ewTmLGEjkRQcIO0rH68+uaFp4Z8T24tjJqKyCKGOOaI30pErAEsd23I3PtJyCcAgEbiKqP4M8WQ6dP5OvSXd7OkkbeffTJEg8tUjZQAcHKlyPVupA5rXWwb7mnD4H0rUWi1CPVru8t5P3sGHieLl3kDKQnPzuGzk5KLnOKseHfAVl4b2C01G/nEVtJbRCcxny1dgxI2oOcgc+gA7DGZB4L1poYbe41SaCCKU/LaahLHmFVcRxqFUbPvJk8/cz1NdN4d06903T5I9SuGuJ3meTc0zSbVJ+VctjoOOAPXGSTRZapf1/V2F76syNO+HWmaagC3d5OUjZImmZCYi0SRB1wowwWPj03N603/hXGmJcQTwXt7DLCwcMhj+YjywuQUI+UQoB+NdfRRd3uBx8Pw/tbOwNjbTSyieaKW4vp5B9oXymVkC7UAOWUknjBYnnNdbFEkEKRQqEjjUKqjsB0FPopXA4Xw34dtPFHwZ8I6fqLN9lGm6fNJEI43WbZEjBHWRGBUkDPAPHWtO48C2M4uBFfXlqJZ1miW3WFVtgIvKKIvlkbShIIYMeeCOKwNN0vWNW+CPhC38PuqXI0yyZi2ozWXyfZwCN8Ssx69Me+cgVjar4f8fWt1HLqGpPeRXctrDHb6ffX0ZV9u2QySRqRHGPmO8IM7gWwQCBa6ef+Q3pr5HTy/DvQ9UvIZrPWtSjbTbiUCOzu02I7Yby3XaQ21sOA2SCecjiqq/DbS9NvIGu/FmredJhLdZ3tELFBG3ygQAsQtunrwpPqaoyeDvHA1Scx3dq9tcGITTLrl1bySbRAC+xIsKxETg4bnzME4HOh/wifieO98wXcN1FHdNIgn1S4LEeTMgcEoxib94g2qcDYWzk4p7LQSSuS2vgbTI4Lawj8XanLJKv2i3xNaiRo1g8gMm2IEqqOPmHcqSeed/wtocOhacLfTtSkvNOwTAjLFhCXdmIZFUEEtjHQbR71xH/AAhPjO3W1ltHs5LuObzpZpdfu1LMRDkZ8k5UmJwV4BBBI7VYXwj45JaQ6pHE39m/ZhENaunRpQysrklMg/KQXGGIbB6ZLb/r+vuEtbX/AK1PSI5opWkEUiOY22OFYHa2AcH0OCDj3p9cfp2i+KYtft7u8urf7Ml1K0sQ1CeQNE0agYQqBu3qTgkhQTjrXYUuiAKKKKQwrm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8oAjn0PT5/F8v2jxFdPNcGO7bRTLAqMI9oV9oQSlQwB+9gnr6VXsdA07UJ9raikN/DfNfzW+nXgfZlipQkru2FkbIAXLBh61neJPCPiW/1XVrnQrmOya7kt3inGsXMbDy0brGqFFG4rlRuDDOcGo5PCni+cs7zW0coL+W8etXIYq08jbCwjBIEcmB1wVGAMAhdF/X9dBvr/XkX4vhlbQxTxL4h1kwzWz23lt9mwivGkZIPk5ztjUckjjpzWnpXg9dF1a41Cz1e9klvJVe6FwsTeaq78LkICOZOucgKo6Vyo8I+PXuLS7XVre1nW/jkuIjq93cRtAqIDtBCDduDnaVKnzOfurjS8XQa7qt54dgskvLC7n837Qbe8uFgtsKCGd4l2uQR8qvtDcjIyavW+4t1qVde+HegkXcmu+LtUs1vZHlVjd29t5RBeV9jLGpxtaTOS3yk56ZE8fgHTLDVLOY+LtURp591tbu9oBMctLsU+Tvb+I8NnA68VFd+EvFUtxM/2q1u1NxJIi3OoTEMGhmQMAY2ER/eoNi/LhC2cnFZd/4I8ez6h51pqFikXmxSrHJqtwywFIpIyIx5WU3CQA7SuNuRgniYpaIctd/M6Kw+Hel29q9tZa1qDGKT946tblhJvjly2IsbtyA9Od5z1GC1+H1lBZjS4/EurNJDJ9ozvthMoaA26/diGAEBwcZyvU4qpe+HPGT6hJd2c8GPtJdLd9dulQx74mAOIzjO2UEYIAcdegz5PBHjVdL+z2mqeTM8VuzzP4hvZWWaPzNxUsh+ViYwVxhgpyM4NUthK6uzqbXwTHaeGbzw/Fq14NOuImjQCOEPDvd2cqRHt534wVIAHFZ9/wDC2wvdYu9Tj1zW7We7ZGZYp4njQjGSiSRsq7iFJwOqjGOa6+ylupbUNfW62025gY0l8wYDEKc4HUYOMcZxViperuxLaxxtn8NbKyvYrtNZ1V5YxbrufyDuWEqUUnys4yucDH3mxjPHZUUU7thZI5vx5/yLtr/2GtK/9OFvV640ATawb+31K+s/MA8+C3ZBHOQMKzblLAj/AGSucYORxVHx5/yLtr/2GtK/9OFvXSUhnD2Pwus7Ris+v6ze27RvG1vP9mCMGi8rOUhVgQvoeo5zT7r4aw3UkUv/AAkmsxSodzyIloTK+8PvbdARnIXoAPlHHXPa0UBvozjbD4a2GnyGVdW1SaXy4IxJKYCyrCyMgyIhxlOh4+ZsYyMLbfDm2tJ5pIde1cLJbyW4jP2crGHRUyv7nOQqKBkkccg5OexooeujBaO6OY0nwUmi6y+pWer30k04jS5+0LC3mxoG2pkICOXJznjoOOKoat8MLPVdWvNQOu6vay3h/eiD7MQQA4C5eFjgCRwOeN3sMdtRQ9dwWmxyKfD2CPVbe+TXdWBhlSUw/wCjlJCu3hv3OcEpk4I5JxgYAk0TwFaaLry6uNV1G9uUSWNftRhwqyMHYDZGpA3AHGf5nPVUU7sVkFFFFIZzd9/yVPQv+wLqX/o+xoovv+Sp6F/2BdS/9H2NFAB48/5F21/7DWlf+nC3rpK5b4i20F54SitbyGOe3m1bTI5YpUDJIpv4AVYHggg4INZWp+EPBdvqL2kXhDw5ClvaNeXM8mjxPtQEgBVCjJ4JJ7Y6c8K9h2O+oryhY/h9b6fBJceAtKvHJETz22iQRxvKFJcKJMEAbHzn7u05wOalaP4dm1jnt/hxZ3KyyJEix6Na5aQ9UGcZK4bd6bTnjBLEepUV5d/Z/gbULy0s9I8C6Gk1xLblZLjSLco0T73ONvIby4nIz6r1zimX2n+B1162tNO8D6BNbsdssn9k25JJlWJSvIIXPmEkjkRkj3dnewHqlFeXFfhktnLdP4E0pY4cedu0m1BjJYqAR2O5XBHUbCTgYJpXjeAltbF4Ph9pVq9xdpDJHd6Nbb0BXeV2g/eKlQOwMi568LcHoevUV5hPbfD63llWb4bWapBAk88p0e1Cwq5YDd3BwhYjHA5OK6eH4e+CJreOU+CtBTeobY2l25K5HQ4Uj8iaAJPhx/ySzwp/2BbP/wBEJXSV5X4e8J+ELX4NaJq9x4Q0W8vG0W1k3PpKTPNK0KYJCoXcljzjJP1qtCfAsPg3TdUvvh5osl7d2csrQRaXbRKJogfMi/eYYNlWwMEgKc0bgeu0V44118PdIsbyTxN4D0W3kt7gopXS7ONHUySKoBZ8blEZ3ZIBP3c5ArQig+Ht5K0dv4A0yEJcRx+bNo9oUkRpWj3LhuBlOp5G4HB5AAem56nRXBeHPDngDxNoZ1Kz8A6VbhZHjNvc6TbLIGU4/hypB4IIbBBBrktOufCP2ZE1L4Y6ZLf3ES3MMFvpFkiiNpUQRlzKwLgSK2TtBBHA6U7O9gPaqK8jll+H1pNFay/DiwurqSCa5ZINJsUMaRtIGBV5MnHlkErkZK8jcBVqyPwtvfE1toP/AAhejQX9yZAiTabaDlGcdASxz5TkEAgYAYqSARJvYOlz1KivOdU0r4faTr/9l3Pw+0xsRJK10ul2YhUPv2gkkMMmNh93AyMnGSMmCX4f3Fot7F8NbQxMu37OdFs1lWQSSRkEl8cGPHp8wOSM4Q7NHrlc34o/5GLwZ/2GpP8A033lQWXgPwHf2FvdweDdA8q4iWVN2lQA7WGR/D71jeI/APg+DXvCccHhPQ40uNWkjmVNNhAkX7DdNtYBeRuVTg91B7U2mnZkppq6DXfGviLTPE93Z2unzT2cMiiMp4fvpty7Yyf3qZQ5zIuRwCAT0wWv4k8UtZ30Wn2k9vKkV5JA8ujXUpmcSybMF3GzChCFOd+8BAAMVj3+iaRY+ObnT7f4eaDqlhAA7QWnhtFkVDEWz9odhCW3ADYQpIYHtS3l98M7G2lu7n4daelkkaSJeNp+nrFKHYquGaQY+ZWHzYHHuMpPRFPc1R4u8XreLp8tuouHmSJbseGr1oSC7gucSYUbPKbl/wC8M/3YtP8AEXik3mn+dZ3M8TIrLb/2TeQkP5M2S0ruQoMioNsmcblPoaq4+HtzqDWdj8PdN+VrZvtT6PZtE0czxqjAbwxBEnXGVxkjoG2fDnh/4feJY75rXwJpFubK5NtItxpNt8xChg6ldwZSGBBz+VVZ2FfW/Qq2njbxT/bWnW93pksltPKqSSx+H72PcpfaWySRFjJzvzkJno4xZ1vxb4m07XLmwt7FnTzglvOmh3dwm0tDgs0bbT8ry5OQMx/hW3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0l0A4u4+InjOJtU+yaDJqJtL5beGO30eZTLHlwZFLS4kQlUXeMbCxJVgBuv2fjjxTczXMMulTwKlwiJcnw/eYRC8o+4WBkJCRfMrAL5uTwprpf8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoT01Bk/h691q7vL+LWPsuy0k8kNBA0fmN94MMyNxsZAR/eDc4xW7XN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNIDpKK5v/hXHgj/AKE3w/8A+CuD/wCJo/4Vx4I/6E3w/wD+CuD/AOJoAPHn/Iu2v/Ya0r/04W9dJXnfjTwD4PtdBtpLXwnocLtq2mxlo9NhUlXvoFZchehViCO4JHeqmp6B4W0XxBfR3PgXQL6xSO38iCy0S3E4eQyD5ndwpGY+wH3hngE0Aen0V5RDJ8N5ruCEfDe0VZiuZW0izCxqxjCs3zZwfOjPAJ+bkcHEUUvw+udstt8OLF0BkjaD+xrLezCSFVKt5gXaROrDGcg5yMYLsw0Z65RXi2r6r8OF0vWk0LwNoc+rabvX7PJpdm4UqHLM4VxhV8twQSG4yFYFc6+uaf4E8Na26av4I0E6b9jScTQ6Pb5hfErNvJIyCI8DC8HOTjkFrDsz1KivHLm9+HF1o6zaJ4H0R57ixuLm3mk0q0mgSSIOTHIY26nynwVJU7ThjWnHZeAY9Tjsbv4e6buluGhEy6PaCNMSFBn5ixyccgfxDgYOCzTsxbK56hRXn3hTQvh94u02a+sfAWkW8McxhBuNMtDvIAJI8ssOM4IOCCCCAQa3f+FceCP+hN8P/wDgrg/+JotYDpKK5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJpAF9/wAlT0L/ALAupf8Ao+xorNtvDmh+H/inpH9g6Np+mefouoeb9itUh8zbPZY3bQM4ycZ9TRQBpePP+Rdtf+w1pX/pwt60dYOiKI/7dezQODGn2plXeGIBXnqCdox0Jx7VnePP+Rdtf+w1pX/pwt6l1vwnBrN99rm1G8tiBFlIWTafLcup+ZTjk569h6CkMp3upeDItLvtSjTSr8BWaVLbyXeZmT7vXBZlbGCeQ3vWisXhvTb2NDFplldt+9VCI0kyEbJ/Bd/4bu2axLb4Z6RBdG5stRvo4H+zEQRtEY9sOwooyhO07ATzzV3UfAtrqWpteyanqEbGfz1jRo9iv8nPKEniMDBJGCR0NVoIq6dq3gOC7meEaLp01pOyo7mCNmKKwLpg5wB5i54PDj1qyG8CvePuTQlnllKZYQ7pWyfxPLMPruqm/wALdHlhZLi7vZnKuBNIYy43BwTnZjP72Q5I6uSc8UkHgvQrqFrq11meXy3Ym5jlibZh5WYZ24HzyEnvlF/u0mHoXnv/AAV5EDzvo6i4ULGr+US6uM9s5BDk56YYk8GluJ/At8ft91JoNwZgT9odoXL7VOfm74VT+Cn0qCT4d6dKysL+/QrH5Y8to148p4gcBMZCSEBuvC88Ut78OtMu/NRLu8tbaRWAtoPLEaZh8njKE/czjnjJ9TTdgLkN74Tu7MkHTBbM643+WFZhGoHHqFZV5wRnFa2n6pp+qQtJpd7bXkcZCs1vKrhTgEA4PHBB/GufuPh9p9zDdRyX1/8A6WSZWDoCf3jSLj5eNrMMeuxQcgYrY0PQLPw/bzwafuEU0okCEKBGAioFXAHAVABnJo06gc74ROjQfCHwhe+ITYx29npVjNHPfbAkEnkoFYM/CtzgHrzVjUB4D0jT9RmmtNAVbFWuLmFUt1ZTKuCW3YAaQcZYjd0zVfwno0et/B/wjA9zcWkkelWUsU9vs3xsIFGQHVlOQSOQevrzUbfCfR1vLi5s9T1i0eWNEiWO5V47baoUmNHVlBYABsg+owanWzHpdBa2vwwt9PaX+zvC2npPFE9xDNBbRMqsPMQSDsfl3AH+6SOlWoNL+G0mpRfZrHwq17dzsYvLhtjJNKh3NjAyzKTk45FZ6fCLTobgz23iDXoZSkSg+dC6rsAGQjxMiliqlsKOVGMc1a074Y2Wn3djO2t6tdmxnWeFJxbbQyoiDhYVx8iBcjBwTzzV6XI1sdHY+HNG0xidN0qzswYzEVt4VjUoccFQAOw7dqgh8HeGLaMpb+HNJiQp5ZWOxiUbc528L0z2rZoqSjl0+Hfh2HxBDqlvYW0AghMUdrFZ26xKDuyQRHvGd7ZAYKcnINX18H+Go1YQ6BpkO6N4sxWiIQjjDqCACAQADjritmigOtzDbwjpcvic65cxC4nFmtlHHNFG6RRgsTtJXcCdxB+bBGOKjm8AeDbgqZ/CWhylRtUvpsJwPTla6CigCnpuk6fo8Lw6VZw2cTsGMcCBFyFCjAHAwqqMD0rH8Uf8jF4M/wCw1J/6b7yukrm/FH/IxeDP+w1J/wCm+8o3A1m0e0R76exijsL2+UCe9toYxM5AwrElSGKjpuBHtVc+FdBe3aK40exuQ8C28rXFskjSxqchXJHzAHnB4zzWtRQBjT+D/DN1dJdXPh3SZriN96TSWMbOrccglcg8Dn2FXrDStO0sSDTLC1sxK2+QW8Kx729TgDJq3RQAUUUUAFFFFABRRRQAUUUUAc348/5F21/7DWlf+nC3q5qHg/w1q91Jc6r4d0m+nl2+ZLc2McjPtGBkspJwOnpVPx5/yLtr/wBhrSv/AE4W9dJQBzFt8O/DNl4gtNV0/SbKza0jdYra3soEiDuVzLgJuD4UDII44q03gbwk0kcjeFtFZ4m3RsdPiyh45B28HgfkK3aKLgZN14U8O3y3C3ug6ZcrdSiacTWcbiWQDAdsj5mA4yeaLrwp4dvr6K9vdA0u4uoUEcc81nG7oo6KGIyAM9K1qKAMd/B/hqSGOKTw7pLRxReTGjWMZVI+fkA28L8zcdPmPrVb/hAPCAuPtEfhbRYrndvWePToRIrddwbbkHPOa6GigDE8LeFNP8I6Y9lpY+R5PMdvJhiLHpysSIucADOMnuTW3RRTvcAooopAc3ff8lT0L/sC6l/6PsaKL7/kqehf9gXUv/R9jRQBF8RbhLXwlFcSiRkh1bTHYRRtI5Av4CdqKCzH0ABJ6AVzvinxJLqs4Okf29bItrLGB/YuqR7ndSAxCW/BUhSDk8FuOhrp/Hn/ACLtr/2GtK/9OFvVXxbd6umtWCaHFO8sCGQjEnku7ukah9pAKhWkc5PG0HFHVBtqcrpGqSWmvGe8PiA2TXDzGOLSNUzwxCBgbf5hsEY25ABDdQSKsT+IrmZnfbrvmG4kZsaTqqrNEd/lrtFt8m0mPIXrtOTyc6S+JfGSWkVw+lRyxvHFIzCxlQoGkkQgoWLblHluQAeN3saddeI/FKSLGtmQoeLdNDpszggKzSDBII5jKg4wRIhyDQ9h21OStr/XLGVXW+169LIyzfaNK1ZVYlm24UW5xjEZJBBOXHTFQWKXVvaWsEh13Ee4PjTdXOCxhUsD9nHPlpKf96Q+prq7Pxh4hM8dsYYH8lUWci0mdnJEYZowGywR3cOOcbVXqSQ2PxR4unKTtpkrJtD/AGYafNEzfJLJgsScH5YkI55ZuOlUrp3J3MPVb/VNQLNFf+IoCEmO2LSNVQSyEOEztg+RRvXgDjZ1JOR0fh3xTFYSXkmqp4hmMzJ5af2JqcojAXBGTbgdcnOM88k4FOl8UeLItWKHTFOnxzRoZxp07NMp3FiqqxKgbG5IPVOu7jq/D11qF7okFxrEKwXb58yNEKhSDjjJJIOMgnGQRwKS2Bu7M7/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukopDPO/APjTS7X4beGreW11xnh0m1RjFoF9IhIhUHa6wlWHoQSD1BroP+E80j/nz8Qf+E5qH/wAYrkis7/ADwmtpLqMM5sNNCyafFdSOo8uPeWW2ZZCuzdkbh25zitGwExOlw38viKQCziWzlgS8jDzDcJTMH+YHpj7QcYxjJ5oWquD0Nz/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABisnwndaofESW91Z6oZfsjPqdxezXCwrcZX5YUaMxMvHBicADORnrQsWbUNVu9PnvNeTUI4HfWohNcIijOYzBjgZ2kDycErnd82KHorj62Ol/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8YrF8J3Gq6Zpfhu1I1R1voBLeyalb3V1KJdqhoy7sDByC2XyvUKORVa98Za/Y+KpLGz0y7mtjf8AlvI2iXzqULxKGWX7gAVpDkfKfLzgbqdve5Sb6XOj/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GK42Lxr48gnjsbnRpnbyImN/wD2FcNFvaVVbKrJuyAWGMD7u/O1sDW1TxF410vRpZFsre9vYLnyWWDSLgpMAXYsoWRiAYwgB+YBzg+xa42bn/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxVjwjLNLospuReBhfXQX7akiybPPcp/rBu27SuO2MYrcoegHN/8J5pH/Pn4g/8JzUP/jFc/wCI/Gmlza94TdLXXAIdWkdg+gXykj7DdL8oMILHLDhcnGTjAJHolc34o/5GLwZ/2GpP/TfeUgD/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrlvEviLV/DvijVJdCstXvZJPLzHLpmoXdudsLHEWz92hLbFJXj5snoa0v8AhJ/E8+pxxW1kY1kvHjMU2iXP7uJUZlJm3hCX2rhsALvwQSpFHS4Gv/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFcppnjnxvff2cZvDc1oJjOtwtzpM6FcK3luNruFG8BSG5YEMCM4Gx4c8W+ItV8VQ2Oo+H7u1sJNPW4N1LYtCok4yCzOdpzkeWVyAASxzgOwrmn/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMVzlzq/iTWJLO1vobqxt21WKOY2unXkbCPDlozIjg4BVP34Ijbd0wCDP4h8Y+KtKvbiHTvDt1qCR6hHCrwafI4MTLnqZBu5HMgG1Mj5WwaX9fl/mN6f16/wCRuf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MVzMnjDxha2MF3cWgmS5RmRIPDd7vh2uUw6hy2TlWAIXjOM/eF/wf4w1zWNXe21nTp4YVt3k8z+xLy1AYbCBulGDkMwwOcxk/xAAWoPQ1/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK4jUNW1prjXf7UttfWy1aGK40z+zoL9pINsjKVby4laBioUlM9iSfmxW7qKQ694j0C6tm8U20E0kkTBTfWqKsaEq0icBcuRzKBux3FNK4m7G1/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWR4l8V+JdK8RXttp2mNPp8VmJIpV0m5nbztyfLmMkOpVm6AFSvOR1z9F8S+Ita8Y6EdQstQs7ZVmWVV0q8gjlO1gJHLnYikqMI43A8hsHlLUb0J/GnjTS7nQbZI7XXARq2muTJoF8gwt9Ax5aEDOAcDqTgAEkCug/4TzSP+fPxB/wCE5qH/AMYo8ef8i7a/9hrSv/Thb1zPivXtW0DxdfzaHbarcyyQQrsfTL+9tchJSdixkRq2RCCR6n3IBpXOm/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8YrHHinxLc6jBHb2bW6TXaxGKfQrpvKjKM24zb1X5iF5wAmSrc1maZ468b3stgLrwzNZiS6liuVuNLnHyAKFZWV3C4dsZbh1UsNvQOwvM6v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8Yrm4vHHi972GH/hFrxo30152mbTpI185dw5zISuSBiLBYhs7uMV0Pw9nv5/B8b6s12119puNzXdvNA7L5zlCEmJdV2lcAk4GBniiwr/1+I//AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrpKKQzm/wDhPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukooA5v8A4TzSP+fPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/wAYrpKKAOJttetNb+KekfYodQi8nRdQ3fbdNuLTOZ7LG3zkXd05xnHGeoorSvv+Sp6F/wBgXUv/AEfY0UAHjz/kXbX/ALDWlf8Apwt66Sub8ef8i7a/9hrSv/Thb10lABRRRQBXhsLO2uJJ7e0gimlOZJI4wrP9SOTViiigAooooAKKKKAOF8Ma8vh/4QeDp2sLu/M2mWUKxWnl7txt1I++6jHGOvcduasr8SLBwXTSdUMIw3nbYdpj2LI0mPM3YVZEJGN3zcA4OKvhrw3ZeJ/hB4LtNTLNbQafYXDQ+XG6T7YVwjq6sCv0weOorqD4b0NiS2i6eSbgXRJtU5mAwJOn3wBjd1oj5/1t/wAEH5f1v/wDnV+ISWVvcDUrG4upreS48x7GNFRVSWVIwQ8gO5hE3TIyOSoIpk/xA0Qalpbz6LeG9uHnhjZ0t/MtwjYkOTJkjA3ER7jgcgdK6GTwl4cmGJtA0uQESA7rKM/6w5k7fxH73r3rMb4ceG11ewvrPTrWxWwYtHa2tlbpGWzndnyyyHIGSjLnAByOKOoPrYyoPilZ62dK/wCEahadbm+jhunfypFgjZtoyyS/ePBG3fjkMFPTv6x/+EQ8N5tT/wAI9pX+hyGW2/0KP9w5O4sny/KSRnI781sU9Lf15C1v/XmFFFFIYUUUUAFc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033lAEWseLJtN8daNo0dsz2l4WS4nNvIRG5VjGPMA2KcpgqTk7lx3rIvPFPiYaNqk9tNpMF3ZETiOeylkUwFnC4KzBXztB3hh3BQGrt/qPhCS51y2v9Fs57vT7hLm6tpILdpbhgiEXCqWy21XA3HBGCB2zduB4GFjqcN2PDwtWuEj1FJfI2GbjYsoPG/hcBuelC2V/62B72NC61K50Pw219rEYvZrdc3BsYxGGGcFwsj8ADkgsSMHGe/Oj4saEFtGnt7q3W7ujaxtLJAB5gbaw/wBbyQSvC5JDAgEA414tR8P3HijUdBiit5rlrJZL1Q0bx+WPlCOu4kfK3QqAQepqo9/8PGtYvMu/DJgRzeRbpLfarLlTKvbI2kbh/dIzxRvqHl/W2n6Gbe/Ery7VrWzsLhtT/sx9QDyxxCONVBOHQTb+o25XcuSPmrY03xtBqFxcA6bd21ta2j3M1xM0eEKSPG0ZVXJyDGxyMj3rn7rRPhnaa493eXWhKkccdodOaO08mHzAdgI2b1DAkhS2w5LYzzWxpeoeB9Psd2jR6FavHa7zaWklqjpG+1ivyttAJdD12kspycina60/rf8A4AO35foZVn8WLC2m8jxJE9jNPdzRwIRGrJEoUruUStuY7gP3e71IUZxf1L4mWOj27zaro+o2kccUcjvLNaBV3sVRS3n7QTtzycYI5zxU9nb/AA7s4xJYQ+GLdLW52hoVt1EU8nyYyPuu2NvqcYpLu18A6RJcafqNh4d0+IwRxyrOltGjoS7rGVPOBsZsEY6kZwcHRC7/ANdRv/Cy9INzcRra3pigjglF1iIQyRy4+YMX4C5G4NgjIwDkZzbz4r2F3oFzdeGYmurqKcxbG8p1VVKlpG2yjC7WHGd4J5Tgitm7bwBBqE8V8fDcd47ok6TeQJGbAKBgeScICAeyjHSmm2+HupRRWTQ+GbuO7lkuo4Clu4mkXIklC/xMMHc3Uc5o0/r+u39djW39f1udXRWZH4i0Joz5OsaeVjthdHbdJhYO0nXhP9rpTtB1u28RaHbarYBhb3IJTeVJwGI6qSpHHUEgikMzPHn/ACLtr/2GtK/9OFvUN94yOkeIdQsb+0kmhihE1u8CoucRlmjYvIMsdpIOAMcEjjM3jz/kXbX/ALDWlf8Apwt6i1Sx8Atrd1Nrdr4bOqLCGuXu44PPEbfuwXLfNtOQvPBzikMzrf4taFdSGKC1vjci0W7NqwiWYAlcqUMgIZQwJONvBAJIxVkfEmw8l2fSdUSSP5mhZItwQb97/wCswQnlPkZydvyhsjKsvw2uoyjL4VmSWLyypFsweMDztvuoGZMdP4veoNMtfh0m6CLRvD2mySSuy28lvbRtN5BJ81Qv3lH3g3YHJxVaC6Cz/EW3k1i4tLO2mjh025VL64nRGUoUc4QLJvVvkz86DK9Bhgaa3xEYa5axNpd2lrLGyTRNHGZreXfEqFmEpQowmT7uSMjPfE2k+GPB3/CSXV3DLp2p6jdEX6pJHbPJGpJxKpRA7DJOHcsRkgEDirFpL4Gkgt7SOPQIRbebNBa5t/3Q+YPIqqSFBAYkjtnPcUlotQer0F8O+N4NbvLaxayvIpprZZhcSRxpE58uNyABI7A4lHBz0PJ4Jp3fxT0KyuYLaaK4F1PJLElv5kAk3IcY2mQctlcAZI3AsFGSIrey+FMIaaxh8I252KTNbfZo2CvgA7lwQDuXHPOR61qPbeBb2ZreSDw9cSR3TwtEyQOVuJFO9SOzsoOR1Izmm9XoBV/4WLbJDLJc6Fq1v5cLThH+zlnQJvBG2U9VzgHB4OccZ1NB8Uwa/c3EEVje2kluMsLpUGcSPGQNrN0aNgfwxmsPW2+HTW2nve6XoGqJcXMWm2qJDbSkMH8sIoY8hCxyq5KjPHWuj0nwvoGgTSS6Foem6ZJKu2R7O0jhLjrglQMijTfoLW1upq0UUUhnN33/ACVPQv8AsC6l/wCj7Gii+/5KnoX/AGBdS/8AR9jRQAePP+Rdtf8AsNaV/wCnC3rpK5b4i3CWvhKK4lEjJDq2mOwijaRyBfwE7UUFmPoACT0AqX/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAOkorm/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigDpKK5v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAD4cf8ks8Kf8AYFs//RCV0led+AfGml2vw28NW8trrjPDpNqjGLQL6RCRCoO11hKsPQgkHqDXQf8ACeaR/wA+fiD/AMJzUP8A4xQB0lFc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFAHSUVzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMUAdJRXN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xQB0lFc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFAHSVzfij/kYvBn/AGGpP/TfeUf8J5pH/Pn4g/8ACc1D/wCMVz/iPxppc2veE3S11wCHVpHYPoF8pI+w3S/KDCCxyw4XJxk4wCQAb+qeB7HVL2/umvb23e+jKuITHhGKqhddyH5iiqvOVwMgA5NQP8PLB/MYajqCSs+6KVTFugT95mNcxkFT5smdwY/NwRgYsf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAR2ngOws9Su7mO+vmt7q1ktTZM0flRo5BbaQm/OR3Y4yfbEGofDyDVbNoNQ8Qa1KTbLbrMssUUkZWQSLIrJGCrgqo4+XA5BJJq3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUf1/X3h/X9fcjPs/hjp2nzCWy1XVY5EjhijcvC7RrFt2AFoySPlP3s/fbGOMVYvhRbxRlB4p15lMBtxkWfCbFT/n3/uoo59PU1tf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFO7Awbn4PabfQzpf+IdenaZw7SLNDCw+aRmGYol4bzpAwOchscYFaviHwBD4h1Brp9d1ayDQpCYbUW5TChwD+8hds4lfv39hVn/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YpPVWY7vchj8B26eSja1qklvDP54t2MOwsUZXziMHDbiTzkH7u0cVR0z4U6Tpb2TJqmr3X2OR5U+2XCTbmZShyWQnhDt4I4AznGa1P8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xijzJsZUHwo0q3vJLoaxrjzPb+VmS7DKrbgRKEK7d42qOm3Cgba6fQNGTw/osWnR3dxeLEzt51zs3sWYsc7FVepPQCs3/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABigYePP+Rdtf+w1pX/pwt6h1zwDaa7rE+pSapqNrcTW5th5HkkRoSpYLvjbqUXIOR1wBk1i+NPGml3Og2yR2uuAjVtNcmTQL5Bhb6Bjy0IGcA4HUnAAJIFdB/wnmkf8+fiD/wAJzUP/AIxQBmW3w7FhIETU7zUYp545J3vXiRolR3k+QQwpu3GR1YMQNrnr0q1cfDyxvNUS+utT1GZo55p44n8kohkDBgB5ecYdh1yRjJOBVn/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABigCDRPh9p+h+IItXh1PVrm4jtRbFLm63xucAeaUAA3kKBnpgDis5/hTaTXYnufEmuTYYsEb7KoBPmd1gB4M0hHPf2FbH/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MU7sClqnw4tdZsbq31LXtble5aJzcJPFFLGYwy/KyRrjcHYMDkYOAFFEXw102G6mnTU9U3zTxTMfNjB/dsxVNwTcVwxU5JO0AZ4q7/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFIDGsfhHpOnRwpZ6zra+XcrcFpLlJi4Vo2SMmRGwi+UgAXBwMEmu9rm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYp3drB1udJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFIAvv8Akqehf9gXUv8A0fY0Vm22vWmt/FPSPsUOoReTouobvtum3FpnM9ljb5yLu6c4zjjPUUUAdtXn3i+7uYvix4NgiuJUikM2+NXIVvl7jvRRQviQPZi+I9PspNB8cmSzgcq4uV3RKcSrbRlZBx94EDDdRis34pfvtT0y2m/eQSQhXiflWDSoGBHQ5HB9RRRSn8C+X/pKKX8Rf19o63wKzSeHYpJCWcxW4LMcnH2eM9fqT+ZrpaKK0qfEzKn8COcvI0HxN0mQIu86VdqWxyR5tvxn8a0tFlklgujK7OVvJlBY5wA5AH0ooqV8Mfn/AOlMt7v5fkZuqWdsvjzQbxbeIXTR3EbThBvKhAdpbrjPaujoopdF/XUDL0oCW91CaUB5Yrp4o3blkTah2g9hnnFO1OWSPUtIWN2VZLplcKcBh5MhwfUZAP4UUUL4ULqyrcRoPH9hIEXedNuVLY5I8yHjP41H4oije+8Ou6KzR6qpRiMlSYpBx6cUUU1tD1/9uYdZ+n/tpwVxp1lc31nLc2dvNJqWpXsF88kSsbqJJ8IkhI+dVAAAbIGOK6v4W2NpYeB7OKxtYbaN4YJGSGMIGdreIsxA7k8k96KKKfwv0X5jnv8AP9Dj7rSNNm1a81aXT7V9SQu63rQKZlYX+wEPjdkIAoOenHSvYqKKUf4a+YS/iy+RxniOWSXVb60ldntntWDQMco37iU8r06gflWheOyeOdKCMVEmm3O8A43bWi259cZOPTJooo/4P5MOn9d0ZGrXVxJ8DdQuXnlac6TKxlLksTsPOetcnrNjaQ31hbw2sMcJWyszGsYCmBlUtFjpsJ6r0PpRRQ93/XSQ/wCX1/WJ6Z4OJPgzSsnP+jKOfTFbVFFVP4mTHZBRRRUjCucsI0T4la2yoqs+m2RYgcsd9wOfwoopoOj/AK6ov+IAE00XCALNHLGqSDhlDSKGAPUZHB9awo7W3b4R31q0ERtxZ3SiIoNmAXwMdMUUVPcuHxIxPiJ97SZP44LUSRN3jYz26FlPY7WZcjsxHQ1e+FsaR6LHFGirHCkqxIowIx9pl4Udh8o6eg9KKK0js/X/ADMvsx+R0F5Gn/CwdKk2L5n9nXa7sc48y34zW5IqvE6uoZWUggjIIoorOf8ACXo/zZovi+4wPAKqnw80FUAVVsIgABgAbRXQ0UVrV/iS9SFsZWggTWklzKN8/wBouI/NbltgnfC564HYVJdSyL4h0+NXYRvFMWUHhiNmMj8TRRWa2H1ZmeMoIryLSLK7iSe1utSjinglUMkqbHO1lPDDIHB9K860fRtMu9V0+6utOtJ7i1uLyOCWSBWeJIpk8tVJGVCZO0DpnjFFFOn8XzX5Cnt8n+Z197o+mXPxgS9uNOtJbuG0tWjneBWkQ5ueQxGR0H5Cu6oopR+BerHL+I/RGIkUa+PJpVRRI+mxhnA5YCR8An2yfzNbdFFC+FfP82OXxP5fkjLvwJddsLeUb4JIpmeJuVYqUIJHQ4PStSiigQUUUUAf/9k=" alt="" width="528" height="510" vspace="0" hspace="0" border="0" style="width:528px;height:510px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>At the time of the primary analysis of PFS, 48 (15%) of the patients had died, and there was no significant<br />difference in overall survival between treatment groups (HR = 0.89; = 99.98%CI = 0.28-2.85; p=0.712).<br />At the time of this analysis, 32 patients (14%) on the vandetanib arm and 16 patients (16%) on the<br />placebo arm had died.<br />Most (95% of the patients) had metastatic disease. Fourteen patients treated with vandetanib, and 3 with<br />placebo had unresectable locally advanced disease only. There is limited clinical experience with<br />vandetanib in patients with unresectable locally advanced disease and without metastasis.</p><p>Statistically significant advantages were seen for vandetanib for the secondary endpoints of response rate,<br />disease control rate, and biochemical response.<br /><strong>Table 2 Summary of other efficacy findings in study 58:</strong></p><p><strong><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM0MQAAkpIAAgAAAAM0MQAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNCAxMToyODowNwAyMDIxOjA2OjI0IDExOjI4OjA3AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjRUMTE6Mjg6MDcuNDEzPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAIIBeAMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APoPWNYstB0x7/U3kS3R44/3ULzOzO6oiqiAsxLMoAAPWsn/AITzSP8Anz8Qf+E5qH/xijx5/wAi7a/9hrSv/Thb10lAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMV0lFAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUActbfEXQby1iurOLXJ7eZBJFLF4ev2SRSMhlIhwQQcgipf+E80j/nz8Qf+E5qH/wAYrnbK31W8+APhy10SGaeWfRbOOWODyfMaM26ghfP/AHfpnd2zjnFUtMj+JMV3bWM1nd2OlxpaRrLbT2TvGoQCQbXBxj5tx3Pk7dvG4Ejq2glornX/APCeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxXIQ3XxMV5Few1x1KSBWkbS1wSjhSCrnkMIiMjGS+eMYDp3xAnWD7Y+pS3LQbWlH2BY4ZBBOnmKMlkcuYz8uRhiOmQDpca3sdf/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWJpMni7TrmOa503UprRZpmuVlNkJpkEKbHPlH5mLqVAG08/NwBTPFmr+IX8ZQaX4ZvbsTNp32prKH7H8gDlSzCb5skHAwSu4LnAzkelvP8AyuJaq7/rWxvf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFcxeL8RLSKNLVtavjLEjs4GmBoXZfmTB2ghWXHfhurdQt7p/i9dRleC31We2W4ceWBpwF0N1vtkkU4B4WUA8OMDpxTt71hX0udN/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWVa3WsWurW8uqWl3NfQzXAdYzGzzWf8BKphR85XaCd2A3JO6o/FVx45i8TSDw7ZalPpzQBQYWsVRXMcmWUytv3B/KxkFeG7YpdB9WjZ/wCE80j/AJ8/EH/hOah/8YqKX4i6DBJDHPFrkb3DmOFX8PX4MjbS21QYeTtVjgdlJ7VgaPY+K59c0ifxFpFxNNazRGa/dbNM4gnjdwI33YJdDjnBY4GK6TxR/wAjF4M/7DUn/pvvKbVhB/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRSGc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUActP8RdBtYxJdRa5CjOkYaTw9fqCzsFVcmHqWYADuSB3qX/AITzSP8Anz8Qf+E5qH/xijx5/wAi7a/9hrSv/Thb10lAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMV0lFAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBiaX4u0rV9VGm2w1CG7aF51jvdLubXeiMqsVMsahsGRMgHPzCiq19/yVPQv+wLqX/o+xooAPHn/ACLtr/2GtK/9OFvXSVy3xFiefwlFFFPJbPJq2mKs0QUvGTfwAMu4FcjqMgj1BrM8QR33hyOF7rxn4onEu84gt9MJUIpZiQ1uOwxxkkkDHNAHeUVw86RWqsbr4palBsOG806am04JIObbg8H8j6U26jlgkSKD4ha7eTtPFCYLZNNZ0LttDEfZuFGGJP8Asn0o62Dpc7qiuKubcWVw0F58UNTglX70cp01WHIHQ23qw/MVCFeS/sbS0+Imt3bXiNKjwLpjKkaqG3n/AEb7vKjIz94etAHd0Vw8ggiiikl+Kt+kc2PKZn0wB8jIwfs3OabamK7CiH4o6kXaPzdm7TCwTAbdgW3TDKc+hHrQB3VFcIsto93Fap8Wb5riZtkcIk0ze7ZxgD7NknIIxWpD4d1K4gSa38f67LFIoZHSHTyrA9CCLXkUAYFl4gfw18AfDl7E8MUraLZxRzTziGOFjbrh2cqwGMcZUgkgd6bovxPjktrfznh1FpnWLfBdI7M/2SObaiInViX4J4IPzYwoz9Bg1TR/hN4Wv4/EniadLjT7GKOzsItM/dmSNAqgzQj5QSF5YnpnPJrS03VtO1PTPtsfxX1CFFIWaOd9LV4HJ27HH2f5WzxjuemaI9Qdrr+v62C3+KrXAuNtnpTLb2rXMjxaxvXaGC7gfK5jBYBnONpWTg7ecPRPjXm2hsLlbO+vhGrG6kvfLilLTiPIkWHZtG7AIwWKkbV6100ctrNvEXxV1FnSWWEpu0wMZIxmRQDbDlRyfQc9KSKa2k2q/wAVr6KUhS0LzaVvQsAQDi3IzyOhPtT0v/XmJ6f16f18zo9A8QDWrnU7aSKKG4025+zypFMZADtBBJ2rgkHOOeMZ9K2q8/e7sxexWkfxXvpZ3BYok+k7kQR+YXKmAHbtwcgHhgemSNWz0S91Gziu9P8AiJrV1bTLujmgTTnRx6hha4IoGdXRXN/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDItIDpKK5v/hF9X/6HvxB/340//wCRaP8AhF9X/wCh78Qf9+NP/wDkWgDpK5vxR/yMXgz/ALDUn/pvvKP+EX1f/oe/EH/fjT//AJFrn/EfhzVI9e8Jq/jTXJTJq0iq7w2OYj9hujuXFsBnAK/NkYY8ZwQAeiUV51cTapa65NYXHiPxilvBLHDJqPkaSYFaQDbkCHzACWAzswD145q0j2kvl+V8Wrx/NTfHtl0s71+bkf6NyPkfn/Zb0NHS4Hd0V59e31jY2hnm+LN5gqTGv2jSVMpAB2qWgAz8y9SB8w9a0rLS59RkuI7D4kavcyWr+XcJCNNcwv8A3WAtjtPsadgOvorz+2nSaG7e5+JWsWLWU5guI7s6WjRHzCilsW5wHKnbnr9eKniFvNdm1h+K99JcBzGYUk0svvG7K7fs2c/I/H+y3oaQHc0V56uo6W09tCvxfume6Utb4m0siUBtp2n7Ng4IIwPQ+lP+0WrTJFB8Vb+difn8ubST5S7GfcwNvnG1SeMnHPQEgDrY7+iuOGnyNpA1UfEzVTpxTzBeD+zfJK/3t/2bbj3zVR5rKONpJPi3dqiBWZmm0sBQyllJP2fuASPUAmgNzvKK4OfMdyLe3+I2tXk6zwwzQ2o0x3g804RnX7PkKcj354FbH/CL6v8A9D34g/78af8A/ItAdbB48/5F21/7DWlf+nC3rpK878aeHNUh0G2aTxprk4OraaoSSGxABN9AA3y2wOVJDDtkDIIyDau7bVrfVPsVv4p8XXpTb581tbaYUgLfdDbrcEk5z8obA5OBQB3VFee6fe2t/Y2twfihqlq9zwLe4fSllR8KTGQLcjcNy5AJ6j1FSmexEcUh+Ll2EmQyRN52l4kQZyyn7PyPlbkf3T6UAd7RXAXd1YWMU8l38W72JLcxicmTTP3XmfcLf6N8obOQTxjnpSSXlhHCXHxbu3+QyKq3GlZcBQ/GbcD7rKc5xhgehoA9AorjrHTptSmnhsfiTq9xPbbRcQxDTXeAsMgOFtjtJFVrh7S0lnju/izeQSW8gjmWWXS1MTlS21gbbg7QTg9gTQB3VFcJLJaQMRN8WryMqxQh5dLGGBII/wCPbrlWGPUH0qTToDqtx9ms/iXqsl1sMptkbS5JBHuKh8Jbn5SR1/Dg8UBsdvRXN/8ACL6v/wBD34g/78af/wDItH/CL6v/AND34g/78af/APItABff8lT0L/sC6l/6PsaKzbbS7vTfinpH2zXdQ1fzNF1Db9tjt18rE9lnb5MSdc85z0GMc5KANLx5/wAi7a/9hrSv/Thb1L4h0LT76ZdT1W+a2js4v3blkVYD5iP5mSODmNRzxjI71F48/wCRdtf+w1pX/pwt6h8U6Jrms30cdpLb/wBnAws8b3MkTHbIWcEKpDBgEHJ6bhjnNLqg6Mhf4d6Rd6Qtkb26kiVJUSRTFuBdQhbOzlgoZcnJwzZzxibTfAllpV5aXf8AaV9O1n5ewTmLGEjkRQcIO0rH68+uaFp4Z8T24tjJqKyCKGOOaI30pErAEsd23I3PtJyCcAgEbiKqP4M8WQ6dP5OvSXd7OkkbeffTJEg8tUjZQAcHKlyPVupA5rXWwb7mnD4H0rUWi1CPVru8t5P3sGHieLl3kDKQnPzuGzk5KLnOKseHfAVl4b2C01G/nEVtJbRCcxny1dgxI2oOcgc+gA7DGZB4L1poYbe41SaCCKU/LaahLHmFVcRxqFUbPvJk8/cz1NdN4d06903T5I9SuGuJ3meTc0zSbVJ+VctjoOOAPXGSTRZapf1/V2F76syNO+HWmaagC3d5OUjZImmZCYi0SRB1wowwWPj03N603/hXGmJcQTwXt7DLCwcMhj+YjywuQUI+UQoB+NdfRRd3uBx8Pw/tbOwNjbTSyieaKW4vp5B9oXymVkC7UAOWUknjBYnnNdbFEkEKRQqEjjUKqjsB0FPopXA4Xw34dtPFHwZ8I6fqLN9lGm6fNJEI43WbZEjBHWRGBUkDPAPHWtO48C2M4uBFfXlqJZ1miW3WFVtgIvKKIvlkbShIIYMeeCOKwNN0vWNW+CPhC38PuqXI0yyZi2ozWXyfZwCN8Ssx69Me+cgVjar4f8fWt1HLqGpPeRXctrDHb6ffX0ZV9u2QySRqRHGPmO8IM7gWwQCBa6ef+Q3pr5HTy/DvQ9UvIZrPWtSjbTbiUCOzu02I7Yby3XaQ21sOA2SCecjiqq/DbS9NvIGu/FmredJhLdZ3tELFBG3ygQAsQtunrwpPqaoyeDvHA1Scx3dq9tcGITTLrl1bySbRAC+xIsKxETg4bnzME4HOh/wifieO98wXcN1FHdNIgn1S4LEeTMgcEoxib94g2qcDYWzk4p7LQSSuS2vgbTI4Lawj8XanLJKv2i3xNaiRo1g8gMm2IEqqOPmHcqSeed/wtocOhacLfTtSkvNOwTAjLFhCXdmIZFUEEtjHQbR71xH/AAhPjO3W1ltHs5LuObzpZpdfu1LMRDkZ8k5UmJwV4BBBI7VYXwj45JaQ6pHE39m/ZhENaunRpQysrklMg/KQXGGIbB6ZLb/r+vuEtbX/AK1PSI5opWkEUiOY22OFYHa2AcH0OCDj3p9cfp2i+KYtft7u8urf7Ml1K0sQ1CeQNE0agYQqBu3qTgkhQTjrXYUuiAKKKKQwrm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8oAjn0PT5/F8v2jxFdPNcGO7bRTLAqMI9oV9oQSlQwB+9gnr6VXsdA07UJ9raikN/DfNfzW+nXgfZlipQkru2FkbIAXLBh61neJPCPiW/1XVrnQrmOya7kt3inGsXMbDy0brGqFFG4rlRuDDOcGo5PCni+cs7zW0coL+W8etXIYq08jbCwjBIEcmB1wVGAMAhdF/X9dBvr/XkX4vhlbQxTxL4h1kwzWz23lt9mwivGkZIPk5ztjUckjjpzWnpXg9dF1a41Cz1e9klvJVe6FwsTeaq78LkICOZOucgKo6Vyo8I+PXuLS7XVre1nW/jkuIjq93cRtAqIDtBCDduDnaVKnzOfurjS8XQa7qt54dgskvLC7n837Qbe8uFgtsKCGd4l2uQR8qvtDcjIyavW+4t1qVde+HegkXcmu+LtUs1vZHlVjd29t5RBeV9jLGpxtaTOS3yk56ZE8fgHTLDVLOY+LtURp591tbu9oBMctLsU+Tvb+I8NnA68VFd+EvFUtxM/2q1u1NxJIi3OoTEMGhmQMAY2ER/eoNi/LhC2cnFZd/4I8ez6h51pqFikXmxSrHJqtwywFIpIyIx5WU3CQA7SuNuRgniYpaIctd/M6Kw+Hel29q9tZa1qDGKT946tblhJvjly2IsbtyA9Od5z1GC1+H1lBZjS4/EurNJDJ9ozvthMoaA26/diGAEBwcZyvU4qpe+HPGT6hJd2c8GPtJdLd9dulQx74mAOIzjO2UEYIAcdegz5PBHjVdL+z2mqeTM8VuzzP4hvZWWaPzNxUsh+ViYwVxhgpyM4NUthK6uzqbXwTHaeGbzw/Fq14NOuImjQCOEPDvd2cqRHt534wVIAHFZ9/wDC2wvdYu9Tj1zW7We7ZGZYp4njQjGSiSRsq7iFJwOqjGOa6+ylupbUNfW62025gY0l8wYDEKc4HUYOMcZxViperuxLaxxtn8NbKyvYrtNZ1V5YxbrufyDuWEqUUnys4yucDH3mxjPHZUUU7thZI5vx5/yLtr/2GtK/9OFvV640ATawb+31K+s/MA8+C3ZBHOQMKzblLAj/AGSucYORxVHx5/yLtr/2GtK/9OFvXSUhnD2Pwus7Ris+v6ze27RvG1vP9mCMGi8rOUhVgQvoeo5zT7r4aw3UkUv/AAkmsxSodzyIloTK+8PvbdARnIXoAPlHHXPa0UBvozjbD4a2GnyGVdW1SaXy4IxJKYCyrCyMgyIhxlOh4+ZsYyMLbfDm2tJ5pIde1cLJbyW4jP2crGHRUyv7nOQqKBkkccg5OexooeujBaO6OY0nwUmi6y+pWer30k04jS5+0LC3mxoG2pkICOXJznjoOOKoat8MLPVdWvNQOu6vay3h/eiD7MQQA4C5eFjgCRwOeN3sMdtRQ9dwWmxyKfD2CPVbe+TXdWBhlSUw/wCjlJCu3hv3OcEpk4I5JxgYAk0TwFaaLry6uNV1G9uUSWNftRhwqyMHYDZGpA3AHGf5nPVUU7sVkFFFFIZzd9/yVPQv+wLqX/o+xoovv+Sp6F/2BdS/9H2NFAB48/5F21/7DWlf+nC3rpK5b4i20F54SitbyGOe3m1bTI5YpUDJIpv4AVYHggg4INZWp+EPBdvqL2kXhDw5ClvaNeXM8mjxPtQEgBVCjJ4JJ7Y6c8K9h2O+oryhY/h9b6fBJceAtKvHJETz22iQRxvKFJcKJMEAbHzn7u05wOalaP4dm1jnt/hxZ3KyyJEix6Na5aQ9UGcZK4bd6bTnjBLEepUV5d/Z/gbULy0s9I8C6Gk1xLblZLjSLco0T73ONvIby4nIz6r1zimX2n+B1162tNO8D6BNbsdssn9k25JJlWJSvIIXPmEkjkRkj3dnewHqlFeXFfhktnLdP4E0pY4cedu0m1BjJYqAR2O5XBHUbCTgYJpXjeAltbF4Ph9pVq9xdpDJHd6Nbb0BXeV2g/eKlQOwMi568LcHoevUV5hPbfD63llWb4bWapBAk88p0e1Cwq5YDd3BwhYjHA5OK6eH4e+CJreOU+CtBTeobY2l25K5HQ4Uj8iaAJPhx/ySzwp/2BbP/wBEJXSV5X4e8J+ELX4NaJq9x4Q0W8vG0W1k3PpKTPNK0KYJCoXcljzjJP1qtCfAsPg3TdUvvh5osl7d2csrQRaXbRKJogfMi/eYYNlWwMEgKc0bgeu0V44118PdIsbyTxN4D0W3kt7gopXS7ONHUySKoBZ8blEZ3ZIBP3c5ArQig+Ht5K0dv4A0yEJcRx+bNo9oUkRpWj3LhuBlOp5G4HB5AAem56nRXBeHPDngDxNoZ1Kz8A6VbhZHjNvc6TbLIGU4/hypB4IIbBBBrktOufCP2ZE1L4Y6ZLf3ES3MMFvpFkiiNpUQRlzKwLgSK2TtBBHA6U7O9gPaqK8jll+H1pNFay/DiwurqSCa5ZINJsUMaRtIGBV5MnHlkErkZK8jcBVqyPwtvfE1toP/AAhejQX9yZAiTabaDlGcdASxz5TkEAgYAYqSARJvYOlz1KivOdU0r4faTr/9l3Pw+0xsRJK10ul2YhUPv2gkkMMmNh93AyMnGSMmCX4f3Fot7F8NbQxMu37OdFs1lWQSSRkEl8cGPHp8wOSM4Q7NHrlc34o/5GLwZ/2GpP8A033lQWXgPwHf2FvdweDdA8q4iWVN2lQA7WGR/D71jeI/APg+DXvCccHhPQ40uNWkjmVNNhAkX7DdNtYBeRuVTg91B7U2mnZkppq6DXfGviLTPE93Z2unzT2cMiiMp4fvpty7Yyf3qZQ5zIuRwCAT0wWv4k8UtZ30Wn2k9vKkV5JA8ujXUpmcSybMF3GzChCFOd+8BAAMVj3+iaRY+ObnT7f4eaDqlhAA7QWnhtFkVDEWz9odhCW3ADYQpIYHtS3l98M7G2lu7n4daelkkaSJeNp+nrFKHYquGaQY+ZWHzYHHuMpPRFPc1R4u8XreLp8tuouHmSJbseGr1oSC7gucSYUbPKbl/wC8M/3YtP8AEXik3mn+dZ3M8TIrLb/2TeQkP5M2S0ruQoMioNsmcblPoaq4+HtzqDWdj8PdN+VrZvtT6PZtE0czxqjAbwxBEnXGVxkjoG2fDnh/4feJY75rXwJpFubK5NtItxpNt8xChg6ldwZSGBBz+VVZ2FfW/Qq2njbxT/bWnW93pksltPKqSSx+H72PcpfaWySRFjJzvzkJno4xZ1vxb4m07XLmwt7FnTzglvOmh3dwm0tDgs0bbT8ry5OQMx/hW3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0l0A4u4+InjOJtU+yaDJqJtL5beGO30eZTLHlwZFLS4kQlUXeMbCxJVgBuv2fjjxTczXMMulTwKlwiJcnw/eYRC8o+4WBkJCRfMrAL5uTwprpf8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoT01Bk/h691q7vL+LWPsuy0k8kNBA0fmN94MMyNxsZAR/eDc4xW7XN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNIDpKK5v/hXHgj/AKE3w/8A+CuD/wCJo/4Vx4I/6E3w/wD+CuD/AOJoAPHn/Iu2v/Ya0r/04W9dJXnfjTwD4PtdBtpLXwnocLtq2mxlo9NhUlXvoFZchehViCO4JHeqmp6B4W0XxBfR3PgXQL6xSO38iCy0S3E4eQyD5ndwpGY+wH3hngE0Aen0V5RDJ8N5ruCEfDe0VZiuZW0izCxqxjCs3zZwfOjPAJ+bkcHEUUvw+udstt8OLF0BkjaD+xrLezCSFVKt5gXaROrDGcg5yMYLsw0Z65RXi2r6r8OF0vWk0LwNoc+rabvX7PJpdm4UqHLM4VxhV8twQSG4yFYFc6+uaf4E8Na26av4I0E6b9jScTQ6Pb5hfErNvJIyCI8DC8HOTjkFrDsz1KivHLm9+HF1o6zaJ4H0R57ixuLm3mk0q0mgSSIOTHIY26nynwVJU7ThjWnHZeAY9Tjsbv4e6buluGhEy6PaCNMSFBn5ixyccgfxDgYOCzTsxbK56hRXn3hTQvh94u02a+sfAWkW8McxhBuNMtDvIAJI8ssOM4IOCCCCAQa3f+FceCP+hN8P/wDgrg/+JotYDpKK5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJpAF9/wAlT0L/ALAupf8Ao+xorNtvDmh+H/inpH9g6Np+mefouoeb9itUh8zbPZY3bQM4ycZ9TRQBpePP+Rdtf+w1pX/pwt60dYOiKI/7dezQODGn2plXeGIBXnqCdox0Jx7VnePP+Rdtf+w1pX/pwt6l1vwnBrN99rm1G8tiBFlIWTafLcup+ZTjk569h6CkMp3upeDItLvtSjTSr8BWaVLbyXeZmT7vXBZlbGCeQ3vWisXhvTb2NDFplldt+9VCI0kyEbJ/Bd/4bu2axLb4Z6RBdG5stRvo4H+zEQRtEY9sOwooyhO07ATzzV3UfAtrqWpteyanqEbGfz1jRo9iv8nPKEniMDBJGCR0NVoIq6dq3gOC7meEaLp01pOyo7mCNmKKwLpg5wB5i54PDj1qyG8CvePuTQlnllKZYQ7pWyfxPLMPruqm/wALdHlhZLi7vZnKuBNIYy43BwTnZjP72Q5I6uSc8UkHgvQrqFrq11meXy3Ym5jlibZh5WYZ24HzyEnvlF/u0mHoXnv/AAV5EDzvo6i4ULGr+US6uM9s5BDk56YYk8GluJ/At8ft91JoNwZgT9odoXL7VOfm74VT+Cn0qCT4d6dKysL+/QrH5Y8to148p4gcBMZCSEBuvC88Ut78OtMu/NRLu8tbaRWAtoPLEaZh8njKE/czjnjJ9TTdgLkN74Tu7MkHTBbM643+WFZhGoHHqFZV5wRnFa2n6pp+qQtJpd7bXkcZCs1vKrhTgEA4PHBB/GufuPh9p9zDdRyX1/8A6WSZWDoCf3jSLj5eNrMMeuxQcgYrY0PQLPw/bzwafuEU0okCEKBGAioFXAHAVABnJo06gc74ROjQfCHwhe+ITYx29npVjNHPfbAkEnkoFYM/CtzgHrzVjUB4D0jT9RmmtNAVbFWuLmFUt1ZTKuCW3YAaQcZYjd0zVfwno0et/B/wjA9zcWkkelWUsU9vs3xsIFGQHVlOQSOQevrzUbfCfR1vLi5s9T1i0eWNEiWO5V47baoUmNHVlBYABsg+owanWzHpdBa2vwwt9PaX+zvC2npPFE9xDNBbRMqsPMQSDsfl3AH+6SOlWoNL+G0mpRfZrHwq17dzsYvLhtjJNKh3NjAyzKTk45FZ6fCLTobgz23iDXoZSkSg+dC6rsAGQjxMiliqlsKOVGMc1a074Y2Wn3djO2t6tdmxnWeFJxbbQyoiDhYVx8iBcjBwTzzV6XI1sdHY+HNG0xidN0qzswYzEVt4VjUoccFQAOw7dqgh8HeGLaMpb+HNJiQp5ZWOxiUbc528L0z2rZoqSjl0+Hfh2HxBDqlvYW0AghMUdrFZ26xKDuyQRHvGd7ZAYKcnINX18H+Go1YQ6BpkO6N4sxWiIQjjDqCACAQADjritmigOtzDbwjpcvic65cxC4nFmtlHHNFG6RRgsTtJXcCdxB+bBGOKjm8AeDbgqZ/CWhylRtUvpsJwPTla6CigCnpuk6fo8Lw6VZw2cTsGMcCBFyFCjAHAwqqMD0rH8Uf8jF4M/wCw1J/6b7yukrm/FH/IxeDP+w1J/wCm+8o3A1m0e0R76exijsL2+UCe9toYxM5AwrElSGKjpuBHtVc+FdBe3aK40exuQ8C28rXFskjSxqchXJHzAHnB4zzWtRQBjT+D/DN1dJdXPh3SZriN96TSWMbOrccglcg8Dn2FXrDStO0sSDTLC1sxK2+QW8Kx729TgDJq3RQAUUUUAFFFFABRRRQAUUUUAc348/5F21/7DWlf+nC3q5qHg/w1q91Jc6r4d0m+nl2+ZLc2McjPtGBkspJwOnpVPx5/yLtr/wBhrSv/AE4W9dJQBzFt8O/DNl4gtNV0/SbKza0jdYra3soEiDuVzLgJuD4UDII44q03gbwk0kcjeFtFZ4m3RsdPiyh45B28HgfkK3aKLgZN14U8O3y3C3ug6ZcrdSiacTWcbiWQDAdsj5mA4yeaLrwp4dvr6K9vdA0u4uoUEcc81nG7oo6KGIyAM9K1qKAMd/B/hqSGOKTw7pLRxReTGjWMZVI+fkA28L8zcdPmPrVb/hAPCAuPtEfhbRYrndvWePToRIrddwbbkHPOa6GigDE8LeFNP8I6Y9lpY+R5PMdvJhiLHpysSIucADOMnuTW3RRTvcAooopAc3ff8lT0L/sC6l/6PsaKL7/kqehf9gXUv/R9jRQBF8RbhLXwlFcSiRkh1bTHYRRtI5Av4CdqKCzH0ABJ6AVzvinxJLqs4Okf29bItrLGB/YuqR7ndSAxCW/BUhSDk8FuOhrp/Hn/ACLtr/2GtK/9OFvVXxbd6umtWCaHFO8sCGQjEnku7ukah9pAKhWkc5PG0HFHVBtqcrpGqSWmvGe8PiA2TXDzGOLSNUzwxCBgbf5hsEY25ABDdQSKsT+IrmZnfbrvmG4kZsaTqqrNEd/lrtFt8m0mPIXrtOTyc6S+JfGSWkVw+lRyxvHFIzCxlQoGkkQgoWLblHluQAeN3saddeI/FKSLGtmQoeLdNDpszggKzSDBII5jKg4wRIhyDQ9h21OStr/XLGVXW+169LIyzfaNK1ZVYlm24UW5xjEZJBBOXHTFQWKXVvaWsEh13Ee4PjTdXOCxhUsD9nHPlpKf96Q+prq7Pxh4hM8dsYYH8lUWci0mdnJEYZowGywR3cOOcbVXqSQ2PxR4unKTtpkrJtD/AGYafNEzfJLJgsScH5YkI55ZuOlUrp3J3MPVb/VNQLNFf+IoCEmO2LSNVQSyEOEztg+RRvXgDjZ1JOR0fh3xTFYSXkmqp4hmMzJ5af2JqcojAXBGTbgdcnOM88k4FOl8UeLItWKHTFOnxzRoZxp07NMp3FiqqxKgbG5IPVOu7jq/D11qF7okFxrEKwXb58yNEKhSDjjJJIOMgnGQRwKS2Bu7M7/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukopDPO/APjTS7X4beGreW11xnh0m1RjFoF9IhIhUHa6wlWHoQSD1BroP+E80j/nz8Qf+E5qH/wAYrkis7/ADwmtpLqMM5sNNCyafFdSOo8uPeWW2ZZCuzdkbh25zitGwExOlw38viKQCziWzlgS8jDzDcJTMH+YHpj7QcYxjJ5oWquD0Nz/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABisnwndaofESW91Z6oZfsjPqdxezXCwrcZX5YUaMxMvHBicADORnrQsWbUNVu9PnvNeTUI4HfWohNcIijOYzBjgZ2kDycErnd82KHorj62Ol/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8YrF8J3Gq6Zpfhu1I1R1voBLeyalb3V1KJdqhoy7sDByC2XyvUKORVa98Za/Y+KpLGz0y7mtjf8AlvI2iXzqULxKGWX7gAVpDkfKfLzgbqdve5Sb6XOj/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GK42Lxr48gnjsbnRpnbyImN/wD2FcNFvaVVbKrJuyAWGMD7u/O1sDW1TxF410vRpZFsre9vYLnyWWDSLgpMAXYsoWRiAYwgB+YBzg+xa42bn/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxVjwjLNLospuReBhfXQX7akiybPPcp/rBu27SuO2MYrcoegHN/8J5pH/Pn4g/8JzUP/jFc/wCI/Gmlza94TdLXXAIdWkdg+gXykj7DdL8oMILHLDhcnGTjAJHolc34o/5GLwZ/2GpP/TfeUgD/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrlvEviLV/DvijVJdCstXvZJPLzHLpmoXdudsLHEWz92hLbFJXj5snoa0v8AhJ/E8+pxxW1kY1kvHjMU2iXP7uJUZlJm3hCX2rhsALvwQSpFHS4Gv/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFcppnjnxvff2cZvDc1oJjOtwtzpM6FcK3luNruFG8BSG5YEMCM4Gx4c8W+ItV8VQ2Oo+H7u1sJNPW4N1LYtCok4yCzOdpzkeWVyAASxzgOwrmn/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMVzlzq/iTWJLO1vobqxt21WKOY2unXkbCPDlozIjg4BVP34Ijbd0wCDP4h8Y+KtKvbiHTvDt1qCR6hHCrwafI4MTLnqZBu5HMgG1Mj5WwaX9fl/mN6f16/wCRuf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MVzMnjDxha2MF3cWgmS5RmRIPDd7vh2uUw6hy2TlWAIXjOM/eF/wf4w1zWNXe21nTp4YVt3k8z+xLy1AYbCBulGDkMwwOcxk/xAAWoPQ1/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK4jUNW1prjXf7UttfWy1aGK40z+zoL9pINsjKVby4laBioUlM9iSfmxW7qKQ694j0C6tm8U20E0kkTBTfWqKsaEq0icBcuRzKBux3FNK4m7G1/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWR4l8V+JdK8RXttp2mNPp8VmJIpV0m5nbztyfLmMkOpVm6AFSvOR1z9F8S+Ita8Y6EdQstQs7ZVmWVV0q8gjlO1gJHLnYikqMI43A8hsHlLUb0J/GnjTS7nQbZI7XXARq2muTJoF8gwt9Ax5aEDOAcDqTgAEkCug/4TzSP+fPxB/wCE5qH/AMYo8ef8i7a/9hrSv/Thb1zPivXtW0DxdfzaHbarcyyQQrsfTL+9tchJSdixkRq2RCCR6n3IBpXOm/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8YrHHinxLc6jBHb2bW6TXaxGKfQrpvKjKM24zb1X5iF5wAmSrc1maZ468b3stgLrwzNZiS6liuVuNLnHyAKFZWV3C4dsZbh1UsNvQOwvM6v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8Yrm4vHHi972GH/hFrxo30152mbTpI185dw5zISuSBiLBYhs7uMV0Pw9nv5/B8b6s12119puNzXdvNA7L5zlCEmJdV2lcAk4GBniiwr/1+I//AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrpKKQzm/wDhPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukooA5v8A4TzSP+fPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/wAYrpKKAOJttetNb+KekfYodQi8nRdQ3fbdNuLTOZ7LG3zkXd05xnHGeoorSvv+Sp6F/wBgXUv/AEfY0UAHjz/kXbX/ALDWlf8Apwt66Sub8ef8i7a/9hrSv/Thb10lABRRRQBXhsLO2uJJ7e0gimlOZJI4wrP9SOTViiigAooooAKKKKAOF8Ma8vh/4QeDp2sLu/M2mWUKxWnl7txt1I++6jHGOvcduasr8SLBwXTSdUMIw3nbYdpj2LI0mPM3YVZEJGN3zcA4OKvhrw3ZeJ/hB4LtNTLNbQafYXDQ+XG6T7YVwjq6sCv0weOorqD4b0NiS2i6eSbgXRJtU5mAwJOn3wBjd1oj5/1t/wAEH5f1v/wDnV+ISWVvcDUrG4upreS48x7GNFRVSWVIwQ8gO5hE3TIyOSoIpk/xA0Qalpbz6LeG9uHnhjZ0t/MtwjYkOTJkjA3ER7jgcgdK6GTwl4cmGJtA0uQESA7rKM/6w5k7fxH73r3rMb4ceG11ewvrPTrWxWwYtHa2tlbpGWzndnyyyHIGSjLnAByOKOoPrYyoPilZ62dK/wCEahadbm+jhunfypFgjZtoyyS/ePBG3fjkMFPTv6x/+EQ8N5tT/wAI9pX+hyGW2/0KP9w5O4sny/KSRnI781sU9Lf15C1v/XmFFFFIYUUUUAFc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033lAEWseLJtN8daNo0dsz2l4WS4nNvIRG5VjGPMA2KcpgqTk7lx3rIvPFPiYaNqk9tNpMF3ZETiOeylkUwFnC4KzBXztB3hh3BQGrt/qPhCS51y2v9Fs57vT7hLm6tpILdpbhgiEXCqWy21XA3HBGCB2zduB4GFjqcN2PDwtWuEj1FJfI2GbjYsoPG/hcBuelC2V/62B72NC61K50Pw219rEYvZrdc3BsYxGGGcFwsj8ADkgsSMHGe/Oj4saEFtGnt7q3W7ujaxtLJAB5gbaw/wBbyQSvC5JDAgEA414tR8P3HijUdBiit5rlrJZL1Q0bx+WPlCOu4kfK3QqAQepqo9/8PGtYvMu/DJgRzeRbpLfarLlTKvbI2kbh/dIzxRvqHl/W2n6Gbe/Ery7VrWzsLhtT/sx9QDyxxCONVBOHQTb+o25XcuSPmrY03xtBqFxcA6bd21ta2j3M1xM0eEKSPG0ZVXJyDGxyMj3rn7rRPhnaa493eXWhKkccdodOaO08mHzAdgI2b1DAkhS2w5LYzzWxpeoeB9Psd2jR6FavHa7zaWklqjpG+1ivyttAJdD12kspycina60/rf8A4AO35foZVn8WLC2m8jxJE9jNPdzRwIRGrJEoUruUStuY7gP3e71IUZxf1L4mWOj27zaro+o2kccUcjvLNaBV3sVRS3n7QTtzycYI5zxU9nb/AA7s4xJYQ+GLdLW52hoVt1EU8nyYyPuu2NvqcYpLu18A6RJcafqNh4d0+IwRxyrOltGjoS7rGVPOBsZsEY6kZwcHRC7/ANdRv/Cy9INzcRra3pigjglF1iIQyRy4+YMX4C5G4NgjIwDkZzbz4r2F3oFzdeGYmurqKcxbG8p1VVKlpG2yjC7WHGd4J5Tgitm7bwBBqE8V8fDcd47ok6TeQJGbAKBgeScICAeyjHSmm2+HupRRWTQ+GbuO7lkuo4Clu4mkXIklC/xMMHc3Uc5o0/r+u39djW39f1udXRWZH4i0Joz5OsaeVjthdHbdJhYO0nXhP9rpTtB1u28RaHbarYBhb3IJTeVJwGI6qSpHHUEgikMzPHn/ACLtr/2GtK/9OFvUN94yOkeIdQsb+0kmhihE1u8CoucRlmjYvIMsdpIOAMcEjjM3jz/kXbX/ALDWlf8Apwt6i1Sx8Atrd1Nrdr4bOqLCGuXu44PPEbfuwXLfNtOQvPBzikMzrf4taFdSGKC1vjci0W7NqwiWYAlcqUMgIZQwJONvBAJIxVkfEmw8l2fSdUSSP5mhZItwQb97/wCswQnlPkZydvyhsjKsvw2uoyjL4VmSWLyypFsweMDztvuoGZMdP4veoNMtfh0m6CLRvD2mySSuy28lvbRtN5BJ81Qv3lH3g3YHJxVaC6Cz/EW3k1i4tLO2mjh025VL64nRGUoUc4QLJvVvkz86DK9Bhgaa3xEYa5axNpd2lrLGyTRNHGZreXfEqFmEpQowmT7uSMjPfE2k+GPB3/CSXV3DLp2p6jdEX6pJHbPJGpJxKpRA7DJOHcsRkgEDirFpL4Gkgt7SOPQIRbebNBa5t/3Q+YPIqqSFBAYkjtnPcUlotQer0F8O+N4NbvLaxayvIpprZZhcSRxpE58uNyABI7A4lHBz0PJ4Jp3fxT0KyuYLaaK4F1PJLElv5kAk3IcY2mQctlcAZI3AsFGSIrey+FMIaaxh8I252KTNbfZo2CvgA7lwQDuXHPOR61qPbeBb2ZreSDw9cSR3TwtEyQOVuJFO9SOzsoOR1Izmm9XoBV/4WLbJDLJc6Fq1v5cLThH+zlnQJvBG2U9VzgHB4OccZ1NB8Uwa/c3EEVje2kluMsLpUGcSPGQNrN0aNgfwxmsPW2+HTW2nve6XoGqJcXMWm2qJDbSkMH8sIoY8hCxyq5KjPHWuj0nwvoGgTSS6Foem6ZJKu2R7O0jhLjrglQMijTfoLW1upq0UUUhnN33/ACVPQv8AsC6l/wCj7Gii+/5KnoX/AGBdS/8AR9jRQAePP+Rdtf8AsNaV/wCnC3rpK5b4i3CWvhKK4lEjJDq2mOwijaRyBfwE7UUFmPoACT0AqX/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAOkorm/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigDpKK5v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAD4cf8ks8Kf8AYFs//RCV0led+AfGml2vw28NW8trrjPDpNqjGLQL6RCRCoO11hKsPQgkHqDXQf8ACeaR/wA+fiD/AMJzUP8A4xQB0lFc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFAHSUVzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMUAdJRXN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xQB0lFc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFAHSVzfij/kYvBn/AGGpP/TfeUf8J5pH/Pn4g/8ACc1D/wCMVz/iPxppc2veE3S11wCHVpHYPoF8pI+w3S/KDCCxyw4XJxk4wCQAb+qeB7HVL2/umvb23e+jKuITHhGKqhddyH5iiqvOVwMgA5NQP8PLB/MYajqCSs+6KVTFugT95mNcxkFT5smdwY/NwRgYsf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAR2ngOws9Su7mO+vmt7q1ktTZM0flRo5BbaQm/OR3Y4yfbEGofDyDVbNoNQ8Qa1KTbLbrMssUUkZWQSLIrJGCrgqo4+XA5BJJq3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUf1/X3h/X9fcjPs/hjp2nzCWy1XVY5EjhijcvC7RrFt2AFoySPlP3s/fbGOMVYvhRbxRlB4p15lMBtxkWfCbFT/n3/uoo59PU1tf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFO7Awbn4PabfQzpf+IdenaZw7SLNDCw+aRmGYol4bzpAwOchscYFaviHwBD4h1Brp9d1ayDQpCYbUW5TChwD+8hds4lfv39hVn/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YpPVWY7vchj8B26eSja1qklvDP54t2MOwsUZXziMHDbiTzkH7u0cVR0z4U6Tpb2TJqmr3X2OR5U+2XCTbmZShyWQnhDt4I4AznGa1P8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xijzJsZUHwo0q3vJLoaxrjzPb+VmS7DKrbgRKEK7d42qOm3Cgba6fQNGTw/osWnR3dxeLEzt51zs3sWYsc7FVepPQCs3/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABigYePP+Rdtf+w1pX/pwt6h1zwDaa7rE+pSapqNrcTW5th5HkkRoSpYLvjbqUXIOR1wBk1i+NPGml3Og2yR2uuAjVtNcmTQL5Bhb6Bjy0IGcA4HUnAAJIFdB/wnmkf8+fiD/wAJzUP/AIxQBmW3w7FhIETU7zUYp545J3vXiRolR3k+QQwpu3GR1YMQNrnr0q1cfDyxvNUS+utT1GZo55p44n8kohkDBgB5ecYdh1yRjJOBVn/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABigCDRPh9p+h+IItXh1PVrm4jtRbFLm63xucAeaUAA3kKBnpgDis5/hTaTXYnufEmuTYYsEb7KoBPmd1gB4M0hHPf2FbH/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MU7sClqnw4tdZsbq31LXtble5aJzcJPFFLGYwy/KyRrjcHYMDkYOAFFEXw102G6mnTU9U3zTxTMfNjB/dsxVNwTcVwxU5JO0AZ4q7/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFIDGsfhHpOnRwpZ6zra+XcrcFpLlJi4Vo2SMmRGwi+UgAXBwMEmu9rm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYp3drB1udJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFIAvv8Akqehf9gXUv8A0fY0Vm22vWmt/FPSPsUOoReTouobvtum3FpnM9ljb5yLu6c4zjjPUUUAdtXn3i+7uYvix4NgiuJUikM2+NXIVvl7jvRRQviQPZi+I9PspNB8cmSzgcq4uV3RKcSrbRlZBx94EDDdRis34pfvtT0y2m/eQSQhXiflWDSoGBHQ5HB9RRRSn8C+X/pKKX8Rf19o63wKzSeHYpJCWcxW4LMcnH2eM9fqT+ZrpaKK0qfEzKn8COcvI0HxN0mQIu86VdqWxyR5tvxn8a0tFlklgujK7OVvJlBY5wA5AH0ooqV8Mfn/AOlMt7v5fkZuqWdsvjzQbxbeIXTR3EbThBvKhAdpbrjPaujoopdF/XUDL0oCW91CaUB5Yrp4o3blkTah2g9hnnFO1OWSPUtIWN2VZLplcKcBh5MhwfUZAP4UUUL4ULqyrcRoPH9hIEXedNuVLY5I8yHjP41H4oije+8Ou6KzR6qpRiMlSYpBx6cUUU1tD1/9uYdZ+n/tpwVxp1lc31nLc2dvNJqWpXsF88kSsbqJJ8IkhI+dVAAAbIGOK6v4W2NpYeB7OKxtYbaN4YJGSGMIGdreIsxA7k8k96KKKfwv0X5jnv8AP9Dj7rSNNm1a81aXT7V9SQu63rQKZlYX+wEPjdkIAoOenHSvYqKKUf4a+YS/iy+RxniOWSXVb60ldntntWDQMco37iU8r06gflWheOyeOdKCMVEmm3O8A43bWi259cZOPTJooo/4P5MOn9d0ZGrXVxJ8DdQuXnlac6TKxlLksTsPOetcnrNjaQ31hbw2sMcJWyszGsYCmBlUtFjpsJ6r0PpRRQ93/XSQ/wCX1/WJ6Z4OJPgzSsnP+jKOfTFbVFFVP4mTHZBRRRUjCucsI0T4la2yoqs+m2RYgcsd9wOfwoopoOj/AK6ov+IAE00XCALNHLGqSDhlDSKGAPUZHB9awo7W3b4R31q0ERtxZ3SiIoNmAXwMdMUUVPcuHxIxPiJ97SZP44LUSRN3jYz26FlPY7WZcjsxHQ1e+FsaR6LHFGirHCkqxIowIx9pl4Udh8o6eg9KKK0js/X/ADMvsx+R0F5Gn/CwdKk2L5n9nXa7sc48y34zW5IqvE6uoZWUggjIIoorOf8ACXo/zZovi+4wPAKqnw80FUAVVsIgABgAbRXQ0UVrV/iS9SFsZWggTWklzKN8/wBouI/NbltgnfC564HYVJdSyL4h0+NXYRvFMWUHhiNmMj8TRRWa2H1ZmeMoIryLSLK7iSe1utSjinglUMkqbHO1lPDDIHB9K860fRtMu9V0+6utOtJ7i1uLyOCWSBWeJIpk8tVJGVCZO0DpnjFFFOn8XzX5Cnt8n+Z197o+mXPxgS9uNOtJbuG0tWjneBWkQ5ueQxGR0H5Cu6oopR+BerHL+I/RGIkUa+PJpVRRI+mxhnA5YCR8An2yfzNbdFFC+FfP82OXxP5fkjLvwJddsLeUb4JIpmeJuVYqUIJHQ4PStSiigQUUUUAf/9k=" alt="" width="537" height="409" vspace="0" hspace="0" border="0" style="width:537px;height:409px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>a Overall response rate = complete + partial responses. Disease control rate = response rate + stable disease at<br />24 weeks. Intent-to-treat (ITT) analysis includes patients who received open-label vandetanib before<br />progression according to the central read.<br />b OR=Odds Ratio. A value &gt; 1 favors vandetanib. The analysis was performed using a logistic regression model<br />with treatment as the only factor.<br />N=Number of events/number of randomised patients;<br />A statistically significant advantage was seen for vandetanib for the secondary endpoint of time to<br />worsening of pain (derived as a composite endpoint using the worst pain score from BPI and patient<br />reported opioid analgesic use) (vandetanib 49%, placebo 57%, HR 0.61, 97.5%CI 0.43-0.87, p&lt; 0.006: 8<br />vs. 3 months). There were no statistically significant differences observed for the exploratory endpoint of<br />diarrhoea (reported as stool frequency).<br />RET mutation status in Study 58:<br />In Study 58, RET mutation testing was performed by using the polymerase chain reaction (PCR) based<br />Amplification Refractory Mutation System (ARMS) assay for the M918T mutation, and direct<br />sequencing of DNA for mutations in exons 10, 11, 13, 14, 15 and 16 (site of M918T mutation) on all<br />sporadic patients where DNA was available (297/298).<br />However, RET status could not be tested in a large proportion of patients (mainly because of unavailable<br />results for direct sequencing of DNA) and response rate was somewhat lower in the patients with<br />unknown RET status compared with RET mutation positive status: 51.8% vs. 35.9 % respectively. In the<br />blinded comparison of vandetanib vs. placebo, only 2 patients known to be RET negative at all 6 exons<br />received vandetanib and none demonstrated responses.</p><p>A post-hoc subgroup analysis of RET negative status based on absence of M918T mutation of the pivotal<br />study 58 was performed. A patient was considered to have a RET mutation if either an M918T mutation<br />by the ARMS assay, or a RET mutation in any exons sequenced was present in the tumour. Actually 79<br />patients were identified by absence of an M918T mutation and no RET mutation identified at any of the<br />other 6 exons tested but in 71 of such patients sequencing of the 6 exons was incomplete. M918T<br />mutation is the most frequent mutation observed in patients with sporadic MTC; however it cannot be<br />ruled out that some patients tested RET negative for M918T mutation might be positive for mutation on<br />other exons.<br />Results according to RET status (positive, unknown and RET M918T mutation negative definition) are<br />presented in Table 3.<br /><strong>Table 3: Summary of efficacy findings in a segment of patients according to RET mutation status</strong></p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM0MQAAkpIAAgAAAAM0MQAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowNjoyNCAxMToyODowNwAyMDIxOjA2OjI0IDExOjI4OjA3AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDYtMjRUMTE6Mjg6MDcuNDEzPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAIIBeAMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APoPWNYstB0x7/U3kS3R44/3ULzOzO6oiqiAsxLMoAAPWsn/AITzSP8Anz8Qf+E5qH/xijx5/wAi7a/9hrSv/Thb10lAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMV0lFAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUActbfEXQby1iurOLXJ7eZBJFLF4ev2SRSMhlIhwQQcgipf+E80j/nz8Qf+E5qH/wAYrnbK31W8+APhy10SGaeWfRbOOWODyfMaM26ghfP/AHfpnd2zjnFUtMj+JMV3bWM1nd2OlxpaRrLbT2TvGoQCQbXBxj5tx3Pk7dvG4Ejq2glornX/APCeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxXIQ3XxMV5Few1x1KSBWkbS1wSjhSCrnkMIiMjGS+eMYDp3xAnWD7Y+pS3LQbWlH2BY4ZBBOnmKMlkcuYz8uRhiOmQDpca3sdf/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWJpMni7TrmOa503UprRZpmuVlNkJpkEKbHPlH5mLqVAG08/NwBTPFmr+IX8ZQaX4ZvbsTNp32prKH7H8gDlSzCb5skHAwSu4LnAzkelvP8AyuJaq7/rWxvf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFcxeL8RLSKNLVtavjLEjs4GmBoXZfmTB2ghWXHfhurdQt7p/i9dRleC31We2W4ceWBpwF0N1vtkkU4B4WUA8OMDpxTt71hX0udN/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWVa3WsWurW8uqWl3NfQzXAdYzGzzWf8BKphR85XaCd2A3JO6o/FVx45i8TSDw7ZalPpzQBQYWsVRXMcmWUytv3B/KxkFeG7YpdB9WjZ/wCE80j/AJ8/EH/hOah/8YqKX4i6DBJDHPFrkb3DmOFX8PX4MjbS21QYeTtVjgdlJ7VgaPY+K59c0ifxFpFxNNazRGa/dbNM4gnjdwI33YJdDjnBY4GK6TxR/wAjF4M/7DUn/pvvKbVhB/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRSGc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUAc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xXSUUActP8RdBtYxJdRa5CjOkYaTw9fqCzsFVcmHqWYADuSB3qX/AITzSP8Anz8Qf+E5qH/xijx5/wAi7a/9hrSv/Thb10lAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMV0lFAHN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xXSUUAc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFdJRQBiaX4u0rV9VGm2w1CG7aF51jvdLubXeiMqsVMsahsGRMgHPzCiq19/yVPQv+wLqX/o+xooAPHn/ACLtr/2GtK/9OFvXSVy3xFiefwlFFFPJbPJq2mKs0QUvGTfwAMu4FcjqMgj1BrM8QR33hyOF7rxn4onEu84gt9MJUIpZiQ1uOwxxkkkDHNAHeUVw86RWqsbr4palBsOG806am04JIObbg8H8j6U26jlgkSKD4ha7eTtPFCYLZNNZ0LttDEfZuFGGJP8Asn0o62Dpc7qiuKubcWVw0F58UNTglX70cp01WHIHQ23qw/MVCFeS/sbS0+Imt3bXiNKjwLpjKkaqG3n/AEb7vKjIz94etAHd0Vw8ggiiikl+Kt+kc2PKZn0wB8jIwfs3OabamK7CiH4o6kXaPzdm7TCwTAbdgW3TDKc+hHrQB3VFcIsto93Fap8Wb5riZtkcIk0ze7ZxgD7NknIIxWpD4d1K4gSa38f67LFIoZHSHTyrA9CCLXkUAYFl4gfw18AfDl7E8MUraLZxRzTziGOFjbrh2cqwGMcZUgkgd6bovxPjktrfznh1FpnWLfBdI7M/2SObaiInViX4J4IPzYwoz9Bg1TR/hN4Wv4/EniadLjT7GKOzsItM/dmSNAqgzQj5QSF5YnpnPJrS03VtO1PTPtsfxX1CFFIWaOd9LV4HJ27HH2f5WzxjuemaI9Qdrr+v62C3+KrXAuNtnpTLb2rXMjxaxvXaGC7gfK5jBYBnONpWTg7ecPRPjXm2hsLlbO+vhGrG6kvfLilLTiPIkWHZtG7AIwWKkbV6100ctrNvEXxV1FnSWWEpu0wMZIxmRQDbDlRyfQc9KSKa2k2q/wAVr6KUhS0LzaVvQsAQDi3IzyOhPtT0v/XmJ6f16f18zo9A8QDWrnU7aSKKG4025+zypFMZADtBBJ2rgkHOOeMZ9K2q8/e7sxexWkfxXvpZ3BYok+k7kQR+YXKmAHbtwcgHhgemSNWz0S91Gziu9P8AiJrV1bTLujmgTTnRx6hha4IoGdXRXN/8Ivq//Q9+IP8Avxp//wAi0f8ACL6v/wBD34g/78af/wDItIDpKK5v/hF9X/6HvxB/340//wCRaP8AhF9X/wCh78Qf9+NP/wDkWgDpK5vxR/yMXgz/ALDUn/pvvKP+EX1f/oe/EH/fjT//AJFrn/EfhzVI9e8Jq/jTXJTJq0iq7w2OYj9hujuXFsBnAK/NkYY8ZwQAeiUV51cTapa65NYXHiPxilvBLHDJqPkaSYFaQDbkCHzACWAzswD145q0j2kvl+V8Wrx/NTfHtl0s71+bkf6NyPkfn/Zb0NHS4Hd0V59e31jY2hnm+LN5gqTGv2jSVMpAB2qWgAz8y9SB8w9a0rLS59RkuI7D4kavcyWr+XcJCNNcwv8A3WAtjtPsadgOvorz+2nSaG7e5+JWsWLWU5guI7s6WjRHzCilsW5wHKnbnr9eKniFvNdm1h+K99JcBzGYUk0svvG7K7fs2c/I/H+y3oaQHc0V56uo6W09tCvxfume6Utb4m0siUBtp2n7Ng4IIwPQ+lP+0WrTJFB8Vb+difn8ubST5S7GfcwNvnG1SeMnHPQEgDrY7+iuOGnyNpA1UfEzVTpxTzBeD+zfJK/3t/2bbj3zVR5rKONpJPi3dqiBWZmm0sBQyllJP2fuASPUAmgNzvKK4OfMdyLe3+I2tXk6zwwzQ2o0x3g804RnX7PkKcj354FbH/CL6v8A9D34g/78af8A/ItAdbB48/5F21/7DWlf+nC3rpK878aeHNUh0G2aTxprk4OraaoSSGxABN9AA3y2wOVJDDtkDIIyDau7bVrfVPsVv4p8XXpTb581tbaYUgLfdDbrcEk5z8obA5OBQB3VFee6fe2t/Y2twfihqlq9zwLe4fSllR8KTGQLcjcNy5AJ6j1FSmexEcUh+Ll2EmQyRN52l4kQZyyn7PyPlbkf3T6UAd7RXAXd1YWMU8l38W72JLcxicmTTP3XmfcLf6N8obOQTxjnpSSXlhHCXHxbu3+QyKq3GlZcBQ/GbcD7rKc5xhgehoA9AorjrHTptSmnhsfiTq9xPbbRcQxDTXeAsMgOFtjtJFVrh7S0lnju/izeQSW8gjmWWXS1MTlS21gbbg7QTg9gTQB3VFcJLJaQMRN8WryMqxQh5dLGGBII/wCPbrlWGPUH0qTToDqtx9ms/iXqsl1sMptkbS5JBHuKh8Jbn5SR1/Dg8UBsdvRXN/8ACL6v/wBD34g/78af/wDItH/CL6v/AND34g/78af/APItABff8lT0L/sC6l/6PsaKzbbS7vTfinpH2zXdQ1fzNF1Db9tjt18rE9lnb5MSdc85z0GMc5KANLx5/wAi7a/9hrSv/Thb1L4h0LT76ZdT1W+a2js4v3blkVYD5iP5mSODmNRzxjI71F48/wCRdtf+w1pX/pwt6h8U6Jrms30cdpLb/wBnAws8b3MkTHbIWcEKpDBgEHJ6bhjnNLqg6Mhf4d6Rd6Qtkb26kiVJUSRTFuBdQhbOzlgoZcnJwzZzxibTfAllpV5aXf8AaV9O1n5ewTmLGEjkRQcIO0rH68+uaFp4Z8T24tjJqKyCKGOOaI30pErAEsd23I3PtJyCcAgEbiKqP4M8WQ6dP5OvSXd7OkkbeffTJEg8tUjZQAcHKlyPVupA5rXWwb7mnD4H0rUWi1CPVru8t5P3sGHieLl3kDKQnPzuGzk5KLnOKseHfAVl4b2C01G/nEVtJbRCcxny1dgxI2oOcgc+gA7DGZB4L1poYbe41SaCCKU/LaahLHmFVcRxqFUbPvJk8/cz1NdN4d06903T5I9SuGuJ3meTc0zSbVJ+VctjoOOAPXGSTRZapf1/V2F76syNO+HWmaagC3d5OUjZImmZCYi0SRB1wowwWPj03N603/hXGmJcQTwXt7DLCwcMhj+YjywuQUI+UQoB+NdfRRd3uBx8Pw/tbOwNjbTSyieaKW4vp5B9oXymVkC7UAOWUknjBYnnNdbFEkEKRQqEjjUKqjsB0FPopXA4Xw34dtPFHwZ8I6fqLN9lGm6fNJEI43WbZEjBHWRGBUkDPAPHWtO48C2M4uBFfXlqJZ1miW3WFVtgIvKKIvlkbShIIYMeeCOKwNN0vWNW+CPhC38PuqXI0yyZi2ozWXyfZwCN8Ssx69Me+cgVjar4f8fWt1HLqGpPeRXctrDHb6ffX0ZV9u2QySRqRHGPmO8IM7gWwQCBa6ef+Q3pr5HTy/DvQ9UvIZrPWtSjbTbiUCOzu02I7Yby3XaQ21sOA2SCecjiqq/DbS9NvIGu/FmredJhLdZ3tELFBG3ygQAsQtunrwpPqaoyeDvHA1Scx3dq9tcGITTLrl1bySbRAC+xIsKxETg4bnzME4HOh/wifieO98wXcN1FHdNIgn1S4LEeTMgcEoxib94g2qcDYWzk4p7LQSSuS2vgbTI4Lawj8XanLJKv2i3xNaiRo1g8gMm2IEqqOPmHcqSeed/wtocOhacLfTtSkvNOwTAjLFhCXdmIZFUEEtjHQbR71xH/AAhPjO3W1ltHs5LuObzpZpdfu1LMRDkZ8k5UmJwV4BBBI7VYXwj45JaQ6pHE39m/ZhENaunRpQysrklMg/KQXGGIbB6ZLb/r+vuEtbX/AK1PSI5opWkEUiOY22OFYHa2AcH0OCDj3p9cfp2i+KYtft7u8urf7Ml1K0sQ1CeQNE0agYQqBu3qTgkhQTjrXYUuiAKKKKQwrm/FH/IxeDP+w1J/6b7yukrm/FH/ACMXgz/sNSf+m+8oAjn0PT5/F8v2jxFdPNcGO7bRTLAqMI9oV9oQSlQwB+9gnr6VXsdA07UJ9raikN/DfNfzW+nXgfZlipQkru2FkbIAXLBh61neJPCPiW/1XVrnQrmOya7kt3inGsXMbDy0brGqFFG4rlRuDDOcGo5PCni+cs7zW0coL+W8etXIYq08jbCwjBIEcmB1wVGAMAhdF/X9dBvr/XkX4vhlbQxTxL4h1kwzWz23lt9mwivGkZIPk5ztjUckjjpzWnpXg9dF1a41Cz1e9klvJVe6FwsTeaq78LkICOZOucgKo6Vyo8I+PXuLS7XVre1nW/jkuIjq93cRtAqIDtBCDduDnaVKnzOfurjS8XQa7qt54dgskvLC7n837Qbe8uFgtsKCGd4l2uQR8qvtDcjIyavW+4t1qVde+HegkXcmu+LtUs1vZHlVjd29t5RBeV9jLGpxtaTOS3yk56ZE8fgHTLDVLOY+LtURp591tbu9oBMctLsU+Tvb+I8NnA68VFd+EvFUtxM/2q1u1NxJIi3OoTEMGhmQMAY2ER/eoNi/LhC2cnFZd/4I8ez6h51pqFikXmxSrHJqtwywFIpIyIx5WU3CQA7SuNuRgniYpaIctd/M6Kw+Hel29q9tZa1qDGKT946tblhJvjly2IsbtyA9Od5z1GC1+H1lBZjS4/EurNJDJ9ozvthMoaA26/diGAEBwcZyvU4qpe+HPGT6hJd2c8GPtJdLd9dulQx74mAOIzjO2UEYIAcdegz5PBHjVdL+z2mqeTM8VuzzP4hvZWWaPzNxUsh+ViYwVxhgpyM4NUthK6uzqbXwTHaeGbzw/Fq14NOuImjQCOEPDvd2cqRHt534wVIAHFZ9/wDC2wvdYu9Tj1zW7We7ZGZYp4njQjGSiSRsq7iFJwOqjGOa6+ylupbUNfW62025gY0l8wYDEKc4HUYOMcZxViperuxLaxxtn8NbKyvYrtNZ1V5YxbrufyDuWEqUUnys4yucDH3mxjPHZUUU7thZI5vx5/yLtr/2GtK/9OFvV640ATawb+31K+s/MA8+C3ZBHOQMKzblLAj/AGSucYORxVHx5/yLtr/2GtK/9OFvXSUhnD2Pwus7Ris+v6ze27RvG1vP9mCMGi8rOUhVgQvoeo5zT7r4aw3UkUv/AAkmsxSodzyIloTK+8PvbdARnIXoAPlHHXPa0UBvozjbD4a2GnyGVdW1SaXy4IxJKYCyrCyMgyIhxlOh4+ZsYyMLbfDm2tJ5pIde1cLJbyW4jP2crGHRUyv7nOQqKBkkccg5OexooeujBaO6OY0nwUmi6y+pWer30k04jS5+0LC3mxoG2pkICOXJznjoOOKoat8MLPVdWvNQOu6vay3h/eiD7MQQA4C5eFjgCRwOeN3sMdtRQ9dwWmxyKfD2CPVbe+TXdWBhlSUw/wCjlJCu3hv3OcEpk4I5JxgYAk0TwFaaLry6uNV1G9uUSWNftRhwqyMHYDZGpA3AHGf5nPVUU7sVkFFFFIZzd9/yVPQv+wLqX/o+xoovv+Sp6F/2BdS/9H2NFAB48/5F21/7DWlf+nC3rpK5b4i20F54SitbyGOe3m1bTI5YpUDJIpv4AVYHggg4INZWp+EPBdvqL2kXhDw5ClvaNeXM8mjxPtQEgBVCjJ4JJ7Y6c8K9h2O+oryhY/h9b6fBJceAtKvHJETz22iQRxvKFJcKJMEAbHzn7u05wOalaP4dm1jnt/hxZ3KyyJEix6Na5aQ9UGcZK4bd6bTnjBLEepUV5d/Z/gbULy0s9I8C6Gk1xLblZLjSLco0T73ONvIby4nIz6r1zimX2n+B1162tNO8D6BNbsdssn9k25JJlWJSvIIXPmEkjkRkj3dnewHqlFeXFfhktnLdP4E0pY4cedu0m1BjJYqAR2O5XBHUbCTgYJpXjeAltbF4Ph9pVq9xdpDJHd6Nbb0BXeV2g/eKlQOwMi568LcHoevUV5hPbfD63llWb4bWapBAk88p0e1Cwq5YDd3BwhYjHA5OK6eH4e+CJreOU+CtBTeobY2l25K5HQ4Uj8iaAJPhx/ySzwp/2BbP/wBEJXSV5X4e8J+ELX4NaJq9x4Q0W8vG0W1k3PpKTPNK0KYJCoXcljzjJP1qtCfAsPg3TdUvvh5osl7d2csrQRaXbRKJogfMi/eYYNlWwMEgKc0bgeu0V44118PdIsbyTxN4D0W3kt7gopXS7ONHUySKoBZ8blEZ3ZIBP3c5ArQig+Ht5K0dv4A0yEJcRx+bNo9oUkRpWj3LhuBlOp5G4HB5AAem56nRXBeHPDngDxNoZ1Kz8A6VbhZHjNvc6TbLIGU4/hypB4IIbBBBrktOufCP2ZE1L4Y6ZLf3ES3MMFvpFkiiNpUQRlzKwLgSK2TtBBHA6U7O9gPaqK8jll+H1pNFay/DiwurqSCa5ZINJsUMaRtIGBV5MnHlkErkZK8jcBVqyPwtvfE1toP/AAhejQX9yZAiTabaDlGcdASxz5TkEAgYAYqSARJvYOlz1KivOdU0r4faTr/9l3Pw+0xsRJK10ul2YhUPv2gkkMMmNh93AyMnGSMmCX4f3Fot7F8NbQxMu37OdFs1lWQSSRkEl8cGPHp8wOSM4Q7NHrlc34o/5GLwZ/2GpP8A033lQWXgPwHf2FvdweDdA8q4iWVN2lQA7WGR/D71jeI/APg+DXvCccHhPQ40uNWkjmVNNhAkX7DdNtYBeRuVTg91B7U2mnZkppq6DXfGviLTPE93Z2unzT2cMiiMp4fvpty7Yyf3qZQ5zIuRwCAT0wWv4k8UtZ30Wn2k9vKkV5JA8ujXUpmcSybMF3GzChCFOd+8BAAMVj3+iaRY+ObnT7f4eaDqlhAA7QWnhtFkVDEWz9odhCW3ADYQpIYHtS3l98M7G2lu7n4daelkkaSJeNp+nrFKHYquGaQY+ZWHzYHHuMpPRFPc1R4u8XreLp8tuouHmSJbseGr1oSC7gucSYUbPKbl/wC8M/3YtP8AEXik3mn+dZ3M8TIrLb/2TeQkP5M2S0ruQoMioNsmcblPoaq4+HtzqDWdj8PdN+VrZvtT6PZtE0czxqjAbwxBEnXGVxkjoG2fDnh/4feJY75rXwJpFubK5NtItxpNt8xChg6ldwZSGBBz+VVZ2FfW/Qq2njbxT/bWnW93pksltPKqSSx+H72PcpfaWySRFjJzvzkJno4xZ1vxb4m07XLmwt7FnTzglvOmh3dwm0tDgs0bbT8ry5OQMx/hW3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0l0A4u4+InjOJtU+yaDJqJtL5beGO30eZTLHlwZFLS4kQlUXeMbCxJVgBuv2fjjxTczXMMulTwKlwiJcnw/eYRC8o+4WBkJCRfMrAL5uTwprpf8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoT01Bk/h691q7vL+LWPsuy0k8kNBA0fmN94MMyNxsZAR/eDc4xW7XN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNIDpKK5v/hXHgj/AKE3w/8A+CuD/wCJo/4Vx4I/6E3w/wD+CuD/AOJoAPHn/Iu2v/Ya0r/04W9dJXnfjTwD4PtdBtpLXwnocLtq2mxlo9NhUlXvoFZchehViCO4JHeqmp6B4W0XxBfR3PgXQL6xSO38iCy0S3E4eQyD5ndwpGY+wH3hngE0Aen0V5RDJ8N5ruCEfDe0VZiuZW0izCxqxjCs3zZwfOjPAJ+bkcHEUUvw+udstt8OLF0BkjaD+xrLezCSFVKt5gXaROrDGcg5yMYLsw0Z65RXi2r6r8OF0vWk0LwNoc+rabvX7PJpdm4UqHLM4VxhV8twQSG4yFYFc6+uaf4E8Na26av4I0E6b9jScTQ6Pb5hfErNvJIyCI8DC8HOTjkFrDsz1KivHLm9+HF1o6zaJ4H0R57ixuLm3mk0q0mgSSIOTHIY26nynwVJU7ThjWnHZeAY9Tjsbv4e6buluGhEy6PaCNMSFBn5ixyccgfxDgYOCzTsxbK56hRXn3hTQvh94u02a+sfAWkW8McxhBuNMtDvIAJI8ssOM4IOCCCCAQa3f+FceCP+hN8P/wDgrg/+JotYDpKK5v8A4Vx4I/6E3w//AOCuD/4mj/hXHgj/AKE3w/8A+CuD/wCJpAF9/wAlT0L/ALAupf8Ao+xorNtvDmh+H/inpH9g6Np+mefouoeb9itUh8zbPZY3bQM4ycZ9TRQBpePP+Rdtf+w1pX/pwt60dYOiKI/7dezQODGn2plXeGIBXnqCdox0Jx7VnePP+Rdtf+w1pX/pwt6l1vwnBrN99rm1G8tiBFlIWTafLcup+ZTjk569h6CkMp3upeDItLvtSjTSr8BWaVLbyXeZmT7vXBZlbGCeQ3vWisXhvTb2NDFplldt+9VCI0kyEbJ/Bd/4bu2axLb4Z6RBdG5stRvo4H+zEQRtEY9sOwooyhO07ATzzV3UfAtrqWpteyanqEbGfz1jRo9iv8nPKEniMDBJGCR0NVoIq6dq3gOC7meEaLp01pOyo7mCNmKKwLpg5wB5i54PDj1qyG8CvePuTQlnllKZYQ7pWyfxPLMPruqm/wALdHlhZLi7vZnKuBNIYy43BwTnZjP72Q5I6uSc8UkHgvQrqFrq11meXy3Ym5jlibZh5WYZ24HzyEnvlF/u0mHoXnv/AAV5EDzvo6i4ULGr+US6uM9s5BDk56YYk8GluJ/At8ft91JoNwZgT9odoXL7VOfm74VT+Cn0qCT4d6dKysL+/QrH5Y8to148p4gcBMZCSEBuvC88Ut78OtMu/NRLu8tbaRWAtoPLEaZh8njKE/czjnjJ9TTdgLkN74Tu7MkHTBbM643+WFZhGoHHqFZV5wRnFa2n6pp+qQtJpd7bXkcZCs1vKrhTgEA4PHBB/GufuPh9p9zDdRyX1/8A6WSZWDoCf3jSLj5eNrMMeuxQcgYrY0PQLPw/bzwafuEU0okCEKBGAioFXAHAVABnJo06gc74ROjQfCHwhe+ITYx29npVjNHPfbAkEnkoFYM/CtzgHrzVjUB4D0jT9RmmtNAVbFWuLmFUt1ZTKuCW3YAaQcZYjd0zVfwno0et/B/wjA9zcWkkelWUsU9vs3xsIFGQHVlOQSOQevrzUbfCfR1vLi5s9T1i0eWNEiWO5V47baoUmNHVlBYABsg+owanWzHpdBa2vwwt9PaX+zvC2npPFE9xDNBbRMqsPMQSDsfl3AH+6SOlWoNL+G0mpRfZrHwq17dzsYvLhtjJNKh3NjAyzKTk45FZ6fCLTobgz23iDXoZSkSg+dC6rsAGQjxMiliqlsKOVGMc1a074Y2Wn3djO2t6tdmxnWeFJxbbQyoiDhYVx8iBcjBwTzzV6XI1sdHY+HNG0xidN0qzswYzEVt4VjUoccFQAOw7dqgh8HeGLaMpb+HNJiQp5ZWOxiUbc528L0z2rZoqSjl0+Hfh2HxBDqlvYW0AghMUdrFZ26xKDuyQRHvGd7ZAYKcnINX18H+Go1YQ6BpkO6N4sxWiIQjjDqCACAQADjritmigOtzDbwjpcvic65cxC4nFmtlHHNFG6RRgsTtJXcCdxB+bBGOKjm8AeDbgqZ/CWhylRtUvpsJwPTla6CigCnpuk6fo8Lw6VZw2cTsGMcCBFyFCjAHAwqqMD0rH8Uf8jF4M/wCw1J/6b7yukrm/FH/IxeDP+w1J/wCm+8o3A1m0e0R76exijsL2+UCe9toYxM5AwrElSGKjpuBHtVc+FdBe3aK40exuQ8C28rXFskjSxqchXJHzAHnB4zzWtRQBjT+D/DN1dJdXPh3SZriN96TSWMbOrccglcg8Dn2FXrDStO0sSDTLC1sxK2+QW8Kx729TgDJq3RQAUUUUAFFFFABRRRQAUUUUAc348/5F21/7DWlf+nC3q5qHg/w1q91Jc6r4d0m+nl2+ZLc2McjPtGBkspJwOnpVPx5/yLtr/wBhrSv/AE4W9dJQBzFt8O/DNl4gtNV0/SbKza0jdYra3soEiDuVzLgJuD4UDII44q03gbwk0kcjeFtFZ4m3RsdPiyh45B28HgfkK3aKLgZN14U8O3y3C3ug6ZcrdSiacTWcbiWQDAdsj5mA4yeaLrwp4dvr6K9vdA0u4uoUEcc81nG7oo6KGIyAM9K1qKAMd/B/hqSGOKTw7pLRxReTGjWMZVI+fkA28L8zcdPmPrVb/hAPCAuPtEfhbRYrndvWePToRIrddwbbkHPOa6GigDE8LeFNP8I6Y9lpY+R5PMdvJhiLHpysSIucADOMnuTW3RRTvcAooopAc3ff8lT0L/sC6l/6PsaKL7/kqehf9gXUv/R9jRQBF8RbhLXwlFcSiRkh1bTHYRRtI5Av4CdqKCzH0ABJ6AVzvinxJLqs4Okf29bItrLGB/YuqR7ndSAxCW/BUhSDk8FuOhrp/Hn/ACLtr/2GtK/9OFvVXxbd6umtWCaHFO8sCGQjEnku7ukah9pAKhWkc5PG0HFHVBtqcrpGqSWmvGe8PiA2TXDzGOLSNUzwxCBgbf5hsEY25ABDdQSKsT+IrmZnfbrvmG4kZsaTqqrNEd/lrtFt8m0mPIXrtOTyc6S+JfGSWkVw+lRyxvHFIzCxlQoGkkQgoWLblHluQAeN3saddeI/FKSLGtmQoeLdNDpszggKzSDBII5jKg4wRIhyDQ9h21OStr/XLGVXW+169LIyzfaNK1ZVYlm24UW5xjEZJBBOXHTFQWKXVvaWsEh13Ee4PjTdXOCxhUsD9nHPlpKf96Q+prq7Pxh4hM8dsYYH8lUWci0mdnJEYZowGywR3cOOcbVXqSQ2PxR4unKTtpkrJtD/AGYafNEzfJLJgsScH5YkI55ZuOlUrp3J3MPVb/VNQLNFf+IoCEmO2LSNVQSyEOEztg+RRvXgDjZ1JOR0fh3xTFYSXkmqp4hmMzJ5af2JqcojAXBGTbgdcnOM88k4FOl8UeLItWKHTFOnxzRoZxp07NMp3FiqqxKgbG5IPVOu7jq/D11qF7okFxrEKwXb58yNEKhSDjjJJIOMgnGQRwKS2Bu7M7/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukopDPO/APjTS7X4beGreW11xnh0m1RjFoF9IhIhUHa6wlWHoQSD1BroP+E80j/nz8Qf+E5qH/wAYrkis7/ADwmtpLqMM5sNNCyafFdSOo8uPeWW2ZZCuzdkbh25zitGwExOlw38viKQCziWzlgS8jDzDcJTMH+YHpj7QcYxjJ5oWquD0Nz/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABisnwndaofESW91Z6oZfsjPqdxezXCwrcZX5YUaMxMvHBicADORnrQsWbUNVu9PnvNeTUI4HfWohNcIijOYzBjgZ2kDycErnd82KHorj62Ol/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8YrF8J3Gq6Zpfhu1I1R1voBLeyalb3V1KJdqhoy7sDByC2XyvUKORVa98Za/Y+KpLGz0y7mtjf8AlvI2iXzqULxKGWX7gAVpDkfKfLzgbqdve5Sb6XOj/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GK42Lxr48gnjsbnRpnbyImN/wD2FcNFvaVVbKrJuyAWGMD7u/O1sDW1TxF410vRpZFsre9vYLnyWWDSLgpMAXYsoWRiAYwgB+YBzg+xa42bn/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxVjwjLNLospuReBhfXQX7akiybPPcp/rBu27SuO2MYrcoegHN/8J5pH/Pn4g/8JzUP/jFc/wCI/Gmlza94TdLXXAIdWkdg+gXykj7DdL8oMILHLDhcnGTjAJHolc34o/5GLwZ/2GpP/TfeUgD/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrlvEviLV/DvijVJdCstXvZJPLzHLpmoXdudsLHEWz92hLbFJXj5snoa0v8AhJ/E8+pxxW1kY1kvHjMU2iXP7uJUZlJm3hCX2rhsALvwQSpFHS4Gv/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFcppnjnxvff2cZvDc1oJjOtwtzpM6FcK3luNruFG8BSG5YEMCM4Gx4c8W+ItV8VQ2Oo+H7u1sJNPW4N1LYtCok4yCzOdpzkeWVyAASxzgOwrmn/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMVzlzq/iTWJLO1vobqxt21WKOY2unXkbCPDlozIjg4BVP34Ijbd0wCDP4h8Y+KtKvbiHTvDt1qCR6hHCrwafI4MTLnqZBu5HMgG1Mj5WwaX9fl/mN6f16/wCRuf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MVzMnjDxha2MF3cWgmS5RmRIPDd7vh2uUw6hy2TlWAIXjOM/eF/wf4w1zWNXe21nTp4YVt3k8z+xLy1AYbCBulGDkMwwOcxk/xAAWoPQ1/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GK4jUNW1prjXf7UttfWy1aGK40z+zoL9pINsjKVby4laBioUlM9iSfmxW7qKQ694j0C6tm8U20E0kkTBTfWqKsaEq0icBcuRzKBux3FNK4m7G1/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xWR4l8V+JdK8RXttp2mNPp8VmJIpV0m5nbztyfLmMkOpVm6AFSvOR1z9F8S+Ita8Y6EdQstQs7ZVmWVV0q8gjlO1gJHLnYikqMI43A8hsHlLUb0J/GnjTS7nQbZI7XXARq2muTJoF8gwt9Ax5aEDOAcDqTgAEkCug/4TzSP+fPxB/wCE5qH/AMYo8ef8i7a/9hrSv/Thb1zPivXtW0DxdfzaHbarcyyQQrsfTL+9tchJSdixkRq2RCCR6n3IBpXOm/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8YrHHinxLc6jBHb2bW6TXaxGKfQrpvKjKM24zb1X5iF5wAmSrc1maZ468b3stgLrwzNZiS6liuVuNLnHyAKFZWV3C4dsZbh1UsNvQOwvM6v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8Yrm4vHHi972GH/hFrxo30152mbTpI185dw5zISuSBiLBYhs7uMV0Pw9nv5/B8b6s12119puNzXdvNA7L5zlCEmJdV2lcAk4GBniiwr/1+I//AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YrpKKQzm/wDhPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABiukooA5v8A4TzSP+fPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/wAYrpKKAOJttetNb+KekfYodQi8nRdQ3fbdNuLTOZ7LG3zkXd05xnHGeoorSvv+Sp6F/wBgXUv/AEfY0UAHjz/kXbX/ALDWlf8Apwt66Sub8ef8i7a/9hrSv/Thb10lABRRRQBXhsLO2uJJ7e0gimlOZJI4wrP9SOTViiigAooooAKKKKAOF8Ma8vh/4QeDp2sLu/M2mWUKxWnl7txt1I++6jHGOvcduasr8SLBwXTSdUMIw3nbYdpj2LI0mPM3YVZEJGN3zcA4OKvhrw3ZeJ/hB4LtNTLNbQafYXDQ+XG6T7YVwjq6sCv0weOorqD4b0NiS2i6eSbgXRJtU5mAwJOn3wBjd1oj5/1t/wAEH5f1v/wDnV+ISWVvcDUrG4upreS48x7GNFRVSWVIwQ8gO5hE3TIyOSoIpk/xA0Qalpbz6LeG9uHnhjZ0t/MtwjYkOTJkjA3ER7jgcgdK6GTwl4cmGJtA0uQESA7rKM/6w5k7fxH73r3rMb4ceG11ewvrPTrWxWwYtHa2tlbpGWzndnyyyHIGSjLnAByOKOoPrYyoPilZ62dK/wCEahadbm+jhunfypFgjZtoyyS/ePBG3fjkMFPTv6x/+EQ8N5tT/wAI9pX+hyGW2/0KP9w5O4sny/KSRnI781sU9Lf15C1v/XmFFFFIYUUUUAFc34o/5GLwZ/2GpP8A033ldJXN+KP+Ri8Gf9hqT/033lAEWseLJtN8daNo0dsz2l4WS4nNvIRG5VjGPMA2KcpgqTk7lx3rIvPFPiYaNqk9tNpMF3ZETiOeylkUwFnC4KzBXztB3hh3BQGrt/qPhCS51y2v9Fs57vT7hLm6tpILdpbhgiEXCqWy21XA3HBGCB2zduB4GFjqcN2PDwtWuEj1FJfI2GbjYsoPG/hcBuelC2V/62B72NC61K50Pw219rEYvZrdc3BsYxGGGcFwsj8ADkgsSMHGe/Oj4saEFtGnt7q3W7ujaxtLJAB5gbaw/wBbyQSvC5JDAgEA414tR8P3HijUdBiit5rlrJZL1Q0bx+WPlCOu4kfK3QqAQepqo9/8PGtYvMu/DJgRzeRbpLfarLlTKvbI2kbh/dIzxRvqHl/W2n6Gbe/Ery7VrWzsLhtT/sx9QDyxxCONVBOHQTb+o25XcuSPmrY03xtBqFxcA6bd21ta2j3M1xM0eEKSPG0ZVXJyDGxyMj3rn7rRPhnaa493eXWhKkccdodOaO08mHzAdgI2b1DAkhS2w5LYzzWxpeoeB9Psd2jR6FavHa7zaWklqjpG+1ivyttAJdD12kspycina60/rf8A4AO35foZVn8WLC2m8jxJE9jNPdzRwIRGrJEoUruUStuY7gP3e71IUZxf1L4mWOj27zaro+o2kccUcjvLNaBV3sVRS3n7QTtzycYI5zxU9nb/AA7s4xJYQ+GLdLW52hoVt1EU8nyYyPuu2NvqcYpLu18A6RJcafqNh4d0+IwRxyrOltGjoS7rGVPOBsZsEY6kZwcHRC7/ANdRv/Cy9INzcRra3pigjglF1iIQyRy4+YMX4C5G4NgjIwDkZzbz4r2F3oFzdeGYmurqKcxbG8p1VVKlpG2yjC7WHGd4J5Tgitm7bwBBqE8V8fDcd47ok6TeQJGbAKBgeScICAeyjHSmm2+HupRRWTQ+GbuO7lkuo4Clu4mkXIklC/xMMHc3Uc5o0/r+u39djW39f1udXRWZH4i0Joz5OsaeVjthdHbdJhYO0nXhP9rpTtB1u28RaHbarYBhb3IJTeVJwGI6qSpHHUEgikMzPHn/ACLtr/2GtK/9OFvUN94yOkeIdQsb+0kmhihE1u8CoucRlmjYvIMsdpIOAMcEjjM3jz/kXbX/ALDWlf8Apwt6i1Sx8Atrd1Nrdr4bOqLCGuXu44PPEbfuwXLfNtOQvPBzikMzrf4taFdSGKC1vjci0W7NqwiWYAlcqUMgIZQwJONvBAJIxVkfEmw8l2fSdUSSP5mhZItwQb97/wCswQnlPkZydvyhsjKsvw2uoyjL4VmSWLyypFsweMDztvuoGZMdP4veoNMtfh0m6CLRvD2mySSuy28lvbRtN5BJ81Qv3lH3g3YHJxVaC6Cz/EW3k1i4tLO2mjh025VL64nRGUoUc4QLJvVvkz86DK9Bhgaa3xEYa5axNpd2lrLGyTRNHGZreXfEqFmEpQowmT7uSMjPfE2k+GPB3/CSXV3DLp2p6jdEX6pJHbPJGpJxKpRA7DJOHcsRkgEDirFpL4Gkgt7SOPQIRbebNBa5t/3Q+YPIqqSFBAYkjtnPcUlotQer0F8O+N4NbvLaxayvIpprZZhcSRxpE58uNyABI7A4lHBz0PJ4Jp3fxT0KyuYLaaK4F1PJLElv5kAk3IcY2mQctlcAZI3AsFGSIrey+FMIaaxh8I252KTNbfZo2CvgA7lwQDuXHPOR61qPbeBb2ZreSDw9cSR3TwtEyQOVuJFO9SOzsoOR1Izmm9XoBV/4WLbJDLJc6Fq1v5cLThH+zlnQJvBG2U9VzgHB4OccZ1NB8Uwa/c3EEVje2kluMsLpUGcSPGQNrN0aNgfwxmsPW2+HTW2nve6XoGqJcXMWm2qJDbSkMH8sIoY8hCxyq5KjPHWuj0nwvoGgTSS6Foem6ZJKu2R7O0jhLjrglQMijTfoLW1upq0UUUhnN33/ACVPQv8AsC6l/wCj7Gii+/5KnoX/AGBdS/8AR9jRQAePP+Rdtf8AsNaV/wCnC3rpK5b4i3CWvhKK4lEjJDq2mOwijaRyBfwE7UUFmPoACT0AqX/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAOkorm/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigDpKK5v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAD4cf8ks8Kf8AYFs//RCV0led+AfGml2vw28NW8trrjPDpNqjGLQL6RCRCoO11hKsPQgkHqDXQf8ACeaR/wA+fiD/AMJzUP8A4xQB0lFc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFAHSUVzf/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMUAdJRXN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xQB0lFc3/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFAHSVzfij/kYvBn/AGGpP/TfeUf8J5pH/Pn4g/8ACc1D/wCMVz/iPxppc2veE3S11wCHVpHYPoF8pI+w3S/KDCCxyw4XJxk4wCQAb+qeB7HVL2/umvb23e+jKuITHhGKqhddyH5iiqvOVwMgA5NQP8PLB/MYajqCSs+6KVTFugT95mNcxkFT5smdwY/NwRgYsf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAR2ngOws9Su7mO+vmt7q1ktTZM0flRo5BbaQm/OR3Y4yfbEGofDyDVbNoNQ8Qa1KTbLbrMssUUkZWQSLIrJGCrgqo4+XA5BJJq3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUf1/X3h/X9fcjPs/hjp2nzCWy1XVY5EjhijcvC7RrFt2AFoySPlP3s/fbGOMVYvhRbxRlB4p15lMBtxkWfCbFT/n3/uoo59PU1tf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFO7Awbn4PabfQzpf+IdenaZw7SLNDCw+aRmGYol4bzpAwOchscYFaviHwBD4h1Brp9d1ayDQpCYbUW5TChwD+8hds4lfv39hVn/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YpPVWY7vchj8B26eSja1qklvDP54t2MOwsUZXziMHDbiTzkH7u0cVR0z4U6Tpb2TJqmr3X2OR5U+2XCTbmZShyWQnhDt4I4AznGa1P8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xijzJsZUHwo0q3vJLoaxrjzPb+VmS7DKrbgRKEK7d42qOm3Cgba6fQNGTw/osWnR3dxeLEzt51zs3sWYsc7FVepPQCs3/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABigYePP+Rdtf+w1pX/pwt6h1zwDaa7rE+pSapqNrcTW5th5HkkRoSpYLvjbqUXIOR1wBk1i+NPGml3Og2yR2uuAjVtNcmTQL5Bhb6Bjy0IGcA4HUnAAJIFdB/wnmkf8+fiD/wAJzUP/AIxQBmW3w7FhIETU7zUYp545J3vXiRolR3k+QQwpu3GR1YMQNrnr0q1cfDyxvNUS+utT1GZo55p44n8kohkDBgB5ecYdh1yRjJOBVn/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABigCDRPh9p+h+IItXh1PVrm4jtRbFLm63xucAeaUAA3kKBnpgDis5/hTaTXYnufEmuTYYsEb7KoBPmd1gB4M0hHPf2FbH/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MU7sClqnw4tdZsbq31LXtble5aJzcJPFFLGYwy/KyRrjcHYMDkYOAFFEXw102G6mnTU9U3zTxTMfNjB/dsxVNwTcVwxU5JO0AZ4q7/wnmkf8+fiD/wAJzUP/AIxR/wAJ5pH/AD5+IP8AwnNQ/wDjFIDGsfhHpOnRwpZ6zra+XcrcFpLlJi4Vo2SMmRGwi+UgAXBwMEmu9rm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYp3drB1udJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFIAvv8Akqehf9gXUv8A0fY0Vm22vWmt/FPSPsUOoReTouobvtum3FpnM9ljb5yLu6c4zjjPUUUAdtXn3i+7uYvix4NgiuJUikM2+NXIVvl7jvRRQviQPZi+I9PspNB8cmSzgcq4uV3RKcSrbRlZBx94EDDdRis34pfvtT0y2m/eQSQhXiflWDSoGBHQ5HB9RRRSn8C+X/pKKX8Rf19o63wKzSeHYpJCWcxW4LMcnH2eM9fqT+ZrpaKK0qfEzKn8COcvI0HxN0mQIu86VdqWxyR5tvxn8a0tFlklgujK7OVvJlBY5wA5AH0ooqV8Mfn/AOlMt7v5fkZuqWdsvjzQbxbeIXTR3EbThBvKhAdpbrjPaujoopdF/XUDL0oCW91CaUB5Yrp4o3blkTah2g9hnnFO1OWSPUtIWN2VZLplcKcBh5MhwfUZAP4UUUL4ULqyrcRoPH9hIEXedNuVLY5I8yHjP41H4oije+8Ou6KzR6qpRiMlSYpBx6cUUU1tD1/9uYdZ+n/tpwVxp1lc31nLc2dvNJqWpXsF88kSsbqJJ8IkhI+dVAAAbIGOK6v4W2NpYeB7OKxtYbaN4YJGSGMIGdreIsxA7k8k96KKKfwv0X5jnv8AP9Dj7rSNNm1a81aXT7V9SQu63rQKZlYX+wEPjdkIAoOenHSvYqKKUf4a+YS/iy+RxniOWSXVb60ldntntWDQMco37iU8r06gflWheOyeOdKCMVEmm3O8A43bWi259cZOPTJooo/4P5MOn9d0ZGrXVxJ8DdQuXnlac6TKxlLksTsPOetcnrNjaQ31hbw2sMcJWyszGsYCmBlUtFjpsJ6r0PpRRQ93/XSQ/wCX1/WJ6Z4OJPgzSsnP+jKOfTFbVFFVP4mTHZBRRRUjCucsI0T4la2yoqs+m2RYgcsd9wOfwoopoOj/AK6ov+IAE00XCALNHLGqSDhlDSKGAPUZHB9awo7W3b4R31q0ERtxZ3SiIoNmAXwMdMUUVPcuHxIxPiJ97SZP44LUSRN3jYz26FlPY7WZcjsxHQ1e+FsaR6LHFGirHCkqxIowIx9pl4Udh8o6eg9KKK0js/X/ADMvsx+R0F5Gn/CwdKk2L5n9nXa7sc48y34zW5IqvE6uoZWUggjIIoorOf8ACXo/zZovi+4wPAKqnw80FUAVVsIgABgAbRXQ0UVrV/iS9SFsZWggTWklzKN8/wBouI/NbltgnfC564HYVJdSyL4h0+NXYRvFMWUHhiNmMj8TRRWa2H1ZmeMoIryLSLK7iSe1utSjinglUMkqbHO1lPDDIHB9K860fRtMu9V0+6utOtJ7i1uLyOCWSBWeJIpk8tVJGVCZO0DpnjFFFOn8XzX5Cnt8n+Z197o+mXPxgS9uNOtJbuG0tWjneBWkQ5ueQxGR0H5Cu6oopR+BerHL+I/RGIkUa+PJpVRRI+mxhnA5YCR8An2yfzNbdFFC+FfP82OXxP5fkjLvwJddsLeUb4JIpmeJuVYqUIJHQ4PStSiigQUUUUAf/9k=" alt="" width="542" height="212" vspace="0" hspace="0" border="0" style="width:542px;height:212px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with<br />vandetanib in one or more subsets of the paediatric population in hereditary medullary thyroid carcinoma,<br />see 4.2 for information on paediatric use.<br />This medicinal product has been authorized under a so called &ldquo;conditional approval&rdquo; scheme. This means that<br />further evidence on this medicinal product is awaited. The European Medicines Agency (EMA) will review<br />new information on the product every year and this SmPC will be updated as necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u>:<br />Following oral administration of vandetanib absorption is slow with peak plasma concentrations typically<br />achieved at a median of 6 hours, range 4-10 hours, after dosing. Vandetanib accumulates approximately<br />8-fold on multiple dosing with steady state achieved from approximately 2 months.<br /><u>Distribution:</u><br />Vandetanib binds to human serum albumin and alpha-1-acid-glycoprotein with in vitro protein binding<br />being approximately 90%. In ex vivo plasma samples from colorectal cancer patients at steady state<br />exposure after 300 mg once daily, the mean percentage protein binding was 93.7% (range 92.2 to 95.7%).<br />The pharmacokinetics of vandetanib at the 300 mg dose in MTC patients are characterised by a volume of<br />distribution of approximately 7450 l.</p><p><u>Biotransformation:</u><br />Following oral dosing of 14C- vandetanib, unchanged vandetanib and metabolites vandetanib N-oxide and<br />N-desmethyl vandetanib were detected in plasma, urine and feces. A glucuronide conjugate was seen as a<br />minor metabolite in excreta only. N-desmethyl-vandetanib is primarily produced by CYP3A4, and<br />vandetanib-N-oxide by flavin-containing monooxygenase enzymes (FM01 and FMO3).<br />N-desmethyl-vandetanib and vandetanib-N-oxide circulate at concentrations of approximately 11% and<br />1.4% of those of vandetanib.<br /><u>Elimination:</u><br />The pharmacokinetics of vandetanib at the 300 mg dose in MTC patients are characterised by a clearance<br />of approximately 13.2 l/h. and plasma half-life of approximately 19 days. Within a 21 day collection<br />period after a single dose of 14C-vandetanib, approximatley 69% was recovered with 44% in faeces and<br />25% in urine. Excretion of the dose was slow and further excretion beyond 21 days would be expected<br />based on the plasma half-life.<br /><u>Special populations:<br />Renal impairment:</u><br />A single dose pharmacokinetic study in volunteers indicated that exposure to vandetanib is enhanced (up<br />to 1.5, 1.6 and 2-fold) in mild, moderate and severe renal impaired subjects respectively compared to<br />subjects with normal renal function (see sections 4.2, 4.4 and 4.5).<br /><u>Hepatic impairment:</u><br />A single dose pharmacokinetic study in volunteers indicated that hepatic impairment did not affect<br />exposure to vandetanib. There is limited data in patients with hepatic impairment (serum bilirubin greater<br />than 1.5 times upper limit of normal (see sections 4.2 and 4.4).<br /><u>Food Effect:</u><br />Exposure to vandetanib is not affected by food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Vandetanib has shown no mutagenic or clastogenic potential.</u><br />In repeat-dose toxicity studies of up to 9 months duration, effects included emesis, body weight loss and<br />diarrhoea in dogs and physeal dysplasia in young dogs and rats with open growth plates. In rats, effects<br />on teeth, kidney and skin were noted. These findings occurred at clinically-relevant plasma<br />concentrations, were largely reversible within 4 weeks of cessation of dosing and were attributable to<br />inhibition of vascular endothelial growth factor receptor (VEGFR) or EGFR.<br />Effects noted in other studies included inhibition of human ether-a-go-go related gene (hERG) current and<br />prolongation of QTc interval in dogs. Elevation of systolic and diastolic blood pressure was observed in<br />rats and dogs. In mice, vandetanib was shown to delay but not prevent wound healing. Vandetanib also<br />showed evidence of phototoxic potential in an in vitro cytotoxicity assay. In an animal model of<br />wound-healing, mice dosed with vandetanib had reduced skin-breaking strength compared with controls.<br />This suggests that vandetanib slows but does not prevent wound healing. The appropriate interval<br />between discontinuation of vandetanib and subsequent elective surgery required to avoid the risks of<br />impaired wound healing has not been determined. In clinical studies, a small number of patients had<br />surgery while receiving vandetanib and there were no reported wound healing complications.<br /><u>Reproductive toxicology:</u></p><p>Vandetanib had no effect on fertility in male rats. In a female fertility study, there was a trend towards<br />increased oestrus cycle irregularity, a slight reduction in pregnancy incidence and increase in implantation<br />loss. In a repeat-dose toxicity study in rats, there was a decrease in the number of corpora lutea in the<br />ovaries of rats given vandetanib for 1 month.<br />In rats, embryofoetal toxicity was evident as foetal loss, delayed foetal development, heart vessel<br />abnormalities and precocious ossification of some skull bones. In a rat pre- and post-natal development<br />study, at doses producing maternal toxicity during gestation and/or lactation, vandetanib increased<br />pre-birth loss and reduced post-natal pup growth. Vandetanib was excreted into milk in rat and found in<br />plasma of pups following dosing to lactating rats.<br /><u>Carcinogenicity:</u><br />Carcinogenicity studies have not been conducted with vandetanib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:<br />Calcium hydrogen phosphate dihydrate<br />Microcrystalline cellulose<br />Crospovidone (type A)<br />Povidone (K 29-32)<br />Magnesium stearate<br />Film-coating:<br />Hypromellose<br />Macrogol (300)<br />Titanium dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/ PVDC/Alu blisters, sealed with aluminium foil, each containing 30 film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Naghi Brothers Company
P.O. Box 273, Jeddah 21411, A Malek RD. In front of Saudi oger, Jeddah, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 July 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>